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Skeletal myogenesis is a tightly regulated process involving a series of 
steps which begins with the initial commitment of multi-potent 
mesodermal progenitors towards the myogenic lineage. Once committed, 
they proliferate as undifferentiated mononucleated myoblasts followed by 
irreversible withdrawal from cell cycle. Concomitantly, they differentiate 
and fuse into multinucleated myotubes. The terminal step of differentiation 
culminates with the maturation of differentiated myotubes into muscle 
fibers. This process of skeletal muscle development and differentiation is 
orchestrated by the combinatorial activity of two transcription factors 
families that include Myogenic Regulatory Factors (MRFs) and the 
Myocyte Enhancer Factor-2 (MEF2).  
The expression and activities of MRFs and MEF2 are tightly controlled by 
both positive and negative regulatory factors. In addition there are several 
chromatin modifiers and remodelling complexes that regulate MRF and 
MEF2 activities and thereby regulating skeletal muscle differentiation. I 
have analyzed the role of one such chromatin modifier G9a, which 
mediates H3 lysine-9 di-methylation (H3K9me2) chromatin marks that are 
associated with transcriptional repression. G9a is expressed at high levels 
in undifferentiated myoblasts and is down-regulated upon differentiation. 
Over-expression of G9a in myoblasts retards skeletal muscle 
differentiation in a methyltransferase activity-dependent manner. RNAi-







differentiation. This is concomitant with early induction of differentiation 
genes myogenin and Troponin T. G9a-dependent impairment of 
differentiation is correlated with H3K9me2 marks on muscle-specific 
promoters. In addition, G9a interacts with and methylates MyoD, a MRF 
that is central to differentiation of skeletal muscle cells. G9a methylates 
MyoD at a single lysine (K) residue 104, suppressing its transcriptional 
activity. This modification blocks the ability of MyoD to activate its 
downstream target genes such as myogenin, resulting in impairment of 
differentiation. Interestingly, K104 in MyoD is also a site for acetylation 
by a histone acetyltransferase P/CAF. Consistent with this, G9a disrupts 
P/CAF-mediated MyoD acetylation which is critical for its transactivation 
function and for execution of the myogenic differentiation program. RNAi 
mediated reduction of G9a results in altered kinetics of MyoD acetylation, 
suggesting a possibility of cross-talk between G9a and P/CAF in 
controlling MyoD transcriptional activity and myogenesis. In addition, 
pharmacological inhibition of P/CAF activity enabled us to identify gene 
networks broadening the spectrum of its regulatory function in skeletal 
muscle differentiation. These findings provide insights into the 
mechanisms by which chromatin modifiers regulate MyoD activity via 
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Skeletal muscle is a complex and highly organized tissue which is involved in 
vital functions such as movement, maintaining posture, stabilizing joints and 
generating heat. It represents a large fraction of body mass accounting for 
approximately 40-45% (Lieber, 1992; Janssen et al., 2000). During 
development, skeletal muscles are established in an elaborately organized 
manner by the process referred to as ‘myogenesis’ which involves an array of 
distinct steps (Tajbakhsh, 2009). Any defect in skeletal myogenesis causes 
great disability in affected people as it might result in dystrophy, regeneration 
defects and other muscular myopathies (Amack and Mahadevan, 2004). 
Therefore, it is essential to understand the molecular mechanism behind 
skeletal muscle development which can form the basis of disease treatment. 
1.1 Skeletal muscle development during embryogenesis 
During embryogenesis, the majority of skeletal muscles of trunk and limbs 
originate from cells of the paraxial mesoderms which lie on either side of the 
neural tube (Wachtler and Christ, 1992). As development proceeds, the 
paraxial mesoderm condenses into segmental epithelial spheres called somites 
(Buckingham, 2001; Tajbakhsh and Cossu 1997; Summerbell and Rigby, 
2000). These somites under the influence of a variety of signals arising from 
notochord and neural tube as well as from the overlying ectoderm and lateral 
mesoderm become compartmentalized into mesenchymal sclerotome and 
epithelial dermomyotome (Figure 1.1a). While the sclerotome gives rise to 







form the myotome (sheet of differentiating skeletal muscle cells) which gives 
rise to skeletal muscles of the trunk and limbs and the remaining structure is 
dermotome, which develops into skin (Braun et al., 1992; Lassar and 
Munsterberg, 1996; Christ and Ordahl, 1995; Ordahl and Le Douarin, 1992). 
The formation of skeletal muscle from the multipotent precursor cells involves 
a multi-step process that begins with the commitment of these cells to the 
muscle fate. The committed cells proliferate to give rise to large pools of 
myoblasts that migrate to their proper sites (Pourquie et al., 1995) and 
continue to divide. When appropriate environmental cues are received, 
proliferating myoblasts exit the cell cycle, differentiate and fuse into multi-
nucleated myotubes (Figure 1.3a). Then the bundle of parallel myotubes 
forms a mature myofiber, the basic contractile unit of skeletal muscle (Lassar 
et al., 1994).   
Studies have shown that myogenic regulatory factors (MRFs) namely Myf5 
and MyoD establish two distinct populations of skeletal muscle precursor cells 
in the myotome that give rise to epaxial and hypaxial muscles respectively 
(Braun and Arnold, 1996). The muscle precursor cells from the dorsal-medial 
lip (DML) of the somite contribute to epaxial muscles of the back and body 
wall whereas muscle precursors from the ventral-lateral lip (VLL) of the 
somite migrate and form hypaxial muscles of the limbs, ventral body wall, 
diaphragm and tongue (Figure 1.1a)  (Ordahl and Douarin, 1992; Christ and 








Figure 1.1a Schematic representation of the embryonic origin of limb and 
trunk skeletal muscle (Nat Rev Genet. 2003; 4:497-507). The paraxial 
mesoderm condenses into segmental epithelial spheres called somites following 
rostrocaudal gradient on either side of the axial structures. These somites under 
the influence of a variety of signals arising from notochord and neural tube as 
well as from the overlying ectoderm and lateral mesoderm become 
compartmentalized into mesenchymal sclerotome and epithelial 
dermomyotome.The myotome forms as a result of migration of cells from the 
dorsal-medial lips (DML) and ventral-lateral lips (VLL) of the dermomyotome. 
Cells from the dorsal-medial lip (DML) of the somite contribute to epaxial 
muscles of the back and body wall whereas muscle precursors from the 
ventral-lateral lip (VLL) of the somite migrate and form hypaxial muscles of 
the limbs, ventral body wall, diaphragm and tongue. 
In addition, a sub-population of cells remains undifferentiated and 
mononuclear termed satellite cells located between the basal lamina and 
sarcolemma of myofibers (Figure 1.1b) (Mauro, 1961; Katz, 1961). It 
accounts for the remarkable property of adult skeletal muscles to adapt to 













Figure 1.1b Satellite cells occupy sublaminar position in adult skeletal muscle 
(J Appl Physiol. 2001; 91(2):534-51). Satellite cells located between the basal 
lamina and sarcolemma of myofibers captured using ultrastructural 
techniques.They have distinctive morphological features such as high nuclear-to-
cytoplasmic ratio with few organelle, a smaller nuclear size compared with the 
adjacent nuclei of myotube. In addition, they have more abundant 
heterochromatin compared to that of myonucleus. 
 
1.2 Signaling molecules in the regulation of skeletal myogenesis 
The myogenic specification and differentiation of the myotome is influenced 
by the complex signalling system provided by microenvironmental factors 
such as Sonic hedgehog (Shh), Wnts, BMP4 and noggin (Figure 1.2) 
(Tajbakhsh and Cossu, 1997). Sonic hedgehog, a signalling molecule 
expressed in the dorsal ventral neural tube and notochord, acts as one of the 
major players in skeletal muscle formation. It induces the expression of paired 







mesoderm and dermomyotome (Fan and Tessier-Lavigne, 1994, Fan et al., 
1995, Johnson et al., 1994). These transcription factors induce the expression 
of their downstream target Myf5 and consequently MyoD, committing cells of 
the myotome to the myogenic lineage (Figure 1.2) (Munsterberg et al., 1995; 
Maroto et al., 1997). Gene disruption studies revealed that Pax3 and Pax7 
have distinct functions with Pax3 being essential for the development of limb 
muscles (Bober et al., 1994), whereas Pax7 is important for satellite cell 
survival and maintenance (Relaix et al., 2006). Consistent with this, in Pax3 
null mice (Splotch mice), dermomyotome is disorganized and the limb 
myogenic progenitors fail to migrate from somites into the growing limbs and 
the developing tongue (Goulding et al., 1994; Tremblay et al., 1998; Epstein 
et al., 1996) while loss of Pax7 results in the death of satellite cells (Relaix et 
al., 2006). 
 Studies have shown that loss of Shh in the neural tube and notochord leads to 
the disruption of epaxial muscles, while hypaxial muscles develop normally 
(Borycki et al., 1999). However, further studies showed that Shh is required 
even for the maintenance and expression of MRFs in hypaxial muscles and 
formation of limb muscle differentiated myotubes (Duprez et al., 1998; Kruger 
et al., 2001).   
In addition to Shh, Wnt (wingless and integrated) family of growth factors, 
expressed in the dorsal-neural tube and members of BMPs (bone morphogenic 







lip of dermomyotome play crucial roles in somite pattterning (Marcelle et al., 
1997). While Wnt family members work in cooperation with Shh to induce 
myogenesis in the dorsal part of isolated somites in vitro (Munsteberg and 
Lassar, 1995), BMPs and Noggin are known to regulate Pax3 expression 
(Figure 1.2) in proliferating muscle precursor cells wherein they either 
promote embryonic muscle growth by increasing Pax3 expressing muscle 
precursor cells or restricts growth by inducing apoptosis (Amthor et al., 1998). 
Figure 1.2 Signaling factors involved in embryonic skeletal muscle formation 
(Physiol Rev. 2004; 84:209-38). Mesodermal somatic cells from the 
dermomyotome (DM) receive signals from the surrounding tissues provided by 
signalling factors like Shh, Wnts, Noggin and BMP4 that induce or inhibit the 
expression of MRFs (Myf5 and MyoD) and commitment to the myogenic lineage. 
The committed myoblasts migrate laterally to form the myotome (MT), which 
eventually gives rise to skeletal muscles of the trunk and limbs. Pax3 promotes 
myogenesis in the lateral myotome. E, ectoderm; LP, lateral plate; SC, 









1.3 Myogenic regulatory factors (MRFs) and skeletal muscle development 
In 1979, Taylor and Jones found that treating the mouse fibroblast cell line 
10T1/2 with the demethylating agent 5-azacytidine resulted in generation of 
clones with skeletal muscle phenotypes. This suggested that DNA 
demethylation was sufficient to induce muscle gene expression in non-muscle 
cells. This was followed by another landmark study in which a single 
myoblast-specific cDNA was isolated and stably transfected into 10T1/2 cells 
which resulted in the conversion of fibroblast-like 10T1/2 cells to skeletal 
muscle cells (Lassar et al., 1986; Davis et al, 1987). The gene encoding this 
sequence was named as “MyoD1” (myoblast determination gene number 1). It 
is expressed exclusively in myogenic lineage in vivo and only in myogenic cell 
lines in vitro.  
The identification of MyoD as an important regulatory gene of skeletal 
myogenesis paved the way for the identification of the roles of other tissue 
specific transcription factors in regulating cell differentiation (Tapscott, 2005). 
The discovery of MyoD (Davis et al., 1987) was soon followed by the 
discovery of myogenin (Edmonson and Olson 1989; Wright et al., 1989), 
Myf5 (Braun et al., 1989) and muscle-specific regulatory factor 4 (MRF4) 
(Rhodes and Konieczny, 1989; Miner and Wold 1990; Braun et al., 1990). 
Each of the four homologous muscle specific transcription factors is capable 
of converting cultured fibroblasts to a muscle phenotype (Braun et al., 1990; 
Wright et al., 1989) and broadly classified under the category ‘MRF’ 







establishment of skeletal muscle lineages (Stockdale and Holtzer, 1961; 
Cooper and Konigsberg, 1961).  
Analysis of MRF expression in cell lines have shown that MyoD and Myf5 are 
expressed first in proliferating undifferentiated muscle cells followed by 
myogenin whose expression is induced when cells begin to terminally 
differentiate (Smith et al., 1993; Andres and Walsh, 1996) followed by MRF4 
expression (Figure 1.3a) during muscle development as well as in adult 
muscle tissue (Hinterberger et al., 1991). 
Figure 1.3a Schematic representation of skeletal muscle differentiation 
(Adapted from Subcell Biochem. 2012; 61:139-50). Pax3 and Pax7 positive 
precursor cells induce the expression of their downstream target Myf5 and 
consequently MyoD, committing cells to the myogenic lineage. The committed 
cells proliferate to give rise to large pools of myoblasts. When appropriate 
environmental cues are received, proliferating myoblasts irreversibly exit the cell 
cycle expressing p21 and early differentiation marker myogenin followed by 
terminal differentiation to form multinucleated myotubes characterized by the 








MyoD and other MRFs contain basic (b) and helix-loop-helix (HLH) domain 
which are the two important domains. In addition, they have one or more 
transactivation domains (TADs) (Figure 1.3b). MRFs share significant 
homology   throughout the highly conserved bHLH domain which accounts 
for their tissue-specific actions (Murre et al., 1989a; Dias et al., 1994). The 
basic domain mediates DNA binding at sequence-specific DNA elements 
known as E-boxes in order to activate transcription. These E-boxes have a 
consensus nucleotide sequence of 5’-CANNTG-3’ that is present in the 
promoters of many muscle specific genes (Davis et al., 1990, Braun et al., 
1990, Lassar et al., 1989). The HLH domain mediates heterodimerization with 
another family of non-myogenic bHLH proteins known as E-proteins 
(HEB/HTF4, E2-2/ITF-2 and E/12/E47) which increase affinity of MRFs for 
muscle specific genes (Murre et al., 1989b; Brennan and Olson, 1990; Lassar 
et al., 1991; Shirakata et al., 1993). TADs are the elements in the amino 
(NH2) and carboxy (COOH) terminal regions (Figure 1.3b) which account for 
the distinct activities of MRFs as the amino acid sequences of these regions 
are very different (Schwartz et al., 1992; Asakura et al., 1993).  
Figure 1.3b Diagrammatic representation of domain structure of MRFs 
(Adapted from Transcription. 2012; 3:1-6). The basic (B) domain; helix-loop-
helix (HLH) motifs; NH2- and COOH-terminal transactivation domains (TADs); 







Although each of the MRFs is capable of driving the entire myogenic 
differentiation program when expressed in non-muscle cells (Munsterberg et 
al., 1995), the distinct expression pattern and gene disruption studies 
suggested that all of them have different functions in vivo. Myf5 mRNA 
transcripts are the first to be expressed in mouse embryo at embryonic day 8 
(E8.0) (Ott et al., 1991). Myogenin is transcribed 12 hours after Myf5 (E8.5), 
followed by MRF4 at E9.0 which exhibits a transient expression pattern. 
MyoD is expressed last at E10.5 and its expression persists throughout 
prenatal life of the mouse (Sassoon et al., 1989; Hinterberger et al., 1991). 
Gene ablation experiments revealed the function of each MRF in myogenesis. 
Myf5 and MyoD have functional redundancy between them as mice deficient 
either in Myf5 or MyoD did not impair skeletal muscle formation (Rudnicki et 
al., 1992) while double mutants Myf5/MyoD fails to develop detectable 
amount of skeletal muscle cells as well as muscle fibers. Thus it was 
concluded from this observation that expression of at least one of them is 
essential for the commitment of cells to myogenic lineage (Rudnicki et al., 
1993). Targeted inactivation of myogenin results in critical loss of skeletal 
muscles that tend to accumulate undifferentiated myoblasts, which results in 
prenatal death. Thus myogenin is crucial for the terminal differentiation of 
committed myoblasts by activation of muscle specific genes, such as muscle 
creatine kinase (MCK) and myosin heavy chain (MHC) (Hasty et al., 1993; 
Nabeshima et al., 1993). Interestingly, mice lacking either MRF4 or MyoD 







MRF4/MyoD double mutants resulted in a critical muscle deficiency similar to 
that observed in myogenin mutants, which clearly revealed an unanticipated 
overlapping function for MyoD and MRF4 in the muscle differentiation 
pathway (Rawls et al., 1998).  
Skeletal myogenesis proceeds in a strict temporal sequence from early to late 
gene expression (Andres and Walsh, 1996; Bergstrom et al., 2002). In 
committed moyblasts, MyoD or Myf5 expression is induced that promotes 
irreversible cell cycle exit by upregulation of CDK inhibitor p21 (Halevy et 
al., 1995) as well as transactivation of early differentiation marker myogenin. 
This results in terminal differentiation characterized by the expression of 
myosin heavy chain and Troponin T (Figure 1.3a) (Sabourin and Rudnicki, 
2000; Tapscptt, 2005; Sartorelli and Caretti, 2005). 
1.4 Myocyte Enhancer Factor 2 (MEF2)  
In addition to MRFs, MEF2 family members play an important role in skeletal 
myogenesis (Olson et al., 1995). MEF2 family are nuclear phosphoproteins 
that were originally purified from muscle cells as myocyte-specific binding 
factor. It is also referred to as RSRF (Related to Serum Response Factor) and 
expressed in all developing muscle cell types (Gossett et al., 1989).  
MEF-2 proteins can physically interact with MRF-E protein heterodimers. 
Like MRFs, they bind a conserved DNA sequence in a majority of muscle 
specific genes. These Mef2-dependent genes encode a large number of 







proteins, as well as other transcription factors. MRF and Mef2 have been 
shown to amplify and regulate each other’s expression (Cjerjesi and Olson 
1991; Lassar et al., 1991). However, unlike MRF, MEF2 genes alone cannot 
activate transcription of muscle genes in vertebrates as they do not possess 
myogenic activity on their own. Instead, they co-operated with MRFs to 
activate muscle gene expression and increased the efficiency of conversion of 
non-muscle cells (Molkentin et al., 1995). There are several studies which 
suggest that MEF2 functions as an important myogenic co-regulator which is 
required by MRFs to initiate myogenesis. It has been shown by in vivo studies 
that MEF2 is essential for the proper regulation of myogenin gene expression 
(Cheng et al., 1993; Yee and Rigby 1993). This reflects the importance of 
MEF2 for the myogenic activity of MRFs and further evidence on this aspect 
came from the observation that in the presence of a dominant negative form of 
MEF2A that binds DNA but lacks a transcriptional activation domain, MyoD 
is incapable of initiating myogenesis in 10T1/2 fibroblasts (Ornatsky et al., 
1997). 
1.5 Negative regulators of myogenesis 
Since MyoD and Mef2 are expressed in proliferating myoblasts, there is a 
need to tightly regulate their expression and activity, as lack of control can 
result in premature muscle differentiation. In addition to positive regulators of 
myogenesis such as MRFs and Mef2, muscle development is controlled by 
many negative regulators. It includes the inhibitor of differentiation (Id) 







binding domain. In proliferating myoblasts, Id is expressed at high levels. 
Thus it forms a complex with E12/E47. This sequesters E12/E47 from forming 
a functionally active heterodimer with MyoD resulting in inhibition of 
terminal differentiation program. However, upon differentiation, Id level 
declines paving the way for E12 and/or E47 to form functional heterodimers 
with MyoD. Thus over-expression of Id in myoblasts results in the inhibition 
of MyoD dependent activation of MCK enhancer (Benezra et al., 1990).  
In addition to Id, proliferating myoblasts express many other negative 
regulators of differentiation; they include Twist, Mist 1, MyoR and Sharp-1 
which inhibit MyoD transcriptional activity, DNA binding and dimerization 
ability with E-proteins (Spicer et al., 1996; Lu et al., 1999; Lemercier et al., 
1998; Azmi et al., 2004). Like Id, ectopic expression or activation of these 
negative regulators inhibits differentiation. Interestingly, some of them are 
regulators of cell cycle progression as well; one such regulator is c-myc which 
belongs to the myc family of proto-oncogenes that share structural similarity 
with the MyoD family of regulators. C-Myc has been strongly implicated in 
the control of cell proliferation in various cell lineages that include muscles 
(Kelly et al., 1983; Sejerson et al., 1985). It is expressed in proliferating 
myoblasts and declines substantially when these cells exit cell cycle and start 
differentiating (Endo and Nadal-Ginard, 1986). It has been shown that over-
expression of c-myc affects MyoD dependent myoblast differentiation (Miner 
and Wold, 1991). Similarly, there are negative effects exerted by protein 







and elevated c-Jun activities (Bengal et al., 1992). 
1.6 Epigenetic regulators of myogenesis 
In addition to positive and negative regulatory factors, that tightly control the 
expression and activities of MRFs and MEF2, there are increasing evidence 
which point to the involvement of chromatin modifying enzymes and 
remodeling complexes that regulate MRF and MEF2 activities and thereby 
skeletal muscle differentiation. Epigenetic modifications play a central role by 
which muscle lineage-specific information encoded in chromatin merges with 
muscle regulatory factors to drive myoblasts through different transitional 
phases in myogenesis (Perdiguero et al., 2009). 
1.7 Chromatin Structure 
The packaging of eukaryotic DNA into an intricate and high-order structure 
known as chromatin is essential to fit it into the nucleus. This plays a vital role 
in the control of gene transcription. The basic structural unit of DNA 
packaging in eukaryotic organism is termed as “nucleosome” (Kornberg, 
1974). It consists of 147 base pairs (bp) of DNA which are super-helically 
wrapped around each histone octomer which is comprised of a central tetramer 
of histones H3 and H4 and two dimers of histones H2A and H2B (Luger et al., 
1997). This highly ordered structure is often compared to thread wrapped 
around a spool as visualization by electron microscopy revealed them as a 
series of nucleosomal beads on a DNA string (Figure 1.7a). “Histones” are 
the basic scaffolding proteins which are responsible for the compaction of the 







example, each eukaryotic cell has about 1.8 meters of linear DNA which when 
wrapped 1.7 times around an octomer of core histones is shrunken to 40,000 
times to about 90μm, which when duplicated and condensed during mitosis, 
results in about 120μm of chromosomes (Redon et al., 2002). The DNA that 
extends between nucleosomal core particles is called linker DNA which is 
approximately 10-80 bp in length. It connects each nuceosome to its neighbors 
resulting in the formation of 30nm of compact chromatin fiber of packed 
nucleosome (Figure 1.7a). 
 
 Figure 1.7a Packaging of eukaryotic DNA within the chromatin structure 








Chromatin within the eukaryotic nucleus can be distinguished into 
euchromatin and heterochromatin based on cytological studies. They were 
initially identified based on how intensely they are stained. The 
heterochromatin is intensely stained, whereas euchromatin is stained less 
intensely. The difference in the intensity of staining is attributed to their 
cytological appearance as heterochromatin has dense packing of DNA as the 
cell returns from metaphase to interphase compared to euchromatin which has 
less compact structure.  
Interestingly, heterochromatin and euchromatin represent two varied structural 
environments that have significant effects on gene expression (Elgin, 1996).  
For example, if a gene is located in a domain where the DNA is less densely 
packed (euchromatin), it has the potential to be transcriptionally active; 
however, when a gene is within or adjacent to a more densely compact domain 
(heterochromatin), it is transcriptionally repressed. The dense packing makes 
heterochromatin less accessible to protein factors which usually bind DNA or 
its associated factors. 
The modulation of chromatin structure is brought about by a broad spectrum 
of enzymes which can have an overall effect over nucleosome stability by 
either disrupting histone-DNA contacts or by covalently modifying histones 
and/or DNA (Sif, 2004). Chromatin modifying complexes are structurally 
classified into two distinct categories which are involved in activating 







Chromatin modifying enzymes contain the catalytic subunits of different 
histone modifying enzymes that are involved in catalyzing the post-
translational modification of histone tails as well as other chromatin factors. 
Such modifications include acetylation, methylation, phosphorylation, poly-
ADP-ribosylation and ubiquitination (Figure 1.7b) (Fischle et al., 2003) 
which have vital roles in regulating gene transcription, heterochromatin 
formation, X chromosome inactivation, DNA replication, DNA repair and 
cellular memory (Zhang and Reinberg, 2001; Jenuwein and Allis, 2001; 
Kouzarides, 2002; Lachner and Jenuwein, 2002; Strahl and Allis, 2000; 
Turner, 2002).  
 
 








The second major class is, ATP-dependent chromatin remodeling complexes 
which can move nucleosome positions, thereby playing a pivotal role in 
altering chromatin structure and increasing accessibility to DNA on the 
surface of histone octomer (Narlikar et al., 2002; Kadam, S. and Emerson, 
B.M. et al.. 2003). 
In addition to histone modifying enzymes and chromatin remodeling 
complexes, there are DNA modifying enzymes which are involved in 
methylating CpG rich sequences which constitute an important epigenetic 
mechanism to repress specific set of genes (Lande-Diner et al., 2007). 
1.8 Histone lysine acetylation 
Of all the histone modifications studied so far, histone acetylation has been the 
most well studied and appreciated (Grunstein et al., 1997). The acetylation of 
histones decreases the positive charges of the histone tails which results in 
reduction of its affinity for the negatively charged DNA, thereby allowing 
greater accessibility for the binding of proteins that regulate transcription to 
chromatin templates (Hong et al., 1993; Workman and Kingston, 1998).  
The most common post-translational modification of histone is acetylation of 
lysines (K) which is controlled through the actions of two families of 
antagonistic enzymes, histone acetyltransferases (HATs) and deacetylases 
(HDACs). They are involved in catalyzing the acetylation/deacetylation of 
histones, thereby acting as transcriptional activators and repressors 







group from acetyl-coenzyme A (acetyl-CoA) to ε-amino group of certain 
lysine side chains within a histone’s basic N-terminal tail region (Loidl, 1994). 
Acetylation of particular lysine residues in histone 3 and 4 (acetyl H3, acetyl 
H4) by acetyltransferases facilitates a more relaxed chromatin structure paving 
the way for gene activation. However, hypoacetylation of histone by 
deacetylases results in closed heterochromatin, which is often associated with 
gene repression. Thus the acetylation status of histones is maintained by the 
counteracting action of HATs and HDACs.  
1.9 Histone Methylation: Arginine and Lysine methylation 
Histone methylation plays an important role in a wide variety of biological 
processes which include transcriptional regulation, heterochromatin formation, 
X-chromosome inactivation and DNA methylation (Martin and Zhang, 2005). 
Unlike histone acetylation, histone methylation does not affect the overall 
charge of the histone tails. However, increase in the number of methyl group 
added increases its basicity and hydrophobicity. This in turn enhances the 
affinity of histone tails for anionic DNA which results in increased resistance 
to tryptic digestion (Baxter and Byvoet, 1975; Byvoet et al., 1972). 
Histones can be methylated on either arginine (R) or lysine (K) residues. 
Histone lysine methylation occurs predominantly on histones H3 and H4 and 
to a lesser extent in histone H1 (DeLange et al., 1970; Sarnow et al., 1981; 
Byvoet et al., 1986). Reported so far are six lysine residues, located on these 







are H3K9, H3K4, H3K27, H3K36, H3K79 and H4K20. Each of these lysine 
residues can be subjected to either mono-, di- or tri-methylation, inducing 
different biological responses unlike lysine acetylation. In addition to 
methylation of lysine residues, the other amino-acid residue which can be 
methylated is arginine. Methylation of arginine results in mono- or di-
methylation (symmetric or asymmetric).  
All of these residues are located within the unstructured N-terminal tail of the 
histone protein with the exception of H3K79 which resides in the globular 
domain (Feng et al., 2002). Depending on the sites of methylation it can signal 
either activation or repression. For example, methylation of H3K9, H3K27 
and H4K20 has been correlated with transcriptional repression whereas 
H3K79, H3K4 and H3K36 are associated with active transcription. On the 
other hand methylation of arginine-8 and -17 (H3R8me and H3R17me) is 
associated with transcriptional activation (Strahl et al., 2001). 
1.10 PRMTs and HKMTs 
Methylation of histone tails is one of the key events in epigenetic silencing 
(Martin and Zhang, 2005). Methylation of histone proteins is carried out by a 
group of conserved enzymes called histone methyltransferases (HMTs) which 
catalyze the transfer of one, two or three methyl groups to lysine and arginine 
residues of histone proteins. They are divided into two main groups: protein 








PRMTs catalyze the transfer of methyl groups from the co-factor S-adenosyl-
L-methionine (SAM), a methyl donor to the guanidino nitrogens of arginine 
residues (Gary and Clarke, 1998) whereas HKMTs catalyze the transfer of a 
methyl group from S-adenosyl-L-methionine (SAM) to a substrate lysine 
(Dillon et al., 2005; Qian and Zhou, 2006). 
Several histone lysine methyltransferases (HKMTs) have been recently 
identified (Strahl et al., 1999; Jenuwein et al., 1998; Kennison, 1995). Their 
catalytic activities are dependent on the evolutionarily conserved SET domain 
which occurs in most proteins that are known to possess histone lysine 
methyltransferase activities with the exception of Dot1/Dot1L. Biochemical 
and genetic analyses had revealed that methylation of different lysine residues, 
with the exception of H3K79 is catalyzed by different SET domain containing 
proteins (Zhang and Reinberg, 2001). It was originally identified as a 130-
residue protein present in the Drosophila PEV-modifier SU (VAR) 3-9 
(Tschiersch et al., 1994), the Polycomb-group protein Enhancer of Zeste [E 
(Z)] (Jones and Gelbart, 1993) and in the trithorax-group protein Trithorax 
(TRX) (Jenuwein et al., 1998).  
The SET domain has unique structure made up of a collection of variable 
length β-strands, a small amount of α-helical structure and an assorted 
collection of extended loops (Xiao et al., 2003). It is flanked by two distinctive 
domains at its N and C termini. There are totally seven main families of SET 







RIZ, SMYD and SUV4-20 families. The SUV39 family molecules were the 
first SET domain protein methyltransferases to be identified and characterized 
in most detail. SUV39h1 (Suppressor of variegation 39h1) was the first to be 
cloned and expressed (Rea et al., 2000). It was followed by its close relative, 
Suv39h2, which was also cloned and characterized (O’Carroll, 2000).  Since 
then many others have been characterized and almost all of them contain a 
SET domain which includes G9a, GLP/Eu-HMT1; SETDB1, SETDB2 and 
DIM5 (Tachibana et al., 2001; Rea et al., 2000; O’Carroll, 2000; Tamaru and 
Selker 2001; Zhang et al., 2002).  Since the discovery of first histone-lysine 
methyltransferases in the year 2000, sixty of them have so far been identified 
to be containing the SET domain. 
1.10.1 H3K9 methyltransferases: Suv39h1/h2 
The well-known SET domain containing H3K9 methyltransferases includes 
Suv39h1/h2, G9a/GLP, SETDB1, SETDB2 and DIM-5 (Tachibana et al., 
2001; Rea et al., 2000; O’Carroll, 2000; Zhang et al., 2002; Tamaru and 
Selker 2001). 
Suv39h1 and Suv39h2 belong to a family of peri-centromeric proteins. They 
share 59% identity over the entire length of the aminoacids and display an 
H3K9 selective HMTase activity (O’Carroll et al., 2000). Suv39h1/h2 act 
predominantly in the pericentric heterochromatin, where they play a crucial 
role in the maintenance of genome stability, and in turn, the development of 







Suv39h2 results in severe impairment of H3K9 trimethylation at the 
pericentric heterochromatic regions. As a consequence, defects such as 
impaired embryonic viability after day E12.5, perturbed chromosome 
segregation and non-homologous recombination between chromatids were 
observed (Peters et al., 2001). These results suggest that Suv39h1 and 
Suv39h2 are responsible for selective regulation of H3K9 trimethylation, 
1.10.2 H3K9 methyltransferase: G9a 
The predominant euchromatic H3K9 methyltransferase described in higher 
eukaryotes is G9a, also known as Euchromatic histone lysine N-
methyltransferase 2 (EHMT2), Bat 8, KMT1C, GAT 8, C6orf30 and NG36. It 
was originally mapped as a gene in the class III region of the human major 
histocompatibility complex locus on human chromosome 6 in an attempt to 
identify genes related to auto immune disorders (Dunham et al., 1990; Spies et 
al., 1989). It was later characterized by Tachibana and others (2001) as 
HKMTase whose catalytic activity was dependent on its SET domain. They 
found structural similarities between G9a and the Suv39h families of 
HKMTases. 
G9a is a large protein with very distinct domains. The human G9a is located 
on chromosome 6 p21.31 and the Mus musculus G9a is located on 
chromosome 17. It exists in two different isoforms generated by alternative 
splicing namely the short and long form. The human G9a, which was initially 







(Figure 1.10.2a) (Milner and Campbell, 1993). It was revealed by further 
analysis that the full length G9a (isoform a) is a product of NG36 and G9a 
transcripts (Figure 1.10.2a). In addition, shorter isoform which lacks exon 10 
(isoform b) has been characterized. In mouse, while the short form (G9a S) 
corresponds to human homolog, the long isoform (G9a L) (Figure 1.10.2a)  
differs with additional 53 residues repeats at the N-terminus compared to 
human full length G9a (isoform a). These additional amino acids have eight 
GR (Gly-Arg) repeats (Tachibana et al., 2002; Esteve et al., 2005). 
 
Figure 1.10.2a Diagrammatic representation of G9a domain structure 
(Adapted from Shankar et al., 2012. Epigenetics). The isoforms of human and 
mouse G9a are shown here. The Cysteine (CS) rich region, ankyrin repeats 
(ANK) and the SET domain with flanking preSET and postSET regions are 
shown. The site for methylation (Me), nuclear localization signals (NLS) and the 







The amino half of G9a has very little similarity with any conserved protein 
domain and it comprises of polyglutamic acid stretch, a cysteine rich region. 
However, the carboxyl half has homology with ANK (ankyrin) repeats 
comprising a series of 6 ANK repeats which are implicated in protein-protein 
interactions in diverse protein families (Davis et al., 1991). It is followed by a 
SET domain flanked by cysteine-rich (Cys) regions (Figure 1.10.2a). 
Study by Ogawa and others (2002) found out that G9a has closely related 
paralog, G9a-like-protein (GLP/EHMT1). GLP is 45% identical with human 
G9a and most of the difference lies in the amino-terminal third of the protein 
(Dillion et al., 2005). 
Biochemical studies have revealed that G9a and GLP possess the same 
substrate specificities on histones. Both enzymes have H3K9 
methyltransferase activity in vitro (Ogawa et al., 2002; Tachibana et al., 
2001). They form a homomeric and heteromeric complex via their SET 
domain when they are transiently expressed; however, endogenously they 
function exclusively as a heteromeric complex in a wide variety  of human and 
mouse cells and exert their enzymatic activity in vivo (Tachibana et al., 2005).  
G9a mediates both mono and di-methylation of H3K9 which is associated 
with transcriptional repression of many euchromatic genes (Tachibana et al., 
2001; Gyory et al., 2004; Nishio and Walsh, 2004; Duan et al., 2005). Studies 
have shown that in addition to mediating H3K9 mono- and di-methylation, 







Further studies have shown that G9a is also involved in H1 and H3K27 
methylation in vivo (Trojer et al., 2009; Weiss et al., 2010; Wu et al., 2011).  
In addition to histones, increasing number of evidences point out that non-
histone proteins too are direct targets for G9a mediated methylation with its 
recognition motif RK found in several non-histone proteins. Its non-histone 
target includes p53, CDYL1 (Chromodomain Y-like protein), WIZ (Widely 
interspaced zinc finger motifs protein), ACINUS and Reptin (Figure 1.10.2b)  
(Ueda et al., 2006; Sampath et al., 2007; Pless et al., 2008; Rathert et al., 
2008; Lee et al., 2010; Huang et al., 2010). While the biological consequence 
of such methylation of non-histone proteins has not been completely explored 
in each case, many transcription factors that are methylated by G9a result in 
negative regulation of their activity. For example, methylation of p53 at K373 
by G9a/GLP inhibits its transcriptional activity (Huang et al., 2010), whereas 
methylation of Reptin at K67 under hypoxic conditions enables reptin-
dependent inhibition of hypoxia responsive genes thereby creating a 
mechanism to adjust the cellular response to hypoxia (Lee et al., 2010). 
Interestingly G9a can automethylate itself at lysine residue K239 resulting in 
the creation of ARKT motif which is very similar to methylated H3 tail, 
making it a perfect candidate for interaction with HP1 thereby generating a 








Figure 1.10.2b G9a methylates non-histone proteins (Adapted from Nucleic 
Acids Res. 2010; 38:3503-11). 
1.10.2.1 Functions of G9a 
G9a plays an essential role in cellular differentiation, development and cell 
cycle progression. It is ubiquitously expressed in most tissues including fetal 
liver, bone morrow, thymus, spleen and peripheral blood leukocytes (Brown et 
al., 2001). G9a mediated H3K9 methylation in euchromatic regions is 
essential for early embryonic development which cannot be compensated by 
other H3K9 methyltransferases (Tachibana, et al., 2002). G9a deficient mouse 
embryos die between embryonic (E) days E9.5-E12.5 with severe growth 
retardation and accumulation of apoptotic cells as H3K9 methylation is 
drastically reduced in euchromatic regions.  
G9a plays a key role in early development by targeting key pluripotency genes 
for post-implantation repression. Oct-3/4, Nanog and Dnmt3L are early 
embryonic genes required for maintenance of pluripotency in embryonic stem 
(ES) cells. They are inactivated by G9a through the establishment of 







through de novo methylation by recruiting DNA methyltransferase Dnmt3a/3b 
via its ANK domain. The establishment of these two separate epigenetic marks 
prevents reprogramming of ES cells to an undifferentiated state. Consistent 
with this, G9a-/- ES cells differentiated with retinoic acid (RA) revert back to 
a pluripotent state by expressing Oct3/4 and Nanog when re-cultured in 
leukemia inhibitory factor (LIF) containing medium (Feldman et al., 2006; 
Epsztejn-Litman et al., 2008). In addition, a recent study shows that Oct3/4 
and Nanog expressions are sustained until E7.5 in G9a null embryos 
(Yamamizu et al., 2012). G9a has also been implicated in lineage specification 
and differentiation of distinct cell types. For example, study by Lehnertz and 
others (2010) shows that CD4
+ 
T from conditional knockout mice in which 
G9a is specifically deleted in T-cells fails to differentiate into Th2 cells 
impairing cytokine induction. 
There are evidences which show that G9a is recruited as a co-repressor by 
various transcriptional factors. 
Study by Nishio and Walsh have shown that CCAAT displacement protein/ 
cut homolog (CDP/cut), a transcriptional factor involved in most cellular 
processes including differentiation, development and proliferation, recruits 
G9a to the promoter p21 which results in the repression of the p21 gene 
(Nishio and Walsh, 2004). Another study has shown that growth factor 
independent 1 (Gfi 1), a transcriptional regulator oncoprotein which plays a 







hematopoietic stem cells, proliferation, apoptosis and differentiation, recruits 
G9a on the promoter of p21 resulting in an increase in H3K9 dimethylation 
thereby represses the expression of p21 (Duan et al., 2005). 
1.11 Chromatin modifying enzymes in undifferentiated myoblasts 
The myogenic activities of MRFs and MEF2 are both positively and 
negatively regulated by different chromatin modifying enzymes (McKinsey et 
al., 2000b). 
1.11.1 HDACs in the control of MyoD and MEF2 activities 
There are three distinct families of HDACs (Thiagalingam et al., 2003) that 
play a crucial role in maintaining the inactive state of muscle regulatory region 
in proliferating myoblasts. They are divided into three categories based on 
their homology to yeast protein: Rpd3p (class I), Hda1p (class II), and Sir2p 
(class III) (Ruijter et al., 2003; North and Verdin, 2004). Class I HDACs are 
expressed ubiquitously, whereas Class II HDACs are expressed in heart, 
skeletal muscle and brain. It was shown that HDAC1, which belongs to Class I 
HDAC subfamily, associates with MyoD through its bHLH domain in 
proliferating myoblasts (Figure 1.11) (Mal et al., 2001; Puri et al., 2001). This 
interaction mediates repression of muscle specific gene expression by 
deacetylation of histones on late muscle promoters MCK and MHC. In 
addition, HDAC1 can deacetylate MyoD in vitro, which may additionally 
contribute to keeping MyoD inactive (Mal and Harter, 2003; Mal et al., 2001).  







and HDAC1 is being disrupted by both the decline in the level of HDAC1 
protein and the hypophosphorylation of the tumor suppressor retinoblastoma 
protein, pRb. Dephosphorylation of pRb facilitates the formation of pRb-
HDAC1 complex which coincides with the disassociation of MyoD-HDAC1 
complex. The formation of this complex represses E2F target genes, which are 
responsible for the G1/S transition (Harbour and Dean 2000). This paves the 
way for transcriptional activation of muscle restricted genes and cellular 
differentiation of skeletal myoblasts (Puri et al., 2001). Conversely, ectopic 
expression of HDAC1 inhibits muscle differentiation. 
Furthermore, class II HDACs namely HDAC 4 and 5 which are expressed in 
proliferating myoblasts interact directly with MEF2 factors resulting in 
repression of MEF2-dependent transcription (Figure 1.11) (Lu et al., 2000; 
McKinsey et al., 2000a; McKinsey et al., 2000b). Consistently, over-
expression of HDAC4/5 inhibits differentiation by inhibiting both early and 
late muscle differentiation genes. They can efficiently block MyoD-dependent 
conversion of fibroblasts into muscle. This effect on MyoD function was 
mediated indirectly through MEF2.  
A third class of HDACs playing a critical role in regulating muscle 
differentiation program is SirT1 (Silent mating type information regulation 2 
homolog 1). It belongs to the family of sirtuins whose activity is NAD (+) 
dependent. It is recruited to muscle regulatory region on chromatin through its 







factor (P/CAF) and MyoD. This association facilitates the deacetylation of 
histones on muscle specific promoter and repression of muscle specific gene 
expression (Figure 1.11). However, upon differentiation, SirT1 expression 
and NAD+/NADH ratio declines resulting in reduced SirT1 activity, thus 
facilitating P/CAF to acetylate histone and MyoD. Over-expression of SirT1 
in myoblasts inhibits MyoD activity and thereby retards muscle 
differentiation. Conversely, reduction in SirT1 levels by RNA interference 
results in premature differentiation (Fulco et al., 2003). Thus all the three 
classes of HDACs are involved in preventing premature activation of muscle 
differentiation program. The repression of muscle specific genes by all the 
three classes of HDACs depends on their catalytic activities.  
In addition to HDACs, which mediate deacetylation of histones in 
proliferating myoblasts, the SET domain containing HKMTs are critical 
mediators of muscle gene repression. Interestingly, the recruitment of the 
HDAC complexes which results in the removal of acetate from histone on the 
muscle promoter, paves the way for subsequent H3K9 methylation by HKMTs 







Figure 1.11 Model for epigenetic regulation of promoters in undifferentiated 
muscle cells. (Adapted from Transcription. 2012; 3:16). In undifferentiated 
muscle cells, transcriptional repression of muscle gene expression is facilitated 
through recruitment of chromatin modifiers such as HDACs (HDAC1, HDAC4/5 
and SirT1) and HKMTs (Suv39h1 and Ezh2), that interact with MyoD, MEF2 and 
YY1 as shown. Suv39h1 and Ezh2 mediate two signature repressive chromatin 
marks H3K9me2/me3 and H3K27me3 respectively that restrain MyoD and MEF2 
activities resulting in closed chromatin configuration.  
1.11.2 Role of HKMTs in myogenesis 
Lysine methyltransferases: Suv39h1, which is associated with H3K9 
trimethylation at the pericentric heterochromatic regions, has been reported to 
be involved in skeletal muscle gene repression. It interacts with MyoD in 
proliferating myoblasts (Figure 1.11) and represses MyoD dependent skeletal 
muscle gene expression such as myogenin, MHC and non-muscle genes such 
as p21. This is by maintaining H3K9 trimethylation at the myogenin promoter 
through its HKMTase activity. However, upon differentiation, the level of 
Suv39h1 declines at protein level and thereby its association with MyoD 
paving the way for the activation of myogenin. When Suv39h1 is over-
expressed in C2C12 cells, it results in severe impairment of myotube 







differentiation permissible condition (Mal, 2006). The requirement of 
Suv39h1 for muscle gene repression in proliferating myoblasts was verified by 
siRNA mediated knockdown of Suv39h1 in muscle cell which resulted in 
activation of MyoD mediated muscle gene expression, confirming its role as 
checkpoint between proliferation and differentiation. 
The Polycomb group (PcG) represents an important and broadly conserved 
group of transcriptional repressors that are involved in maintaining the silent 
state of Drosophila homeotic (HOX) genes, which are essential for proper 
embryonic development. They remodel chromatin through epigenetic 
modifications which dynamically define cellular identity by maintaining 
transcriptional patterns, throughout development and adulthood 
(Shuettengrubber and Cavalli, 2009; Simon and Kingston, 2009). 
Enhancer of Zeste [E (Z)] which is the SET domain containing proteins with 
HKMTase activity belongs to the PcG family (Kuzmichev et al., 2002). Ezh1 
and Ezh2 are the two related genes that have been isolated and characterized 
(Laible et al., 1997). The Polycomb Repressor Complex (PRC2) contains 
three core subunits--Enhancer of zeste homolog 2 (Ezh2), Embryonic 
Ectoderm Development (EED), and Suppressor of Zeste 12 (SUZ12).  Ezh2, 
an H3K27 methyltransferase is the catalytic subunit of PRC2. It transfers a 
methyl moiety from S-adenosyl methionine to H3K27 resulting in H3K27 
trimethylation and thereby repressing gene expression. It is expressed during 







processes which include multi-cellular development, cancer development and 
stem cell biology.  
Ezh2 also plays a crucial role in skeletal muscle differentiation which is 
associated with transcriptional repression. Ezh2 is expressed in proliferating 
myoblasts (Figure 1.11) and declines upon differentiation and becomes 
undetectable in differentiated myotubes which coincides with the activation of 
terminal myogenic program (Caretti et al., 2004; Juan et al., 2009). Over-
expression of Ezh2 inhibits muscle differentiation and this differentiation 
block is mediated by the SET domain as the deletion of this domain renders 
Ezh2 incapable of blocking myogenic differentiation and transcription.  
Van der vlag and Otte (1999) showed that Ezh2 interacts with the histone 
deacetylase HDAC1 suggesting that both histone deacetylation and 
methylation are in sync to ensure transcriptional repression. This work was 
further expanded by Caretti and others (2004) who, based on their data on a 
two-step activation model of muscle gene expression, suggested that in 
proliferating myoblasts, the DNA-binding protein YY1 recruits a complex 
containing both Ezh2 and HDAC1 on the regulatory regions of 
transcriptionally inactive muscle specific genes. This transcriptional silencing 
is being mediated via histone methylation (H3K27) and histone deacetylation. 
However, upon transcriptional activation, chromatin repressive complexes of 
Ezh2, YY1 and HDAC1 disassociate and H3K27 becomes hypo-methylated. 







transcriptional regulators namely the serum responsive factor (SRF), whose 
interaction with the CarG-box is required for muscle specific transcription to 
proceed and the MyoD family of transcription factors and associated 
acetyltransferases. 
1.12 Chromatin modifying enzymes and remodeling complexes during 
differentiation 
1.12.1 P/CAF and p300  
P/CAF (p300/CBP associated factor) is one of the most important members of 
the HATs family. It is a transcriptional co-activator involved in various 
biological functions and part of the large protein complexes that include p300, 
another important acetyltransferase. They are both involved in acetylating 
H3K9 under diverse physiological conditions. In skeletal myogenesis, these 
transcriptional co-activators are essential for the myogenic factor MyoD to 
initiate the expression of skeletal muscle genes. Although it is difficult to 
delineate the distinct roles played by P/CAF and p300 as both of these factors 
can acetylate MyoD in addition to mediating histone acetylation, studies have 
revealed that p300 first acetylates H3 and H4 within the promoter region and 
then recruits P/CAF which then interacts (Figure 1.12)  and directly acetylates 
MyoD (Figure 3.1.12) at lysine residues 99, 102 and 104 which is conserved 
across species and in every member of MRF family resulting in its 
transactivation (Sartorelli et al., 1999; Dilworth et al., 2004; Aziz et al., 2010). 
This increases the affinity of MyoD for its transcriptional DNA target, 







transcription and differentiation. Thus, the acetylation of MyoD by P/CAF is 
functionally very relevant, as the study with mutant MyoD (RRR), wherein 
lysine residues at 99, 102 and 104 were substituted with arginine had clearly 
shown that non-acetylable MyoD loses its transcriptional and myogenic ability 
(Sarorelli et al., 1999). 
 
Figure 1.12 Model for epigenetic regulation of promoters in differentiated 
muscle cells. (Adapted from Transcription. 2012; 3:16). In differentiated 
muscle cells, the expression of co-repressors such as HDACs and HKMTs 
declines and also their association with MyoD. These paves way for subsequent 
recruitment of other chromatin modifiers such as HATs (PCAFs and P300), 
PRMTs (CARM1, PRMT5) and chromatin remodelling complexes (SWI/SNF, 
Brg1/Brm), mediating active chromatin marks H3K9ac, H3K14ac, H3R8me, 
H3R17me and extensive reprogramming of muscle promoters that facilitates open 
chromatin configuration and activation of MyoD and Mef2 dependent gene 











In addition to p300 and P/CAF, SWI/SNF remodeling complexes play an 
essential role in triggering myogenesis by reading the combinations of histone 
marks generated by muscle specific transcription factors and shaping the DNA 
of target muscle genes during myoblasts transition from muscle precursors to 
myotubes (Albini and Puri, 2010). 
1.12.2 ATP-dependent chromatin remodeling enzymes: SWI/SNF 
complex 
On the basis of similarities of their ATPase sub-units, the ATP-dependent 
chromatin remodeling complexes are divided into three classes, namely, 
Swi2/Snf2, ISW1, and Mi-2 proteins. These ATPases are the catalytic 
subunits, the motors of the complexes. They remodel chromatin structure by 
hydrolyzing ATP to enhance the accessibility of chromosomal DNA which is 
a prerequisite for various steps in transcription (Eisen et al., 1995; Lusser and 
Kadonaga, 2003).     
There is a variety of chromatin remodeling enzymes and one of the important 
and best studied classes among these enzymes is SWI/SNF. It is a 2MDa 
multi-subunit DNA dependent ATPase which plays an important role in the 
regulation of gene transcription by altering chromatin structure (Cairns et al., 
1994; Cote, 1994). It comprises of the products of several genes originally 
identified in yeast by defects in mating type switching (SWI) and/or sucrose 
fermentation (SNF: sucrose non-fermenter) and is highly conserved among 
eukaryotes. The unique feature of this family is the presence of a 







related gene 1 (BRG1) which facilitates recognition and binding with 
acetylated lysine residues within histone N-terminal tails in vitro (Horn and 
Peterson, 2001; Martens and Winston, 2003). In addition to these ATPase sub-
units which provide the enzymatic activity necessary for chromatin 
remodeling, there are 4-12 sub units referred to as Brg1 and Brm-associated 
factor (BAF) which regulate the ATPase activity (Simone et al., 2006). They 
mediate interaction with specific transcription factors thereby controlling cell 
type-specific and signal regulated SWI/SNF distribution along the genome 
(Chi et al., 2004). 
Studies have shown that the interaction between Brg1, Brm and acetylated 
histones accounts for the stable binding of SWI/SNF to hyperacetylated 
chromatin within the regulatory regions of muscle genes. SWI/SNF chromatin 
remodelers facilitate muscle-specific gene expression by altering chromatin 
structure at the regulatory regions of both early and late myogenic genes (de la 
sarna et al., 2001; de la sarna et al., 2005; Ohkawa et al., 2007; Simone et al., 
2004). SWI/SNF interacts with both MyoD and Mef2 proteins and this 
interaction is necessary for MyoD to activate muscle gene transcription 
(Figure 1.12). Recently, the findings of Forcales and others (2012) revealed a 
critical role for BAF60c during skeletal myogenesis. They identified BAF60c 
as a MyoD binding partner (Figure 1.12). Importantly, their finding revealed 
that BAF60c co-localizes with MyoD at the myogenic promoter prior to the 
activation of transcription without other SWI/SNF subunits such as Brg1. 







most of its target genes resulting in the impairment of their transcription. This 
absence of MyoD also prevented the binding of BAF60c to the chromatin of 
myogenin suggesting BAF60c and MyoD facilitate each other’s bindings to 
muscle specific loci. 
1.12.3 PRMT4 and PRMT5 
Prmt4 also known as coactivator arginine methyltransferase1 (CARM1) 
belongs to type I methyltransferase which dimethylates histones H3 arginine 
R17. It was originally discovered in a yeast two-hybrid screen to identify 
proteins that interact strongly with the glucocarticoid receptor interacting 
protein 1 (GRIP). It interacts with and methylates transcriptional co-activators 
such as p300 and GRIP1. CARM1 mediated methylation of R17 of histone H3 
enhances GRIP1 mediated transcriptional activation (Chen et al., 1999; Bauer 
et al., 2002). 
PRMT5, which is a type II methyltransferase, was first discovered in a yeast 
two-hybrid screen to identify proteins interacting with JAK2. Hence it is also 
known as Janus kinase binding protein 1 (Branscombe et al., 2001). It 
symmetrically dimethylates histone H3 arginine 8 (H3R8) and plays a crucial 
role in transcriptional repression. 
Studies by various groups have shown that these two members of the PRMT 
family, CARM1 and PRMT5 play a crucial role in skeletal myogenesis.   
CARM1 functions as a secondary co-factor for Mef2 mediated transcription in 







manner in the regulation of muscle specific gene expression. It is expressed in 
proliferating myoblasts and increases upon differentiation and reaches peak in 
multinucleated myotubes. In vitro studies show that CARM1 interacts with 
GRIP1 as well as MEF2 proteins directly. However, it doesn’t interact with 
either MyoD or myogenin. In addition, it has been demonstrated that MEF2-
GRIP1 complex interacts with CARM1 in the cellular context as well, and 
thus accounts for the co-activation of MEF2C mediated transcription (Figure 
1.12). Hence, it positively regulates skeletal myogenesis, as inhibition of 
CARM1 inhibits differentiation and disrupts the expression of myogenin and 
MEF2 that are involved in initiating the differentiation cascade. 
Studies have shown that PRMT5 mediated methylation of H3R8 is essential 
for the interaction of the SWI/SNF ATPase Brg1, for chromatin remodeling of 
myogenin locus and for all subsequent events leading to gene activation 
(Figure 1.12). The loss of PRMT5 results in the substantial reduction in the 
recruitment of Brg1 at the myogenin promoter and this affects the subsequent 
events such as histone methylation, ATP-dependent chromatin remodeling, 
and MyoD binding resulting in abrogation of myogenin expression. Thus the 
arginine methyltransferase PRMT5 is important for MyoD mediated skeletal 









1.13 Role of HKMTs in skeletal muscle pathology 
It is clear from all the above discussions that a crucial role is played by 
epigenetic chromatin modifiers such as HATs, HDACs and HKMTs in 
modifying chromatin to epigenetically promote or repress transcription. Thus 
the impact of these chromatin modifying enzymes as well as the chromatin 
remodelers on transcription factors such as MRFs and MEF2 translates into a 
vital role in shaping almost all aspects of skeletal muscle development 
positively and negatively. However, any aberrant form of either transcription 
factors or their regulators and their deregulation may lead to numerous muscle 
diseases such as congenital myasthenias, myotonic dystrophy, 
rhabdomyosarcoma and defects in skeletal muscle regeneration (Martin et al., 
2003). 
There are growing evidences which point out that transcription factors such as 
MyoD associate with histone modifying enzymes namely HDACs and 
HKMTs even in differentiation permissible condition that results in abrogation 
of their transcriptional activity leading to defect in skeletal muscle 
differentiation and tumorigenicity such as Rhabdomyosarcoma (Lee et al., 
2011; Ciarapica et al., 2009). 
1.13.1 HKMTs in Rhabdomyosarcoma 
Rhabdomyosarcoma (RMS) is a highly malignant and most common soft 
tissue sarcoma of childhood and adolescence which accounts for 







stated to be 4 to 7 cases per million children (Kramer et al., 1983).  It 
continues to pose a major challenge in clinical management in spite of 
advances in its treatment, due to recurrence and metastasis. It originates as a 
consequence of disruption of growth and differentiation pathways of 
myogenic precursor cells. As a result RMS has poorly differentiated 
mesenchymal stem cells with morphological and biochemical similarities to 
primitive skeletal muscle cells.  
RMS is classified into two major morphological subtypes, embryonal (ERMS) 
and alveolar (ARMS), and several minor sub-types based on their 
histopathologic features. ERMS is the most common (60%) and treatable sub-
type occurring usually in infants and children less than ten years of age, most 
frequently in the head and neck, genitourinary tract, and the retroperitoneum. 
ARMS accounts for approximately 25-30% of RMS and represents a highly 
aggressive tumor in adolescents and young children. It occurs typically in the 
trunk and extremities and has a poorer prognosis (Tsokos et al., 1992). These 
clinical and pathologic differences between ERMS and ARMS occur as a 
result of distinct genetic alterations and clinical prognosis (Merlino and 
Helman, 1999; Anderson et al., 1999).  
ARMS carry a distinct genetic signature: Pax3-FKHR and Pax7-FKHR fusion 
products generated as a result of 2;13 or 1;13 of pathogenetic chromosomal 
translocations, the consequence of these specific translocations being altered 







compared to wild-type proteins. This paves the way for harboring oncogenic 
behavior by altering growth, differentiation and apoptosis pathways. However, 
ERMS is less genetically defined (Mercado et al., 2008) and has allelic loss at 
chromosome 11p15.5. 
In spite of the morphologic differences and the fact that they affect different 
patient populations, ERMS and ARMS share the common characteristic of 
defects in both differentiation program and cell cycle arrest which result in 
uncontrolled proliferation and incomplete myogenesis. This is despite the fact 
that RMS cells generally express one or both of the key early myogenic 
regulators of differentiation namely Myf5 and MyoD as well as its target gene, 
myogenin (Scrable et al., 1989; Sebire et al., 2003; Ren et al., 2008; Tapscott 
et al., 1993). Although it is well known that MyoD has the capability to drive 
the entire process of skeletal muscle terminal differentiation and when stably 
transfected in non-muscle cells can convert it to skeletal muscle cells, yet the 
ability of MyoD in bringing about such differentiation in RMS is impaired. 
One of the main reasons put forth for such defectiveness is the loss of MyoD’s 
transactivation ability. Although it is able to bind to its cognate DNA 
sequences, MyoD fails to induce muscle gene transcription in the RMS cells. 
Moreover, ectopic expression of MyoD is not sufficient to induce myogenesis. 
It was concluded by Tapscott and others (1993) based on their experimental 
results that the inactivity of MyoD in RMS may be due to the presence of 
inhibitor that may suppress its function or the absence of a factor that enables 







It has been shown by other studies that RMS might arise as a result of 
disruption of mutually exclusive yet tightly coupled pathways of muscle 
differentiation and growth arrest. There are several evidences which point to 
the involvement of p21 in the process of normal muscle differentiation by 
inhibiting CDK’s thereby inducing cell cycle arrest. MyoD which is involved 
in the induction of muscle-differentiation specific genes, promotes cell cycle 
exit by inducing the expression of p21 (Halevy et al., 1995). However, in 
RMS, the expression of MyoD does not lead to cell cycle arrest or terminal 
differentiation, implicating that MyoD pathway is functionally defective. 
Study by Weintraub and others in 1997 revealed that the expression of p21 
and MyoD has an inverse relationship in these tumors. For example, those cell 
lines and tumors that express high levels of MyoD were found to express low 
levels of p21 and vice-versa. This result suggested that endogenous MyoD/p21 
pathway is highly compromised and hence unable to induce cell cycle arrest 
and terminal differentiation. However, forced expression of wild-type p21 
resulted in marked inhibition of cell proliferation. Thus they concluded from 
their findings that concurrent expression of MyoD and p21 is critical for the 
integrity of the differentiation pathway in skeletal muscle cells and such 
cooperative expression is defective in RMS pathogenesis. 
There are growing evidences which confirm the relevance of epigenetic 
alterations such as post translational modifications in the progression of cancer 
(Jones et al., 2002; Ting et al., 2006; Sparmann et al., 2006). The one in 







methylation patterns of histones H3 and H4. 
A recent study by (Lee et al., 2011) had shown that histone methyltransferase 
Suv39h1 (KMT1A) aberrantly mediates H3K9 methylation in alveolar 
rhabdomyosarcoma (ARMS). Their study shows that Suv39h1 is over-
expressed in differentiation permissible condition thereby preventing ARMS 
growth arrest which is a pre-requisite to myogenic differentiation.  
The previous study from the same lab (Mal et al., 2006) had shown that 
Suv39h1 is expressed in proliferating myoblasts in C2C12 cells and associates 
with MyoD and represses MyoD dependent muscle gene expression through 
its HKMTase activity thereby maintaining the undifferentiated state in 
myoblasts. However, its expression declines upon myogenic differentiation 
and thereby its association with MyoD. Similarly in human skeletal myoblasts 
(HSMM), Suv39h1 is expressed in proliferating myoblasts and declines upon 
differentiation. Conversely, its expression is deregulated in ARMS cells as it is 
induced in differentiation permissible condition resulting in increased 
association between MyoD and Suv39h1causing a substantial increase in the 
occupancy and activity of Suv39h1 on the myogenin promoter. However, 
knock-down of Suv39h1 restores MyoD transcriptional activity, arresting cell 
proliferation and induces terminal differentiation of ARMS cells. Thus their 
study demonstrated that down-regulation of Suv39h1 ablates its ability to 
maintain the cells continuously at proliferative state resulting in shifting of the 







as seen by the compromised ability of rhabdomyosarcoma cell to form 
colonies on soft agar and tumors in mice. 
Additional findings point to a role of other HKMTs in rhabdomyosarcomas. 
Ezh2, a H3K27 methyltransferase which is another well-known negative 
regulator of skeletal myogenesis, is over-expressed in various tumors 
particularly in aggressive and poorly differentiated breasts and prostrate 
carcinomas and is associated with poor prognosis (Simon et al., 2008; Caretti 
et al., 2004). Consistent with this, studies have shown that Ezh2 is over-
expressed in RMS compared with normal myoblasts (Ciarapica et al., 2009). 
This work was further expanded by another group recently (Marchesi et al., 
2012) to analyze the functional role of Ezh2 in RMS. They further confirmed 
that Ezh2 is over expressed in RMS cell lines and in addition, siRNA mediated 
knockdown of Ezh2 in rhabdomyosarcoma cells resulted in the re-activation of 
muscle-specific genes and partial recovery of the differentiated phenotype 
with the formation of myotube-like cells. Moreover, down-regulation of Ezh2 
restores MyoD binding to its target muscle-specific genes in RMS cells. 
These studies shed light on the altered expression of HKMTs in pathological 
conditions and their impact on the normal functions of major transcription 
factors like MyoD that lead to defect in the execution of terminal 
differentiation programs. Thus targeting HKMTs through pharmacological 
intervention may lead to treatment of aggressive pediatric muscle cancer and 







1.14 Perspectives and aims of study 
The major aim of this thesis is to analyze the epigenetic regulation of skeletal 
myogenesis. 
Skeletal myogenesis is a multi-step process, which involves commitment, 
proliferation and differentiation of skeletal muscle precursor cells and 
culminates in the formation of muscle. This process requires the coordinated 
expression of various transcription factors like MyoD, Myogenin, Myf5 and 
MRF4 that control different stages of myogenesis. 
There is growing evidence that recruitment of chromatin modifying enzymes 
and remodeling complexes epigenetically reprogram muscle promoters that 
either permit or block MRF and Mef2 activities. 
Although MyoD and Mef2 factors are expressed in committed myogenic 
precursor cells and have the ability to trigger the differentiation program, their 
transcriptional activity is prevented by recruitment of HDACs and HKMTs. 
For instance, in undifferentiated myoblasts, muscle promoters exhibits a key 
epigenetic modification on H3K9 characterized by reduced acetylation, a mark 
of active transcription, as well as increased di-methylation (H3K9me2) which 
is a transcriptional repression mark (Zhang et al., 2002; Mal and Harter, 
2003). This occurs as a result of association of MyoD with co-repressors such 
as HDAC1, and the SET domain containing histone methyltransferase 
Suv39h1 that mediates H3K9 deacetylation and tri-methylation (H3K9me3) 
respectively (Puri et al., 2001; Mal et al., 2001; Mal, 2006). In addition to 







Ezh2 (Caretti et al., 2004). Thus reduced acetylation and increased 
methylation results in a closed chromatin configuration that restrains MyoD 
activity. However upon differentiation, the expression of HDACs and HKMTs 
declines and also their association with MyoD. Subsequently other chromatin 
modifiers such as p300 and P/CAF (HATs) are recruited. p300 mediates 
acetylation of H3 and H4 at muscle promoters followed by P/CAF which 
interacts and directly acetylates MyoD. This results in transactivation of 
MyoD which in turn activates genes important in muscle differentiation 
(Sartorelli et al., 1999; Dilworth et al., 2004; Aziz et al., 2010). 
G9a is a predominant H3K9 methyltransferase in euchromatin and is 
associated with transcriptional silencing. However, it has not been implicated 
in regulation of skeletal myogenesis, although the role of other histone lysine 
methyltransferases like Suv39h1 and Ezh2 are well established in skeletal 
muscle development and differentiation. 
The first part of my thesis work demonstrates that G9a is a negative regulator 
of skeletal muscle differentiation that plays a dominant role in MyoD 
activation through chromatin modifications as well as its methylation. It 
inhibits myogenesis in a methyltransferase activity dependent manner. G9a 
overexpressing cells exhibit increased H3K9me2 on myogenic promoters. In 
addition, G9a interacts with MyoD and methylates at K104 restraining MyoD 
transcriptional activity. Interestingly, K104 is an overlapping site for G9a 
mediated methylation and P/CAF mediated acetylation, suggesting the 







the second part of my thesis work demonstrates the cross-talk between G9a, 
and P/CAF to control MyoD activity. Protein interaction studies revealed that 
G9a alters the ability of P/CAF to interact with MyoD and correspondingly 
MyoD acetylation. Moreover, depletion of G9a in proliferating myoblasts by 
siRNA mediated knockdown alters the kinetics of acetylation. In addition to 
its impact on MyoD acetylation, the use of a selective P/CAF inhibitor in 
muscle cells followed by microarray analysis has allowed us to identify novel 






















2. Materials and Methods 
2.1 Preparation of Basal Media 
Basal media was prepared with Dulbecco’s Modified Eagle’s Medium 
(DMEM) with high glucose (Sigma Aldrich) supplemented with 3.7g/L of 
Sodium bicarbonate (Sigma Aldrich) and 1% penicillin-streptomycin (Sigma 
Aldrich), which was then filtered using a filtration unit. 
2.2 Cell culture 
2.2.1 C2C12 Cell Culture 
C2C12 cells (mouse myoblasts cell line) were cultured at 50-60% density in 
growth medium (GM) containing DMEM supplemented with 20% fetal 
bovine serum (FBS) (Hyclone) and 1X penicillin-streptomycin. For 
differentiation assays, C2C12 cells were cultured at high density (80-90%) in 
GM and induced to differentiate in differentiation medium (DM) made in 
DMEM supplemented with 2% horse serum (Gibco).  
2.2.2 HEK293T and C3H10T1/2 Cell Culture 
HEK293T and C3H10T/2 (10T1/2) cells were cultured in DMEM 
supplemented with 10% FBS. 10T1/2 cells were switched to DM (DMEM 
supplemented with 2% horse serum) for myogenic conversion assays. 
2.2.3 Rh30 Cell culture 
Rh30 (ARMS cell line) cells were cultured at 50-60% density in RPMI 1640 
basal medium supplemented with 10% FBS and switched to DM (RPMI 1640 







All cultures were incubated at 37˚C, in a humidified 5% CO2 incubator 
(Sanyo). 
2.3 DNA constructs 
Plasmids EGFP-G9a, EGFP-G9a∆SET (1-830 aa), Flag-G9a (1001 aa), Flag-
G9a∆ANK (814 aa) were kindly provided by Dr. Martin J. Walsh, (Mt Sinai 
School of Medicine, New York, NY 10029). Myc-MyoD, Flag-MyoD, Flag-
MyoD (K104R), Flag-MyoD (RRR) were kindly provided by Dr.Vittorio 
Sartorelli (National Institute of Arthritis, Musculoskeletal and Skin diseases, 
Bethesda, MD20892) and Flag-P/CAF was kindly provided by Dr.Yoshihiro 
Nakatani (National Institutes of Health). For luciferase reporter assays, a 
firefly luciferase reporter construct (4R-tk-Luc) containing four tandem E 
boxes from the Muscle Creatine Kinase (MCK) enhancer upstream of the 
thymidine basal promoter was used (kindly provided by Dr.Robert S. Krauss, 
Mt Sinai School of Medicine, New York, NY 10029 ). 
2.4 Treatment of cells with G9a and PCAF inhibitors 
2.4.1 Treatment of cells with BIX-01294 
BIX-01294 (a diazepin-quinazolin-amine derivative), a small molecule 
inhibitor of G9a and GLP methyltransferase activity (Kubicek et al., 2007, 
Gazzar et al., 2008, Chang et al., 2009) was used. To determine the optimal 
BIX-01294 concentration, 0 to 6µM was tested in C2C12 cells and 
C3H10T1/2 cells. Treatment with 2.5µM resulted in enhanced differentiation 
and a concentration higher than 4µM resulted in cell death. Thus 2.5µM was 







C3H10T1/2 cells cultured in GM were incubated with 2.5µM BIX-01294 for 8 
hours and cells in DM were incubated with 2.5µM BIX-01294 for another four 
days. As controls, cells were treated with 2.5µM DMSO (vehicle). Cell lysates 
were collected at the end of respective time points and analyzed by western 
blot. Differentiated cells were immunostained with anti-MHC antibody. 
2.4.2 Treatment of cells with UNC0638 
UNC0638, a chemical probe which selectively inhibits G9a and GLP 
methyltransferase activity with higher potency and lower toxicity (Vedadi et 
al., 2011) compared to BIX-01294 was used. After trying different titrations 
(0-3µM) in Rh30 cells, 1.5µM was found to be the optimal concentration and 
was used for subsequent experiments. 
Rhabdomyosarcoma cells (Rh 30) were seeded in a six-well plate at a density 
of 0.1 million cells for day 0 time point and 0.2 million cells were seeded for 
differentiation. Cells were treated with 1.5µM of UNC0638; and control cells 
were treated with 1.5µM of DMSO. The following day, cell lysates were 
collected for Day 0 time point. For differentiation, medium was changed from 
GM to DM along with 1.5µM of UNC0638. Cell lysates were collected at 
different time points as indicated in the figures (results section). 
 2.4.3 Treatment of cells with embelin 
Embelin (a hydroxy benzoquinone class of natural compound), a small 
molecule inhibitor of PCAF was used. To determine the optimal embelin 
concentration, 0 to 20µM was tried in C2C12 cells. As treatment with 10µM 







10µM resulted in cell death; 10µM was used for subsequent experiments. An 
equivalent concentration of its analogue derivative, MJTK-4 (an inactive 
compound) was used as control, in addition to DMSO treated cells.  
2.5 Transformation 
100ng of DNA was added to 25-50µL of DH5α competent cells, mixed by 
tapping gently and incubated on ice for thirty minutes. Cells were subjected to 
heat shock at 42ºC for 45 seconds and quickly cooled on ice for 2 minutes. 
The transformed cells were grown in 1mL of pre-warmed LB (Luria-Bertani) 
broth in an orbital shaker at 37ºC at 200 rpm for 1 hour. The LB broth 
containing transformed cells were centrifuged at 13,000 rpm for 1 minute; the 
supernatant was decanted, and 100µL of fresh LB broth was added to the 
pellet for resuspension. 70µL of the cultured medium were plated into LB agar 
plates containing ampicillin (100µg/mL) and incubated overnight at 37˚C. The 
next day, colonies were picked and inoculated in a starter culture of 2mL of 
LB medium containing ampicillin and incubated in an orbital shaker at 37˚C 
overnight with vigorous shaking (200 rpm). After overnight incubation, the 
starter culture was diluted by transferring 2mL of the starter culture into1L 
conical flask containing 300mL of LB-ampicillin and grown overnight in an 
orbital shaker at 37˚C with vigorous shaking (200 rpm).  
On the next day, the bacterial culture was transferred into centrifuge (GSA) 
bottles (Nalgene-Thermo Scientific) and harvested by centrifugation in GSA 
rotor at 5000 rcf for 15 minutes at 4˚C. The supernatant was decanted and 







resuspended completely in 4mL of buffer P1 (with RNaseA added) by 
vortexing and pipetting. The resuspended bacterial pellet was transferred to 
50mL tube. The bacterial cells were lysed using 4mL of buffer P2 by 
vigorously inverting the sealed tubes 4-6 times and incubated at room 
temperature for 5 minutes. Pre-chilled buffer P3 was then added to the lysate, 
mixed thoroughly and was incubated on ice for 15 minutes.  
After 15 minutes incubation on ice, the lysate was centrifuged at 4000 rpm for 
30 minutes at 4˚C; the clear supernatant was then collected in another 50mL 
eppendorf tube. The supernatant was again centrifuged at 4000 rpm for 15 
minutes at 4˚C to avoid the presence of any suspended material which could 
clog Quiagen-tip. Qiagen midi column was equilibrated with 4mL of buffer 
QBT. The cleared lysate was filtered into the pre-equilibrated column. The 
column was washed with 10mL of buffer QC. The wash was repeated one 
more time with 10mL of buffer QC to ensure removal of all contaminants. The 
DNA was then eluted using 5mL of buffer QF, precipitated by adding 
isopropanol, and centrifuged at 13,000 rpm for 30 minutes at 4˚C. Then the 
supernatant was carefully decanted and the DNA pellet was washed with 2mL 
of 70% ethanol; centrifuged at 13,000 rpm for 10 minutes at 4˚C. The 
supernatant was again carefully decanted and the pellet was air-dried for 10 
minutes. The air-dried DNA pellet was redissolved in TE buffer (pH 8.0). The 









2.6 Transient Transfection 
2.6.1 Transient Transfection of plasmids 
A day before transfection, one million cells were seeded on a 100 mm-
diameter plate. The plasmid was transfected into cells using Lipofectamine 
Plus (Invitrogen) according to manufacturer’s protocols. 
Briefly, on the day of transfection, 4µg plasmid was diluted in 300µL of basal 
DMEM (without serum) in a 1.5mL eppendorf tube. To this, 15µL of Plus 
reagent was added, mixed and incubated for 15 minutes at room temperature. 
In another tube, 20µL of lipofectamine reagent was diluted in 300µL of basal 
DMEM (without serum) and mixed.  
The pre-complexed DNA (with Plus reagent) was mixed with diluted 
lipofectamine reagent and incubated for 15 minutes at room temperature. The 
medium for cells plated for transfection was replaced from serum-containing 
to serum-free medium. 
After 15 minutes of incubation, the transfection mixture in the tube was added 
in a drop-wise manner to the cells. The cells were incubated at 37ºC in 5% 
CO2 incubator for 4-5 hours. At the end of incubation time period, the basal 
DMEM (without serum) was replaced with complete medium. 
 2.6.2 Transient Transfection for dual-luciferase reporter assay 
10T1/2 cells were transfected with 50ng of 4R-tk-Luc and MyoD in the 
absence and presence of 50ng of EGFP-G9a or EGFP-G9aΔSET in a 24-well 







4R-tk-Luc in the absence and presence of 50ng of EGFP-G9a or EGFP-
G9aΔSET. 
Transfection was carried out using the Lipofectamine Plus (Invitrogen) 
according to the manufacturer’s protocol. 5ng of renilla luciferase was used as 
an internal control. pCS2-empty expression was added to normalize the 
amount of DNA. 
 After 48 hours of transfection, media was removed from the plate and rinsed 
with 1XPBS. Cells were harvested by lysing with 1X Passive Lysis Buffer and 
gently rocking the plate for 15 minutes at room temperature. The luciferase 
activities were measured using Tecan microplate reader and Magellan 6 
software.100μL of LAR II was added to 20μL of the lysates dispensed in a 96-
well plate and measured for firefly luciferase signal. This was followed by the 
addition of 100μL of Stop and Glo reagent to stop the firefly luciferase 
activity and measure the renilla luciferase activity. The firefly luciferase 
reading was normalized to that of renilla luciferase signal for each individual 
well. All the transfections were carried out in triplicates and repeated at least 
two times. 
2.6.3 Transient transfection of siRNAs 
A day before transfection, 0.1 million cells were seeded in a six-well plate. On 
the day of transfection, each well was transfected with 100nM of siRNA 
specific for G9a (Dharmacon; on-target plus smart pool) or control scrambled 







Sequences for human and mouse siG9a are shown in Table II and Table III 
respectively.  
The siRNAs were transfected into the cells using Lipofectamine RNAi Max 
(Invitrogen) according to manufacturer’s protocol. Six microliters of siRNAs 
were added to 100μL of basal DMEM and 3μL of RNAi Max Lipofectamine 
was added to 100μL of basal DMEM. The two reaction mix tubes were 
combined, mixed well and incubated for 15 minutes at room temperature. The 
mixture was added drop-wise to each well containing 1mL of basal DMEM. 
After three hours, transfection medium (serum free basal DMEM) was 
aspirated and replaced with fresh complete medium. 48 or 72 hours after 
transfection, C2C12 myoblasts or Rh30 cells were switched from GM to DM 
for differentiation time points. 
 2.7 Western Blotting 
 2.7.1 Protein Extraction 
At appropriate time points, the medium was aspirated from the 100 mm-
diameter plate or six-well plates using pasteur pipette and washed with 3mL of 
1X PBS to remove any residual medium. Total protein extraction was carried 
out using Radioimmunoprecipitation assay (RIPA) lysis buffer containing 
50mM NaCl (Numi), 1mM EDTA (Sigma-Aldrich), 50mM Tris-HCl (1
st
 
Base), 1% Triton X-100 (USB), 0.05% SDS (Numi), 1X Protease inhibitor 
(Roche) and 0.1% Sodium deoxycholate (Sigma-Aldrich). Lysates were 
collected using cell scraper (SPL Life Sciences) and transferred to pre-chilled 







rotator (Barnstead Thermolyne) at 4ºC for 30 minutes before being spun 
(Eppendorf Centrifuge 5417R) at 12000 rpm for 15 minutes at 4ºC. The 
supernatant was transferred to another empty 1.5mL eppendorf tube and stored 
at -20ºC, while the pellet was discarded. 
2.7.2 Bradford Protein Assay 
Protein concentration was measured using Bio-Rad Protein Assay Kit (Bio-
Rad). One part of the Bradford reagent was diluted with four parts of MilliQ 
water. 1μL of protein sample was added to 1mL of diluted reagent in a 
cuvette, vortexed to ensure homogeneity and incubated at room temperature 
for 5 minutes (cuvette containing 1mL of diluted reagent was used as a blank). 
Protein concentration was measured by absorbance (ABS) at 595 nm using 
spectrophotometer. 
2.7.3 SDS-PAGE 
A 10% resolving gel and 4% stacking gel were casted using 30% Acrylamide-
Bis solution 37.5:1 (2.6% C). Protein lysate was mixed with 1X loading dye in 
1.5mL eppendorf tube and heated at 95ºC for 5 minutes. Protein samples were 
spun at 12,000 rpm for 1 minute and loaded into wells of SDS-PAGE gel. Gel 
containing protein lysate samples were electrophoresed into 1X running buffer 
(3.03g Tris base, 14.4g glycine, 10ml of 10% SDS/L) at 80V for fifteen 
minutes, followed by 95V for two hours until the dye front reached the end of 
the plate. After electrophoresis, the gel was removed and proteins were 







Healthcare) in 1X transfer buffer (3.03g Tris base, 14.4g glycine, 20% 
ethanol/L) for 1.5 hours at 100V. 
2.7.4 Immunodetection 
The nitrocellulose membrane with protein was blocked with 5% w/v skimmed 
milk in 1X PBST with 0.1% Tween-20 (Bio-Rad) for one hour at room 
temperature. The membrane was incubated with diluted primary antibody in 
5% milk in PBST for one hour at room temperature or overnight in 4°C. 
Unbound primary antibody was removed by washing thrice with 1X PBST. 
Following this, the membranes were incubated with horse radish peroxidase 
conjugated secondary antibodies (goat anti-mouse or rabbit IgG (Sigma) at 
1:5,000 dilution for one hour at room temperature. 
The following primary antibodies required overnight incubation at 4ºC : rabbit 
polyclonal anti-MyoD (Santa Cruz Biotechnology) at 1:500 dilution, rabbit 
polyclonal anti-Myogenin (Santa Cruz Biotechnology) at 1:400 dilution, 
mouse monoclonal anti-GFP (Santa Cruz Biotechnology) at 1:400 dilution, 
rabbit polyclonal anti-G9a (Cell signaling technology) at 1:300 dilution, rabbit 
polyclonal anti-acetyl-lysine (Ac lysine) (Abcam) at 1:1000 dilution, rabbit 
polyclonal anti-methyl-lysine (Me lysine) (Abcam) at 1:1000 dilution. 
The following primary antibodies were all incubated at room temperature for 
one hour: monoclonal anti-Myc (Sigma) at 1:2000 dilution, monoclonal anti-
Flag (Sigma) at 1:1000 dilution, monoclonal anti-Troponin T (Sigma) at 







monoclonal anti-EF1-α (Upstate Biotechnology) at 1:1000 dilution; (the last 
two were used as internal controls). 
2.7.5 Visualization 
The bound antibodies were detected using the detection reagent (Amersham 
ECL Western Blotting System, GE Healthcare) for one minute. The blot was 
exposed to X-ray film (Thermo Scientific) for different exposure times. 
2.8 Immunoprecipitation 
The following steps were used for co-immunoprecipitation: 
20μL of anti-mycagarose beads (Sigma Aldrich) or anti-flag agarose beads 
(Sigma Aldrich) were added to 1.5mL eppendorf  tubes and washed twice with 
1x PBS. The supernatant was decanted and the beads were retained by 
centrifuging at 12,000 rcf. To the beads, 500μg of cell lysates were added and 
topped up to 500μL with RIPA lysis buffer containing 1X protease inhibitor. 
The tubes were incubated overnight on a rotator at 4ºC. The next day, the 
samples were spun at 10,000 rcf for 5 minutes at 4ºC. The supernatant was 
discarded carefully without disturbing the beads. The beads were washed with 
RIPA lysis buffer (without 1X protease inhibitor) four times for five minutes 
in rotator at 4ºC. At the end of the last wash, the supernatant was removed by 
centrifugation at 10,000 rcf for three minutes and the beads were retained. To 
the beads, 2X sample buffer was added, mixed gently by tapping. Samples 
were boiled on the heat block (for denaturation of proteins) at 95ºC for 10 








The following steps were carried out for endogenous immunoprecipitation: 
15μL of A/G plus agarose beads (Santa Cruz Biotechnology) were added to 
1.5mL eppendorf tubes. To the beads, 1mg of cell lysates were added and the 
tube was incubated on ice and tapped every ten minutes thrice, for a total of 
thirtyminutes. At the end of thirty minutes, samples were spun at 10,000 rcf 
for five minutes, the supernatant was collected in another tube and the beads 
were discarded. This step is meant for pre-clearing the lysates. To this pre-
cleared lysates, 2μg of antibody was added and topped up to 500μL with RIPA 
lysis buffer containing 1X protease inhibitor and incubated overnight at 4ºC 
on a rotator. The next day, 20μL of A/G plus agarose beads were added to 
each sample containing tubes and again incubated at 4ºC on a rocker for 2 
hours. The samples were spun at 10,000 rcf for five minutes at 4ºC. The 
supernatant was removed and the beads retained. The beads were washed with 
RIPA lysis buffer (without 1X protease inhibitor) three times for five minutes 
on rotator at 4ºC. At the end of the last wash, supernatant was removed by 
spinning at 10,000 rcf for three minutes and the beads were retained. To the 
beads, 2X sample buffer was added, mixed gently by tapping gently before 
heating the sample at 95˚C for 10 minutes. Samples were spun at 10,000 rcf 
for two minutes and then loaded into SDS-PAGE. 
2.9 In vitro methylation assay 
In vitro methylation assay was carried out as described (Nishio et al., 2004). 
Briefly, 3µg of purifiedpoly-histidine–tagged recombinant proteins, full length 







purified full length human MyoD (hMyoD) fused to a GST affinity tag in a 





C] SAM (Perkin Elmer), 
50mM SAM (Sigma). GST-histone H3 tail (1-57) was used as a control. In 
addition to G9a, human Set7/9 (H3K4 methyltransferase) was also used. 
Proteins were separated using 15% SDS-Polyacrylamide gel and visualized on 
the gel by coomassie blue staining and fluorography. 
2.10 Liquid chromatography-mass spectrometry (LC-MS) analysis 
LC-MS analysis (Thermo Electron, Finnigan LTQ) was carried out using the 
tryptic digestion of recombinant MyoD polypeptide treated with wild-type 
G9a or its mutant G9aΔSET. 
2.11 Quantitative real-time polymerase chain reaction (Q-PCR) 
Total mRNA was isolated using TRIZOL (Invitrogen) according to the 
manufacturer’s instructions. First strand cDNA was synthesized using AMV 
Reverse transcriptase (Promega) according to the manufacturer’s instructions 
with 2µg of RNA. QPCR was performed using Lightcycler 480 SYBR Green 
1 Master Kit (Roche). GAPDH was used as an internal control. Gene specific 
primer sequences for G9a, MCK, MRF, MYH1 and GAPDH are provided in 
Table I.  QPCR reaction was performed in triplicates to obtain CT values.  CT 
values of the samples were normalized to internal control GAPDH to obtain 









2.12 Cell culture for differentiation assay  
C2C12 or Rh30 cells were seeded in six well plates (Greiner bio-one). For day 
0 time point, 0.1 million cells (50% - 60% confluent) were seeded per well in 
GM and for differentiation time points, 0.27 million cells (80% - 90% 
confluent) were seeded and then switched to DM for various differentiation 
time points.  
2.13 MyoD dependent myogenic conversion assay 
 2.7×10
6 
C3H10T1/2cells were seeded on six-well plate in GM, a day before 
transfection. On the day of transfection, each well was transfected with 1.5μg 
of MyoD alone or co-transfected with either 0.5μg of EGFP-G9a or EGFP-
G9aΔSET in basal DMEM using Lipofectamine Plus reagent (Invitrogen) 
according to manufacturer’s protocols. pCS2-empty expression was added to 
normalize the amount of DNA. The cells were incubated at 37ºC in 5% CO2 
incubator for 3 hours. At the end of incubation, medium was replaced from 
basal DMEM (without serum) to serum containing DMEM. At the end of 24 
hours of transfection, cells were switched to DM for 96 hours (Day 4). 
2.14 Immunofluorescence  
C2C12 or 10T1/2 cells were cultured on Thermonax plastic cover slips 
(Rochester NY, USA) with GM in a six-well plate and switched to DM. At the 
end of three to four days of differentiation, media was aspirated from 
differentiating cells and a sufficient volume of 1X PBS (Phosphate Buffered 
Saline) was added to wash the cells. Washing was done thrice by gently 







paraformaldehyde for 10 minutes. Fixed cells were washed three times with 
1X PBS for 5 minutes each. Cells were then permeabilized and blocked with 
0.5% Triton-X-100 in 1X PBS with 10% horse serum for one hour at room 
temperature.  
After one hour of blocking, cells were incubated for one hour at room 
temperature with the following antibodies:  
Myosin Heavy Chain, anti-MHC (MY32) antibody (Sigma) at 1:400; anti-
MyoD (5.8A) antibody (Santacruz Biotechnology) and anti-G9a (C6H3) 
antibody (Cell Signaling) at 1:300 concentrations were used. Cells were 
washed with 1X PBS thrice, for five minutes each. Secondary antibody 
coupled with Alexafluor (Alexafluor 508 and Alexafluor 488) at 1:250 was 
added for one hour. Cells were again washed with 1X PBS thrice, for five 
minutes each. Nuclei were counterstained with DAPI (Vector Laboratories, 
Inc., Burlingame, CA). 
2.15 Myogenic index 
Myogenic index was calculated by quantifying the ratio of nuclei in 
MHC
+
myotubes/total nuclei. At least 400 nuclei were counted.   
2.16 Immunofluoroscence microscopy 
Immunofluorescence images were taken using the fluorescence microscopy 
(Nikon Eclipse TE-2000U) with Metamorph software version 7.0r3 with 10X 








2.17 Chromatin immunoprecipitation (ChIP) assays 
ChIP assays were carried out using ChIP assay kit as described earlier 
(Gulbagci et al. 2009). Briefly, C2C12 cells were cultured in GM (Day 0) and 
switched to DM (Day 2). Cells were then fixed in 1% formaldehyde for 10 
minutes at 37ºC. Fixed cells were washed with 1X PBS and scraped from 
culture plate. Cells were resuspended in SDS lysis buffer (50mM Tris-Cl PH 
8.1, 1% SDS, 10mM EDTA, 1µg/mL aprotinin, 1mM PMSF, 1µg/mL 
pepstatin A). Cells were sheared by sonication to obtain DNA fragments and 
the chromatin was immunoprecipitated with 2µg antibodies directed against 
H3K9ac (histone 3 acetyl lysine 9, Abcam), H3K9K14ac (histone 3 acetylated 
lysine 9 and lysine 14, Upstate), H3K9me2 (histone 3 dimethyl Lysine 9, 
Upstate). The cross links were then heat reversed at 65ºC and DNA was 
purified using phenol chloroform. DNA was quantified by Q-PCR using 
primers which are specific to myogenin and MCK promoter sequence and β-
actin as described in Table I. Each sample was performed in triplicates and the 
values obtained were normalized to β-actin. 
2.18 Global H3K9 acetylation 
C2C12 cells were cultured in GM (Day 0) and then switched to DM with 
10µM of embelin or MJTK-4 (control) and induced to differentiate for two 
days (Day 2). Total protein extraction was carried out using 1X Laemmli 
buffer containing 62.5mM Tris, pH 6.8, 10% glycerol and 2% SDS. Samples 
were heated for 10 minutes at 90ºC and allowed to cool down to room 







and heated for 5 minutes at 90ºC after addition of 5X loading buffer. It was 
then analyzed by western blot for H3K9ac using anti-H3K9ac antibody 
(Abcam). HistoneH3 levels were assayed as a control using anti-histone H3 
antibody (Abcam). 
2.19 Microarray on C2C12 cells 
C2C12 cells were cultured in GM for 24hours (Day 0) in the presence of 
10µM embelin or DMSO (control) and induced to differentiate in DM in 
presence of 10µM embelin or DMSO for another 24 hours (Day1) and 
48hours (Day2) respectively. Total RNA was isolated from proliferating and 
differentiated C2C12 cells with Trizol (Invitrogen). The experiment was 
carried out with two biological replicates obtained from DMSO or embelin 
treated cells.  RNA was cleaned using RNeasyMinElute Cleanup Kit (Qiagen) 
and reverse transcribed, labeled and subsequently hybridized to Illumina 
mouse WG-6 v2.0 array.  
Normalization of gene expression data in Genespring GX 12.0(Agilent) was 
carried out by shifting the intensities to 75th percentile and baseline 
transformation was done to median of all samples (treated and control). 
Statistical significance was determined by the two-tailed, un-paired (p<0.05) 
student’s t test and all significant changes above 1.5-fold were selected 
(Bionivid Technology, Bangalore). Gene ontology (GO) and significantly 
altered signaling pathway identification was carried out using GeneSpring GX 







Biological network analysis was carried out using Genespring GX v.12.0.  A 
total of 171 Genes that are annotated to be involved in myogenic 
differentiation was obtained from Entrez Gene database. Biological networks 
were produced by comparing the input list to a reference list containing >1.4 
million reactions which was generated by natural language processing 
algorithm and from different interaction databases. Expanded networks were 
constructed by setting an advanced filter that included the categories of 
binding, expression, metabolism, promoter binding, protein modification and 
regulation. 
2.20 Statistical analyses 
All graphs shown indicate mean values and error bar indicate standard 
deviation (SD). Statistical significance was determined by two-tailed, un-
paired Student’s t test and p values of <0.05 were considered to be statistically 
significant. Different degrees of statistical significances were indicated by 
asterisks as follows: 
* 
is p < 0.05; 
** 
is p < 0.01; 
*** 





























3.1 Role of G9a in skeletal muscle differentiation 
3.1.1 Analysis of G9a expression during skeletal muscle differentiation 
To examine whether G9a has a role in skeletal myogenesis the expression of 
G9a was analyzed in skeletal muscle cells. Total mRNA and protein levels 
were examined in undifferentiated and differentiated C2C12 cells by 
quantitative real time PCR (Q-PCR) and western blot. G9a mRNA was 
expressed in undifferentiated cells (Day 0) and was rapidly down-regulated 
after culture of cells in differentiation medium for three days (Day 3) (Fig 
3.1.1.A). Similarly, G9a protein also declined upon induction of 
differentiation, which inversely correlated with the expression of MyoD and 
its target gene Troponin T (a terminal marker for differentiation) which were 
up-regulated upon differentiation (Fig 3.1.1.B).  From these data, it is clear 
that G9a is expressed at high levels in proliferating myoblasts and its 
expression declines upon differentiation. This suggests that the decline of G9a 








Figure 3.1.1 The expression of G9a decreases during skeletal muscle 
differentiation: (A) Q-PCR analyses of G9a expression using RNA isolated from 
undifferentiated (Day 0) and differentiated (Day3) C2C12 cells. GAPDH was 
used as a loading control. Raw data provided in Table IV. (B) G9a, MyoD and 
Troponin T proteins were analyzed using  cell extracts from C2C12 cells at the 










3.1.2 Overexpression of G9a inhibits skeletal muscle differentiation 
To test whether G9a regulates myogenesis, gain of function studies were 
carried out. Since G9a is down-regulated during myogenic differentiation in 
C2C12 cells, the consequences of ectopic expression of G9a in C2C12 cells 
under conditions that normally promote differentiation was analyzed. C2C12 
cells were transfected with full length G9a (FLAG-G9a). Empty vector (pCS2) 
transfected cells were used as controls (Fig 3.1.2.A). Cells were switched to 
DM and induced to differentiate for four days. C2C12 cells expressing full 
length G9a (FLAG-G9a) were examined for their ability to differentiate, 
compared to control vector (pCS2) cells. In contrast to control cells, FLAG-
G9a cells exhibited a morphological defect in the formation of elongated 
multinucleated myotubes suggesting a defect in myogenic differentiation (Fig 
3.1.2.B). To further validate these findings, control and G9a overexpressing 
cells were fixed with paraformaldehyde and immunostained with anti-myosin 
heavy chain (MHC
+
) antibody, which is a cellular marker of terminal 
differentiation. As shown in (Fig 3.1.2.C) the percentage of MHC
+
 cells was 
reduced upon G9a overexpression. In addition, cell lysates were collected at 
Day 0, 1 and 3 time points and analyzed for expression of myogenin, which 
was down-regulated (Fig 3.1.2.D). These data show that G9a causes an overall 










Figure 3.1.2 A&B Over-expression of G9a inhibits skeletal muscle 
differentiation: (A) C2C12 myoblasts were transfected with full-length FLAG-
G9a or pCS2 (vector control) and analyzed for G9a expression by Western blot 
analyses. β-actin was used as internal control. (B) Control and Flag-G9a 
expressing cells were then switched to differentiation medium for four days and 
the myoblast differentiation defect was observed in FLAG-G9a over-expressing 
cells compared to control cells by capturing the image at 10X magnification using 








Figure 3.1.2 C&D Over-expression of G9a inhibits skeletal muscle 
differentiation. (C) Differentiated cells (Day 4) were also immunostained with 
anti-MHC (green) antibody. Nuclei were stained with DAPI (blue). Images were 
captured under fluorescent microscope using 10X magnification. (D) Cell lysates 
were analyzed by western blot for myogenin expression at days 0, 1 and 3. β-actin 









3.1.3 G9a represses myogenesis in a methyltransferase activity dependent 
manner 
To examine whether G9a represses myogenic differentiation in a SET domain 
dependent manner, we over-expressed a deletion mutant lacking the SET 
domain (EGFP-G9aΔSET) in addition to expressing full length G9a (EGFP-
G9a) in C2C12 cells (Fig 3.1.3.A). Control cells were transfected with empty 
vector (pCS2). Western blot analysis showed that both proteins were 
expressed at similar levels (Fig 3.1.3.B). Cells expressing EGFP-G9a and 
EGFP-G9a∆SET were compared to control vector (EGFP) cells for their 
ability to differentiate. Morphological analysis of cells indicated that EGFP-
G9a overexpression caused a defect in myotube formation (Fig 3.1.3.C). 
However, EGFP-G9aΔSET overexpressing cells differentiated normally 
similar to control (EGFP) cells (Fig 3.1.3.C). This suggests that G9a requires 








Figure 3.1.3A&B G9a represses myogenic differentiation in a 
methyltransferase activity dependent manner: (A) Diagrammatic 
representation of full length G9a (1-1001 aa) and a deletion construct G9AΔSET 
(1-830 aa) which lacks catalytic activity. (B) C212 myoblasts were transfected 
with full length EGFP-G9a or EGFP-G9aΔSET and analyzed for expression by 
western blot. EGFP-G9a and EGFP-G9aΔSET were expressed at equivalent 







Fig 3.1.3C G9a represses myogenic differentiation in a methyltransferase 
activity dependent manner. (C) Cells were switched to differentiation medium 
for indicated time points (Day 1 and Day 3) and differentiation was observed by 







3.1.4 Myogenic differentiation is enhanced by knockdown of G9a in 
muscle cells  
Since ectopic expression of G9a results in impairment of myotube formation 
with the repression of differentiation associated genes, we examined whether 
G9a silencing has an effect on the overall differentiation program. 
Proliferating C2C12 cells were transfected for 72 hrs with 100nM scrambled 
siRNA or G9a specific siG9a. As shown in Fig 3.1.4.A, siG9a reduced 
endogenous G9a levels in C2C12 cells. Densitometric quantification of 
western blots revealed a 71% down-regulation of G9a expression at protein 
level compared to control cells that were untransfected, or those expressing 
siRNA. To assess the effect of G9a knockdown on myogenesis, control and 
siG9a cells were induced to differentiate into myotubes after 72 hrs of 
transfection. As expected, siRNA transfected cells had no effect on the overall 
morphological differentiation compared to control cells. In contrast, C2C12 
cells transfected with siG9a exhibited enhanced muscle differentiation within 
two days of culture in differentiation medium as seen by the increase in the 
number of myotubes compared to untransfected C2C12 cells or those 
expressing siRNA (Fig 3.1.4.B). This was also reflected by increased number 
of MHC
+
 cells (Fig 3.1.4.C) as well as a significant increase in the myogenic 
index (Fig 3.1.4.D) compared to controls (untransfected and siRNA cells). 
Western blot analyses was performed for Myogenin as well as Troponin T on 
cell extracts obtained from G9a depleted cells (siG9a) or control 
(untransfected and siRNA) C2C12 cells. The expressions of both proteins, 








Fig 3.1.4A&B Knockdown of G9a enhances skeletal muscle differentiation 
(A) C2C12 myoblasts were transfected with siRNA against G9a (siG9a), 
scrambled siRNA (siRNA) or left untransfected (control). Lysates were collected 
for day 0 and analyzed for the knockdown of endogenous G9a at protein level by 
Western blot. (B) Cells were subjected to differentiation by transferring to 
differentiation medium for 48 hours (Day 2) and the extent of myoblast 
differentiation was observed in siG9a cells compared to siRNA and untransfected 
control cells by capturing the image at 10X magnification using phase contrast 
microscopy. A significant increase in the number of myotubes was observed in 







Fig 3.1.4C&D Knockdown of G9a enhances skeletal muscle differentiation. 
(C) Differentiated cells (Day 2) were also immunostained with anti-MHC (green) 
antibody. Nuclei were stained with DAPI (blue). Images were captured under 
fluorescent microscope using 10X magnification. (D) Quantification of myogenic 
index from 4 randomly chosen microscopic fields (calculated as the ratio of 
MHC-positive stained nuclei to the total nuclei in each field. At least 400 nuclei 







siG9a cells. Values obtained were represented as means with error bar indicating 
standard deviations. Statistical significance was determined by the two-tailed, un-
paired Student’s t-test and p-values of <0.05 were considered to be statistically 
significant. p-value obtained is shown as *** [p < 0.001]  
Fig 3.1.4E Knockdown of G9a enhances skeletal muscle differentiation: (E) 
Cell lysates were analyzed by western blot for myogenic markers myogenin and 
Troponin T expression at days 0, 1 and 2. EF1α (53Kda) was used as internal 
control. 
 
3.1.5 G9a represses MRF transcriptional activity 
Since G9a is expressed in proliferating myoblasts and represses muscle 
specific genes that are induced during muscle differentiation, its effect on the 
transcriptional activity of Myogenic Regulatory Factors (MRFs) was 
examined by luciferase assays in C2C12 cells. C2C12 myoblasts were 
transfected with the MRF reporter 4R-tk-Luc (which contains four tandem E 
boxes from the Muscle Creatine Kinase (MCK) enhancer upstream of the 
thymidine basal promoter) in the absence and presence of EGFP-G9a or 
EGFP-G9aΔSET. EGFP-G9a strongly repressed the reporter activity in a 







activity dependent, as EGFP-G9aΔSET had no effect on the reporter activity 
(Fig 3.1.5). Since C2C12 cells express Myf5 and MyoD, this suggested that 
G9a may inhibit endogenous MyoD and/or Myf5 activity.  
Figure 3.1.5 G9a represses MRF transcriptional activity: C2C12 cells were 
transfected with 4R-tk driven firefly luciferase reporter 4R-tk-Luc, 50 ng in the 
absence and presence of increasing amount of EGFP-G9a or EGFP-G9aΔset (50, 
25 and 10 ng). Luciferase activity was measured 48 hours after transfection and 
was represented as percent luciferase activity in which the control was assigned a 
value of 100%. Data represent the mean ± SD. Statistical significance was 
determined by Student’s t test and p-values of <0.05 were considered to be 








3.1.5.1 G9a represses MyoD transcriptional activity 
To examine the effect of G9a specifically on MyoD activity, 10T1/2 cells 
(non-muscle cells) were transfected with 4R-tk-Luc in the absence and 
presence of MyoD, along with EGFP-G9a or EGFP-G9aΔSET. As expected, 
transfection of MyoD in 10T1/2 fibroblasts resulted in induction of reporter 
activity. Co-expression of EGFP-G9a blocked the MyoD-dependent activation 
of 4R-tk-Luc. However co-expression of EGFP-G9aΔSET, failed to inhibit 
MyoD dependent transcriptional activity (Fig 3.1.5.1). 
 
Figure 3.1.5.1 G9a represses MyoD transcriptional activity: 10T1/2 cells were 
transfected with 4R-tk-Luc (50ng) along with MyoD (50ng) in the absence and 
presence of EGFP-G9a or EGFP-G9aΔset (50ng). Luciferase activity was 
measured 48 hours after transfection and was represented as percent luciferase 
activity in which the control was assigned a value of 100%. Data represent the 
mean ± SD. Statistical significance was determined by Student’s t test and p-value 
obtained is shown as ** [p< 0.01].   









3.1.6 G9a interferes with the function of MyoD 
Since G9a inhibits MRF activity and specifically MyoD activity, this raised 
the possibility that it may interfere with MyoD function. Thus to test whether 
MyoD loses its ability to activate the myogenic program in the presence of 
G9a, myogenic conversion assays were performed. 10T1/2 cells were 
transfected with MyoD alone, or together with equivalent amounts of EGFP-
G9a or EGFP-G9aΔSET (Fig 3.1.6.A) and subjected to myogenic 
differentiation assays. Consistent with the effect of G9a on MyoD 
transcriptional activity, EGFP-G9a, but not EGFP-G9aΔSET mutant inhibited 
MyoD dependent myogenic conversion, again indicating that G9a blocked 
MyoD in a methyltransferase activity dependent manner. This was evidenced 
by a significant reduction in the presence of MHC
+ 
myotubes (Fig 3.1.6.B) as 
well as myogenic index (Fig 3.1.6.C). To validate these findings, western blot 
analysis was performed for the expression of Troponin T. A significant 
reduction in the expression of Troponin T was apparent in cells co-transfected 
with MyoD and EGFP-G9a but not those expressing MyoD (Fig 3.1.6.D). 








Figure 3.1.6A G9a interferes with the function of MyoD: (A) C3H10T1/2 
fibroblasts were transiently transfected with MyoD alone or co-transfected with 
either EGFP-G9a or EGFP-G9aΔSET and analyzed for their expression by 
western blot. EGFP-G9a and EGFP-G9aΔSET were expressed at equivalent 
amount. EF1α was used as internal control. 
 
 
Figure 3.1.6B G9a interferes with the function of MyoD: (B) Cells were then 
subjected to MyoD dependent myogenic conversion assays by transferring to 
differentiation medium for 96 hours (Day 4). Differentiated cells (Day 4) were 
immuno-stained with anti-MHC (green) antibody. Nuclei were stained with DAPI 









Figure 3.1.6 C&D G9a interferes with the function of MyoD: (C) The 
percentage of MHC+ cells was quantified (myogenic index) relative to MyoD, 
which was given a value of 100%. A significant decrease in myogenic index was 
apparent in cells expressing EGFP-G9a and Myc-MyoD compared to controls 
(Myc-MyoD and EGFP-G9aΔSET) over-expressing cells. Data represent the 
mean ± SD. Statistical significance was determined by Student’s t test and p-value 
obtained is shown as *** [p< 0.001]. (D) Cell lysates were analyzed by western 
blot for the expression of Troponin T at day 4, which was inhibited in cells over-









3.1.7 G9a interacts physically with MyoD  
Since G9a inhibits MyoD dependent gene transcription, this raised possibility 
that G9a may interact with MyoD. To test whether G9a associates with MyoD, 
co-immunoprecipitation assays were performed. 293T cells were transfected 
with full length Myc-tagged MyoD and full length Flag-tagged G9a, either 
individually or together. Immunoprecipitation of either Myc-tagged MyoD, or 
Flag-tagged G9a, revealed a strong interaction between G9a and MyoD (Fig 
3.1.7).  
 
Figure 3.1.7 G9a and MyoD interact in cultured cells: HEK293T cells were 
transfected with Myc-tagged MyoD and/or FLAG-tagged G9a either individually 
or together. MyoD was immunoprecipitated using anti-Myc agarose beads, and 
anti-Flag antibodies were used to detect the presence of G9a in the 
immunoprecipitates by western blot analysis. Similarly, G9a was 
immunoprecipitated using anti-Flag agarose beads, and anti-Myc antibodies were 
used to detect the presence of MyoD in the immunoprecipitates by Western blot 
analysis. Immunoprecipitation of either G9a, or MyoD from 293T cells, revealed 
an interaction between the two proteins. Lysates (input) were analyzed for G9a 









3.1.8 Endogenous MyoD associates with G9a in proliferating muscle cells 
Although the previous experiments indicated that G9a interacts with MyoD, 
this interaction was assessed in non-muscle cells by exogenous co-expression 
of MyoD and G9a. As MyoD is exclusively expressed in skeletal muscle cells, 
it was important to test their association in skeletal muscle cells. To examine 
whether endogenous MyoD interacts with G9a in C2C12 cells, 
immunoprecipitation assays were carried out. Since G9a is expressed at high 
levels in proliferating myoblasts and its expression declines upon 
differentiation, C2C12 cell lysates were collected from cells cultured in GM 
(Day 0) and after induction of differentiation in DM (Day 2). Endogenous 
MyoD was immunoprecipitated from extracts of C2C12 cells with anti-MyoD 
antibody. The immunoprecipitated proteins were then immunoblotted with 
G9a antibody. The result showed that endogenous MyoD interacted with G9a 
in myoblasts; and this interaction diminished upon induction of differentiation 
(Fig 3.1.8). 
 
Figure 3.1.8 Endogenous MyoD associates with G9a: Endogenous MyoD was 
immunoprecipitated from lysates of C2C12 cells grown either in GM (Day 0) or 
DM for 48 hrs (Day 2) using anti-MyoD antibody (or IgG in control) and the 
presence of G9a in the immunoprecipitate detected by immunoblotting with anti-
G9a antibody. Input shows expression of G9a and MyoD in the lysates. EF1α was 








3.1.9 Endogenous G9a co-localizes with MyoD 
As G9a interacts with MyoD endogenously, co-localization of these two 
endogenous proteins in C2C12 myoblasts was examined. C2C12 cells cultured 
in growth medium were fixed, and immunostained with anti-G9a and anti-
MyoD antibody. Nuclei were stained with DAPI (Blue). Consistent with the 
endogenous interaction of G9a with MyoD, both the nuclear proteins were 
noticeably co-localized (Fig.3.1.9). 
 
Figure 3.1.9 G9a co-localizes with MyoD: C2C12 cells were cultured in GM 
(Day 0). Cells were then immunostained with anti-G9a antibody and anti-MyoD 
antibody. Nuclei were stained with DAPI (blue). Images were captured under 
fluorescent microscope using 20X magnification. G9a (red) and MyoD (green) 
co-localization was apparent in myoblasts. 
 
3.1.10 Over-expression of G9a increases H3K9me2 on myogenin promoter 
It has been shown by previous studies that G9a preferentially di-methylates 
H3K9 (Tachibana et al., 2002, Rice et al., 2003) which is associated with 
transcriptional repression. To understand the mechanisms by which G9a 







genes that are induced by MyoD, chromatin immunoprecipitation (ChIP) 
assays were performed to determine whether there is any enrichment of 
H3K9me2 on the MyoD target myogenin promoter. C2C12 cells over-
expressing EGFP (vector control) and EGFP-G9a were cultured in GM (day 0) 
and differentiated for two days (day 2). Cell lysates were collected at the 
respective time points and subjected to sonication to shear chromatin and 
immunoprecipitated with H3K9me2 antibody. Consistent with previous 
reports, H3K9me2 levels were higher on the myogenin promoter in 
proliferating myoblasts which declined substantially upon differentiation (Fig 
3.1.10) (Zhang et al., 2002). However, upon EGFP-G9a overexpression, a 
significant increase in the enrichment of H3K9me2 was seen in both 










Figure 3.1.10 G9a alters H3K9me2 levels on myogenin promoter: C2C12 cells 
over-expressing EGFP- (vector control) or EGFP-G9a were cultured in GM 
(Day0) and induced to differentiate in DM for two days (Day 2). Cells were 
analyzed by ChIP assays to determine the H3K9me2 on the myogenin promoter. 
Cell lysates were subjected to immunoprecipitation with H3K9me2 antibody and 
the chromatin were analyzed by Q-PCR using primers for the myogenin promoter 
and β-actin. Data represent the mean ± SD. Statistical significance was 
determined by Student’s t test and p-value obtained is shown as * [p< 0.05]. Data 
provided by Mr. Teng-Kai Chung. 
3.1.11 Over-expression of G9a decreases H3K9K14ac mark on myogenin 
promoter 
To assess for alteration in H3K9K14ac levels which are associated with 
transcriptional activation, similar ChIP assays were carried out with EGFP and 
EGFP-G9a over-expressing cells using acetylated H3K9K14ac antibody. 
There was a significant reduction in H3K9K14ac levels in G9a over-







The increase in H3K9me2 and reduction of H3K9K14ac levels (3.1.10 & 
3.1.11) at the myogenin promoter upon G9a over expression correlates with 
repression of myogenin and MHC expression. 
 
Figure 3.1.11 G9a alters H3K9K14ac levels on myogenin promoter 
C2C12 cells over-expressing EGFP- (vector control) or EGFP-G9a were cultured 
in GM (Day0) and induced to differentiate in DM for two days (Day 2). Cells 
were analyzed by ChIP assays to determine the H3K9K14ac on the myogenin 
promoter. Cell lysates were subjected to immunoprecipitation with H3K9K14ac 
antibody and the chromatin were analyzed by Q-PCR using primers for the 
myogenin promoter and β-actin. Data represent the mean ± SD. Statistical 
significance was determined by Student’s t test and p-value obtained is shown 
as** [p< 0.01]. Data provided by Mr. Teng-Kai Chung. 
 
3.1.12 MyoD has G9a methylation consensus at K104 
Previous reports have shown that G9a methylates non-histone substrates 
including CDYL1, WIZ, ACINUS and C/EBPβ in addition to mediating 
H3K9me1 and H3K9me2 (Rathert et al., 2008). Since G9a interacts with 
MyoD and inhibits MyoD function in a methyltransferase activity dependent 
manner, this raised the possibility that MyoD could be a non-histone target of 







Arg-Lys (RK) sequence (Rathert et al., 2008). We analyzed MyoD cDNA 
across many species which revealed a single conserved G9a methylation 
consensus RK at K104 (Fig 3.1.12). 
Figure 3.1.12 Schematic representation of MyoD domain structure with its G9a 
methylation consensus K104 and P/CAF acetylation consensus K99, K102 and 










3.1.12.1 G9a methylates MyoD  
To test the possibility whether G9a methylates at K104, immunoprecipitation 
assays were performed. 293T cells were transfected with full-length Myc-
tagged MyoD and EGFP-tagged G9a, individually and together. In addition, 
EGFP-tagged G9aΔSET was co-transfected with Myc-MyoD. 
Twenty-four hours post-transfection, cell lysates were harvested and checked 
for expression of the Myc-MyoD, EGFP-G9a and EGFP-G9aΔSET (Fig 
3.1.12.1). Cell lysates were immunoprecipitated with Myc-agarose beads and 
immunoprecipitates were analyzed by western blot initially for the interaction 
of EGFP-G9a and EGFP-G9aΔSET with MyoD. Consistent with our previous 
result, G9a interacted with MyoD (Fig 3.1.12.1). In addition to this, G9aΔSET 
interacted with MyoD as well, clearly indicating that this association of G9a 
with MyoD is independent of the catalytic SET domain of G9a (Fig 3.1.12.1). 
To examine whether G9a methylates MyoD, the blot was then probed for 
MyoD methylation using anti-methyl-lysine (Me-Lys) antibody. The result 
revealed a strong methylation of MyoD by G9a (Fig 3.1.12.1), whereas there 
was no corresponding methylation band observed for the lane co-expressing 
MyoD and EGFP-G9aΔSET, indicating that MyoD is methylated by G9a 








Figure 3.1.12.1 G9a methylates MyoD in vivo: HEK293T cells were transfected 
with full length Myc-tagged MyoD, EGFP-tagged G9a, SET domain deleted 
mutant EGFP-tagged G9aΔSET either individually or together. MyoD was 
immunoprecipitated using anti-Myc agarose beads followed by immuno-blotting 
with anti-GFP antibody to detect the association of MyoD with G9a and 
G9aΔSET in the immunoprecipitates as well as its methylation using anti-methyl 
lysine (Me-Lys) antibody. Lysates (input) were analyzed for G9a, G9aΔSET and 
MyoD expression by Western blot analysis. EF1α was used as internal control. 
 
3.1.12.2 Endogenous MyoD methylated by G9a in proliferating myoblasts 
From the above experiments it appeared that G9a associates with and may 
methylate MyoD. This work was further expanded in C2C12 cells to examine 
whether G9a can methylate MyoD endogenously in skeletal muscle cells. 
C2C12 cells were cultured in growth medium and differentiation medium and 
endogenous MyoD was immunoprecipitated from extracts of C2C12 cells at 
day 0 and day 2 with MyoD antibody. As a negative control IgG antibody was 
used to immunoprecipitate Day 0 lysates. The immunoprecipitated proteins 







above result, endogenous MyoD was methylated by G9a at day 0 (Fig 
3.1.12.2) and methylation declined upon induction of differentiation at day 2 
(Fig 3.1.12.2). This may be due to decline in endogenous G9a expression. 
 
Figure 3.1.12.2 Endogenous MyoD methylated by G9a: Endogenous MyoD 
was immunoprecipitated from lysates of C2C12 cells grown either in GM (Day 0) 
or DM for 48 hrs (Day 2) using anti-MyoD antibody (or IgG in control lane) and 
the presence of G9a in the immunoprecipitate detected by immunoblotting with 
anti-G9a antibody. Then the blot was analyzed for MyoD methylation using anti-
Me-Lys antibody. Input shows expression of G9a and MyoD in the lysates. EF1α 
was used as internal control. 
 
3.1.12.3 Modulation of endogenous G9a levels impacts MyoD methylation 
 
Although it is clear from the above experiment that MyoD is methylated in 
skeletal muscle cells, it was still not obvious whether methylation is mediated 
specifically by G9a. 
To determine whether MyoD methylation requires G9a, endogenous G9a 
levels in myoblasts were modulated by two strategies and its corresponding 
impact on MyoD methylation was examined. First, G9a was over-expressed in 







immunoprecipitated 24 hours post transfection. As expected, over-expression 
of G9a resulted in significant increase in MyoD methylation compared to 




Figure 3.1.12.3A Overexpression of G9a increases MyoD methylation: (A) 
C2C12 myoblasts were transfected with EGFP-G9a and EGFP (control). Lysates 
were collected at day 0. Input shows the over-expression of G9a compared to 
endogenous G9a as well as MyoD expression at protein level. β-actin was used as 
internal control. Endogenous MyoD was immunoprecipitated from lysates of 
C2C12 myoblasts over-expressing EGFP-G9a and EGFP (control) using anti-
MyoD antibody. It was followed by immuno-blotting with anti-Me-Lys antibody. 
 
Second, endogenous G9a was targeted by siRNA knockdown. C2C12 cells 
were transfected with scrambled siRNA control or siRNA targeted to G9a 
(siG9a). Forty-eight hours post-transfection, cell lysates were collected and 
MyoD was immunoprecipitated using MyoD antibody and immuno-blotted 







level modulates endogenous MyoD methylation. Compared to control 
(siRNA) cells, siG9a cells exhibited a marked reduction of MyoD methylation 
(Fig 3.1.12.3B). 
Figure 3.1.12.3B Knockdown of G9a decreases MyoD methylation: (B) 
C2C12 myoblasts were transfected with siG9a and control siRNA. Lysates were 
collected at day 0. Input shows the knockdown of endogenous G9a at protein 
level as well as the expression of MyoD. β-actin was used as internal control. 
Endogenous MyoD was immunoprecipitated from lysates of C2C12 myoblasts 
expressing siG9a and control siRNA using anti-MyoD antibody. Then the blot 
was analyzed for MyoD methylation using anti-Me-Lys antibody.  
 
Thus it is clear from above strategies (3.1.12.3A & B) that targeting G9a 










3.1.13 G9a interacts with MyoD through its ankyrin repeats domain 
It has been shown by previous studies that ankyrin repeats (ANK) domain of 
G9a is involved in protein-protein interaction. So to examine the possibility 
whether G9a associates with MyoD through its ankyrin repeats, 293T cells 
were transfected with full length Myc-tagged MyoD and co-transfected with 
either full-length Flag-tagged G9a or ANK domain deleted mutant Flag-
tagged G9aΔANK. 
Twenty-four hours post-transfection, cell lysates were harvested and then 
checked for the expression of Myc-MyoD, Flag-G9a and Flag-G9aΔANK. All 
proteins were expressed at equivalent amounts (Fig 3.1.13). Cell lysates were 
immunoprecipitated with Myc-agarose beads and immunoprecipitates were 
probed by western blot for interaction of G9a and G9aΔANK with MyoD 
using anti-Flag antibody. Immunoblot analysis revealed that wild-type G9a 
interacted with MyoD consistent with the previous results obtained. However, 
this interaction was disrupted completely as G9aΔANK failed to interact with 
MyoD (Fig.3.1.13) which indicates that ANK domain of G9a is necessary for 
its association with MyoD. 
To further determine whether the association between these two proteins is 
essential for G9a mediated MyoD methylation, the same blot was then 
analyzed for its methylation using anti-Me-Lys antibody. There was no 
methylation signal detected with G9aΔANK compared to wild-type G9a 
suggesting the importance of interaction between these two proteins for 







Figure 3.1.13 G9a interacts with MyoD through its ankyrin repeats domain: 
HEK293T cells were transfected with full length Myc-tagged MyoD, Flag-tagged 
G9a, Flag-tagged G9aΔANK either individually or together. MyoD was 
immunoprecipitated using anti-Myc agarose beads followed by immuno-blotting 
with anti-Flag antibody to detect the association of MyoD with G9a and 
G9aΔANK in the immunoprecipitates as well as its methylation using anti-Me- 
Lys antibody. Lysates (input) were analyzed for G9a, G9aΔANK and MyoD 
expression by Western blot analysis. β-actin was used as internal control. 
 
3.1.14 G9a methylates MyoD directly 
To examine whether G9a directly methylates MyoD, in vitro methylation 
assays were performed using 3µg of purified recombinant full length human 
G9a (hG9a), the SET mutant (hG9aΔSET) which was incubated with 2µg of  
purified full length human MyoD (hMyoD) fused to a GST affinity tag. GST-
histone H3 tail (1-57) was used as a control. In addition to G9a, human Set7/9 
(H3K4 methyltransferase) was also used. G9a methylated MyoD, although at a 







methylation with G9aΔSET clearly indicating that G9a directly methylates 
MyoD in a SET domain dependent manner. Set7/9 also weakly methylated 
MyoD (Fig 3.1.14) suggesting the role of other methyltransferases in 
modulating MyoD by methylating it directly. 
 
 
Figure 3.1.14 G9a methylates MyoD directly: In vitro methylation of 2µg of 
recombinant GST-tagged human MyoD by G9a using 3µg of purified poly-
histidine-tagged-recombinant G9a, G9aΔSET and Set7/9. Proteins were separated 
on a 15% polyacrylamide gel and visualized by coomassie blue staining and 
fluorography.  GST-H3 was used as a positive control. Data provided by SiDe Li 
from Dr. Martin Walsh’s lab 
 
3.1.15 G9a methylates MyoD at K104 
 
To identify the site of MyoD methylation, tryptic peptides of recombinant 
MyoD were treated with full length G9a or with SET mutant (G9aΔSET). 







site for methylation (Fig 3.1.15) which is consistent with a G9a methylation 
consensus at this residue. 
Figure 3.1.15 G9a methylates MyoD at K104: Liquid chromatography-mass 
spectrometry (LC-MS) analysis of tryptic peptides of the recombinant MyoD after 
treatment with wild-type G9a or mutant G9aΔSET. Data provided by SiDe Li 
from Dr. Martin Walsh’s lab.  
 
3.1.16 G9a methylates MyoD at K104 (RRR used) in vivo 
To further validate that K104 is the methylation site on MyoD, 293T cells 
were transfected with full length Flag-tagged MyoD and Flag-tagged mutant 
MyoD (RRR) in which K99, K102 and K104 are mutated to arginine 








Twenty-four hours post-transfection, cell lysates were harvested and checked 
for expression of Flag-MyoD, Flag-MyoD (RRR) and EGFP-G9a (Fig 3.1.16). 
Cell lysates were immunoprecipitated with Flag-agarose beads and 
immunoprecipitates were probed by western blot for methylation using anti-
Me-Lys antibody. Consistent with the previous results, wild-type MyoD was 
methylated in the presence of G9a; however, G9a failed to methylate MyoD 
(RRR) (Fig 3.1.16). 
Collectively (3.1.15 & 3.1.16), these data clearly show that G9a methylates 
MyoD at K104. 
Figure 3.1.16 G9a methylates MyoD at K104 in vivo: HEK293T cells were 
transfected with full length Flag-tagged MyoD and point mutant Flag-tagged 
MyoD (RRR) either individually or together with EGFP-tagged G9a. MyoD was 
immunoprecipitated using anti-Flag agarose beads followed by immuno-blotting 
with anti-GFP antibody to detect the association of MyoD and MyoD (RRR) with 
G9a in the immunoprecipitates as well their methylation using anti-Me-Lys 
antibody. Lysates (input) were analyzed for G9a, MyoD and MyoD (RRR) 








3.1.17 MyoD (K104R) has higher myogenic potential than wild-type 
MyoD 
To address the relevance of G9a mediated MyoD methylation and H3K9me2 
in G9a-dependent inhibition of differentiation, myogenic conversion assay 
was carried out. 10T1/2 cells were transfected with pCS2 (vector control) and 
equivalent amount of wild-type MyoD and MyoD (K104R) (Fig 3.1.17A). 
These cells were then differentiated for four days in the absence and presence 
of 2.5µM of BIX-01294. Cell lysates were collected at day 0 and day 4 and 
analyzed for the expression of Troponin T by western blot analysis. As 
expected, MyoD alone resulted in the myogenic conversion as well as the 
expression of Troponin T which was further augmented in the presence of 
2.5µM of BIX-01294 (Fig 3.1.17B). In comparison to wild-type MyoD, 
MyoD K104R exhibited higher myogenic conversion potential reflected by the 
higher expression of Troponin T and myogenic index which, however, was 
unresponsive to BIX-01294 (3.1.17B & C). 
These data point out that mutation of K104 to arginine (K104R) makes MyoD 
non-responsive to G9a mediated methylation, thereby enhancing MyoD 
dependent activation of myogenin and muscle differentiation. Thus it shows 
that MyoD methylation plays a dominant role in G9a dependent inhibition of 
skeletal muscle differentiation compared to its modulation of H3K9me2 mark 









Figure 3.1.17A&B:  MyoD (K104R) has higher myogenic potential than wild-
type MyoD: (A) 10T1/2 fibroblasts were transiently transfected with either wild-
type MyoD or mutant MyoD (K104R) and pCS2 (vector control) and analyzed for 
their expression by western blot. Cells were then subjected to MyoD dependent 
myogenic conversion assays by transferring to differentiation medium for 96 
hours (Day 4) in the absence and presence of 2.5µM of BIX-01294. (B) Cell 
lysates were collected at day 0 and day 4 and analyzed for the expression of 
Troponin T in the MyoD and MyoD (K104R) over-expressing cells in the absence 









Figure 3.1.17C MyoD (K104R) has higher myogenic potential than wild-type 
MyoD: (C) Myogenic index was quantified and it reflected the higher myogenic 
potential of MyoD (K104R) compared to wild-type MyoD. Data represent the 
mean ± SD. Statistical significance was determined by Student’s t test and p-value 
obtained is shown as ** [p< 0.01].   
3.2 Role of P/CAF in skeletal muscle differentiation 
Previous studies have established a key and critical role for HATs p300 and 
P/CAF in skeletal myogenesis with their distinct functions. During 
differentiation, p300 first acetylates H3 and H4 within the promoter region and 
then recruits P/CAF which interacts with and directly acetylates MyoD at 
lysine residues 99, 102 and 104 (Fig 3.1.12) resulting in its transactivation 
(Sartorelli et al., 1999; Dilworth et al., 2004; Aziz et al., 2010). This increases 
the affinity of MyoD for its DNA target, switching on genes for differentiation 
thereby controlling myogenic transcription and differentiation. Since my 
results showed that G9a methylates MyoD at lysine residue K104, which is 







possibility that G9a might disrupt P/CAF-mediated MyoD acetylation which is 
critical for its transactivation function and for execution of the myogenic 
program. To investigate this possibility as well as to study the wider role of 
P/CAF in skeletal muscle differentiation we used a selective P/CAF inhibitor 
(Embelin) to determine its impact on MyoD and muscle differentiation.  
3.2.1 G9a disrupts P/CAF mediated MyoD acetylation 
G9a negatively impacts the transactivation ability of MyoD to execute the 
myogenic program by methylating it directly at K104 in undifferentiated 
myoblasts. On the other hand, P/CAF does the opposite by directly acetylating 
MyoD at K99, K102 and K104 during differentiation and thereby turning on 
MyoD transcriptional activity (Sartorelli et al., 1999; Duquet et al., 2006). It is 
interesting to note that the same lysine residue K104 which is conserved 
across species and through all MRFs (Figure 3.1.12) is subjected to both 
methylation and acetylation at different stages of differentiation. So to analyze 
whether G9a disrupts the ability of P/CAF to acetylate MyoD, 
immunoprecipitation assay was performed. 
293T cells were transfected with full length Myc-tagged MyoD alone or 
together with EGFP-tagged G9a and Flag-tagged P/CAF. Twenty-four 
hours post-transfection, cell lysates were harvested and checked for expression 
of Myc-MyoD, EGFP-G9a and Flag-P/CAF (Fig 3.2.1). Cell lysates were 
immunoprecipitated with Myc-agarose beads and immunoprecipitates were 
probed by western blot for association of P/CAF with MyoD using anti-Flag 







P/CAF (Sartorelli et al., 1999). However, in the presence of G9a, MyoD-
P/CAF interaction was reduced to an undetectable level (Fig 3.2.1). To 
determine whether this loss of association correlated with altered MyoD 
acetylation, we performed immunoblot analysis for P/CAF mediated MyoD 
acetylation in the presence of G9a using anti-acetyl lysine (Ac-Lys) antibody. 
Consistent with the negative impact on MyoD and P/CAF association, G9a 
was able to abrogate P/CAF mediated MyoD acetylation as well (Fig 3.2.1). 
 
Figure 3.2.1 G9a abrogates P/CAF mediated MyoD acetylation: HEK293T 
cells were transfected with full length Myc-tagged MyoD either individually or 
together with Flag-tagged P/CAF and EGFP-tagged G9a. MyoD was 
immunoprecipitated using anti-Myc agarose beads followed by immuno-blotting 
with anti-Flag antibody to detect the association of MyoD and P/CAF in the 
presence of G9a compared to control. It was followed by immuno-blotting with 
anti-Ac-Lys) antibody. Lysates (input) were analyzed for G9a, MyoD and P/CAF 









3.2.2 Modulation of endogenous G9a level and its impact on MyoD 
acetylation 
To determine whether MyoD acetylation can be modulated by depletion of 
endogenous G9a levels in myoblasts, siRNA knockdown approach was carried 
out. C2C12 cells were transfected with scrambled siRNA control or siRNA 
targeted to G9a (siG9a). Forty-eight hours post-transfection, cells were 
switched to DM with 10mM each of nicotinamide (NAM), which is an 
inhibitor of class III NAD-dependent Sir-2 family deacetylases and sodium 
butyrate, an HDAC inhibitor, in order to preserve P/CAF mediated MyoD 
acetylation and induced to differentiate for two days. Cell lysates were 
collected at day 0 and day 2. MyoD was immunoprecipitated using anti-MyoD 
antibody and immuno-blotted with anti-acetyl-lysine antibody (Ac-Lys) to 
assess whether the knockdown of G9a modulates endogenous MyoD 
acetylation. Compared to control (siRNA) cells, siG9a cells showed an early 
induction of MyoD acetylation at Day 0 (Fig 3.2.2). Western blot analyses 
performed for Troponin T on cell extracts obtained from G9a depleted (siG9a) 
or control (siRNA) C2C12 cells showed that expression of TroponinT was 








Figure 3.2.2 Modulation of endogenous G9a level and its impact on MyoD 
acetylation: C2C12 myoblasts were transfected with siG9a and control siRNA. 
Lysates were collected at day 0 and day 2. Endogenous MyoD was 
immunoprecipitated from lysates of C2C12 myoblasts expressing siG9a and 
control siRNA using anti-MyoD antibody. The blot was analyzed for MyoD 
acetylation using anti-Ac-Lys antibody. Input shows the knockdown of 
endogenous G9a as well as the expression of MyoD and Troponin T. β-actin was 
used as internal control. 
 
3.2.3 Titration of embelin in C2C12 cells 
Embelin, (a hydroxy benzoquinone class of natural compound) is a cell 
permeable small molecule which was originally identified by its pro-apoptotic, 
anti-tumourogenic, anti-cancer and anti-viral activity (Reuter et al., 2010; 
Hussein et al., 2000). However, the molecular mechanisms behind these 
biological activities are not well understood. Works done in collaboration with 
Prof Tapas Kundu’s lab have established that embelin is a selective P/CAF 







As embelin specifically targets P/CAF acetyltransferase activity, we wanted to 
analyze its impact on skeletal muscle differentiation. To first determine the 
concentration of embelin that could be used, C2C12 myoblasts were cultured 
with varying concentrations of embelin (0-20µM) and switched to DM and 
induced to differentiate for two days. As treatment with 10µM resulted in 
impairment of myotube formation (Fig.3.2.3) and a concentration higher than 
10µM induced cytotoxicity (Fig.3.2.3), 10µM was used as an optimum 
concentration for subsequent experiments. An equivalent concentration of its 




Figure 3.2.3 Titration of embelin in C2C12 cells: C2C12 cells were cultured in 
GM and switched to DM and treated with different concentrations of embelin or 
MJTK-4 (control) for 48 hours (Day2). Myoblast differentiation was observed by 








3.2.4 Embelin inhibits muscle differentiation 
To analyze the impact of targeting P/CAF acetyltransferase activity on muscle 
differentiation, C2C12 cells were cultured in GM and switched to DM with 
10µM of embelin or its inactive analogue MJTK-4 (control) and induced to 
differentiate for two days. Untreated and 10 µM of DMSO treated cells were 
used as additional controls. 
On day 2, differentiation was examined morphologically in embelin treated 
cells compared to MJTK-4, DMSO treated and untreated cells. We noticed an 
impairment of myotube formation in embelin treated cells compared to 
controls as evidenced by reduced myotube formation with overall defect in the 
formation of differentiated cells (Fig 3.2.4A). 
 
Figure 3.2.4A Embelin inhibits muscle differentiation: (A) C2C12 cells were 
cultured in GM (D0) and switched to DM and treated with 10µM of Embelin or 
MJTK-4 (control) for 48 hours (D2). Untreated and vehicle (DMSO) treated cells 
were used as additional controls. Myoblast differentiation was observed by phase-
contrast microscopy. Impaired myotube formation was evident in embelin treated 







This was also reflected by reduction in the number of (MHC
+
) cells (Fig 
3.2.4.B) as well as myogenic index at D3 (Fig 3.2.4C). To further investigate 
the mechanisms underlying the inhibition of myogenic differentiation, we 
analyzed expression of myogenin and Troponin T, which are MyoD target 
genes and are dependent on its transcriptional activity. Both genes were 
substantially down-regulated in embelin treated cells as shown in the western 
blot (Fig 3.2.4D). 
 
Figure 3.2.4B Embelin inhibits muscle differentiation: (B) For MHC staining, 
C2C12 cells were treated with embelin, MJTK-4 and vehicle (DMSO) for 72 
hours (D3). The cells were then immuno-stained for MHC using anti-MHC (red) 
antibody and the nuclei were stained with DAPI (blue). Images were captured 
under fluorescent microscope using 10X magnification. There was a significant 









Figure 3.2.4 C&D Embelin inhibits muscle differentiation: (C) Quantification 
of myogenic index from 4 randomly chosen microscopic fields (at least 400 
nuclei were calculated) revealed a significant decrease in the number of MHC+ 
cells in embelin treated cells compared to controls. Values obtained were 
represented as means with error bar indicating standard deviations. Statistical 
significance was determined by the two-tailed, un-paired Student’s t test and p-
values of <0.05 were considered to be statistically significant. p-value obtained is 
shown as *** (p < 0.001). (D) C2C12 cells were left untreated (D0) or treated 
with10µM of Embelin or MJTK-4 for 24 hours (D1) or 72 hours (D3) in DM. 
Cell lysates were analyzed by western blot for myogenic markers such as 








3.2.5 Embelin affects P/CAF mediated MyoD acetylation 
It has been shown by previous studies that p300 first acetylates H3 and H4 
within the promoter region and then recruits P/CAF which interacts and 
directly acetylates MyoD to initiate skeletal myogenesis (Sartorelli et al., 
1999; Dilworth et al., 2004; Aziz et al., 2010). To examine whether treatment 
of cells with embelin results in altered MyoD acetylation, co-
immunoprecipitation assays were performed. 293T cells were transfected with 
either Myc-tagged MyoD or Flag-tagged P/CAF alone or together in the 
presence of either 15µM embelin or MJTK-4. In addition, the cells were also 
treated with 10mM of NAM and sodium butyrate. Twenty-four hours post-
transfection, cell lysates were harvested using RIPA lysis buffer, to which 
10mM of NAM and sodium butyrate were added and checked for expression 
of Myc-MyoD and Flag-P/CAF. Cell lysates were immunoprecipitated with 
Myc-agarose beads and immunoprecipitates were probed by western blot for 
P/CAF mediated MyoD acetylation using anti-acetyl-lysine (Ac-Lys) 
antibody. As expected, MyoD was acetylated when it was co-expressed with 
P/CAF (Fig 3.2.5). However, treatment with embelin resulted in reduction in 
MyoD acetylation compared to untreated and MJTK-4 control. However, 








Figure 3.2.5 Embelin affects P/CAF mediated MyoD acetylation: HEK293T 
cells were transfected with full length Myc-tagged MyoD, Flag-tagged P/CAF 
either individually or together in the presence of 15µM of Embelin or MJTK-4 
(control). Untreated cells were used as an additional control. MyoD was 
immunoprecipitated using anti-Myc agarose beads followed by immuno-blotting 
with anti-Flag, anti-Ac-Lys and anti-Myc antibody. Lysates (input) were analyzed 
for MyoD and P/CAF expression by western blot analysis. β-actin was used as 
internal control. 
3.2.6 Embelin does not alter H3K9 acetylation on muscle promoters 
To examine for any alteration in the level of histone H3K9 acetylation on 
muscle promoters upon embelin treatment, ChIP assays were carried out on 
myogenin (Fig 3.2.6A) and MCK promoter (Fig 3.2.6B) by treating C2C12 
cells with10µM of embelin and MJTK-4 for two days in differentiation 
medium. D0 cells were left untreated. We observed no alteration in H3K9 







3.2.6A & 3.2.6B) show the specificity of embelin as selective P/CAF 
inhibitor. In addition, these data are in clear agreement with and further 
validate the previous literature about distinct roles played by p300 and P/CAF, 
wherein p300 was shown to first acetylate H3 and H4 within the promoter 
region and then recruit P/CAF which then interacts and directly acetylates 
MyoD resulting in its transactivation (Sartorelli et al., 1999; Dilworth et al., 
2004; Aziz et al., 2010). 
 
Figure 3.2.6A Embelin treatment does not alter H3K9 acetylation on 
myogenin promoter: (A) H3K9 acetylation of the myogenin promoter was 
analyzed by ChIP assays. C2C12 cells were cultured in GM (Day 0) and switched 
to DM and treated with 10µM of Embelin or MJTK-4 (control) for 48 hrs (Day 
2). Cell lysates were subjected to ChIP assays using H3K9ac antibody. DNA was 
analyzed by Q-PCR using primer for the myogenin promoter and the values 
obtained were normalized to β-actin. Statistical significance was determined by 
Student’s t test and p-value obtained was not statistically significant (p< 0.22).  








Figure 3.2.6B Embelin treatment does not alter H3K9 acetylation on MCK 
promoter: (B) H3K9 acetylation of the MCK promoter was analyzed by ChIP 
assays. C2C12 cells were cultured in GM (Day 0) and switched to DM and treated 
with 10µM of Embelin or MJTK-4 (control) for 48 hrs (Day 2). Cell lysates were 
subjected to ChIP assays using H3K9ac antibody. DNA was analyzed by Q-PCR 
using primer for the MCK promoter and the values obtained were normalized to 
β-actin. Statistical significance was determined by Student’s t test and p-value 
obtained was not statistically significant (p< 0.069). Experiments were done by 
Mr. Wai Kay Kok. 
 
3.2.7 Embelin treatment results in alteration of global H3K9 acetylation 
during differentiation 
As the preceding result shows that embelin treatment results in no alteration of 
H3K9 acetylation on muscle promoters, we went on to check whether such 
treatment results in alteration of global H3K9ac. C2C12 cells were cultured in 
GM and then switched to DM with 10µM of embelin or MJTK-4 (control) and 







analyzed by western blot for H3K9ac using anti-H3K9ac antibody. The level 
of H3K9ac increased upon differentiation (D2) in control cells treated with 
MJTK-4 compared to D0. Surprisingly, H3K9ac decreased in D2 cells upon 
embelin treatment to the level seen in D0 cells (Fig 3.2.7). This result is in 
contrast to what was seen by ChIP assays on the myogenin and MCK 
promoters upon embelin treatment, where the level of H3K9ac remains 
unaltered. This suggests that global H3K9ac is mediated by both by both p300 
and P/CAF. This finding is interesting as it sheds light on the previously 
unreported role of P/CAF in mediating global H3K9ac in muscle cells. 
Figure 3.2.7 Embelin treatment results in alteration of global H3K9 
acetylation during differentiation: C2C12 cells were cultured in GM (D0) and 
switched to DM with 10µM of embelin or MJTK-4 for 48 hrs (D2). Cell lysates 
were collected at day 0 and day 2. Global H3K9 acetylation was determined using 










3.2.8 Embelin affects a wide array of muscle specific gene expression 
during differentiation 
While the role of P/CAF in acetylation and activation of MyoD has been 
reported, its genome wide targets in myogenesis have not been reported. To 
identify genes whose expression is altered upon embelin treatment by 
targeting P/CAF acetyltransferase activity, C2C12 cells were cultured in GM 
for 24 hours (Day 0) in the presence of 10µM of DMSO (control) or embelin 
and then switched to DM for another 24 hrs (Day 1) and 48 hrs (Day 2) 
respectively. From these cells, total RNA was isolated, reverse transcribed, 
labelled and subsequently hybridized to Illumina mouse WG-6 v2.0 array. 
Our microarray data revealed that there was no significant difference in the 
global gene expression until day 1 in cells treated with embelin compared to 
control (DMSO) cells (Fig 3.2.8), although the absolute change in the 
expression pattern from day 0 to day 1 was slightly lower in embelin treated 
cells compared to control (Fig 3.2.8). However, a significant change was 
observed in gene expression pattern in cells that were treated with embelin for 
2 days compared to control (DMSO) cells (Fig 3.2.8). This change in 
expression pattern of many muscle specific genes on day 2 upon embelin 
treatment is consistent with the impairment of myotube formation seen 
morphologically on day 2 in the earlier results (Fig 3.2.4A). As trans-
activation of MyoD by P/CAF mediated acetylation is essential for MyoD to 







myosin heavy chain (MYH1) and MRF4 and validated their significant 




Figure 3.2.8A Embelin treatment results in alteration of a set of genes during 
differentiation: (A) C2C12 cells were cultured in GM for 24 hours (Day 0) in the 
presence of 10µM of DMSO or embelin and then switched to DM for another 24 
hrs (Day 1) and 48 hrs (Day 2) respectively. From day 1 and day 2 DMSO and 
embelin treated cells, total RNA was isolated, reverse transcribed, labelled and 







expression of various genes after 24 hours and 48 hours treatment with DMSO 





Figure 3.2.8B&C Embelin treatment results in alteration of a set of genes 
during differentiation: (B) Expression of few MyoD responsive genes like 
myosin heavy chain (MYH1) and MRF4 in the embelin treated C2C12 cells 
were validated by Q-PCR. The fold expression of muscle-specific genes in the 
embelin treated over DMSO (control) treated C2C12 cells was calculated and 







expression were quantified and standardized against the house-keeping gene 
GAPDH. Values obtained were represented as means with error bar indicating 
standard deviations. Statistical significance was determined by Student’s t test 
and p-value obtained is shown as * [p< 0.05], *** [p< 0.001]. Microarray data 
provided by Mr. Vinay Kumar. 
 
3.2.9 Biological network analysis from microarray data obtained from 
embelin treated cells Vs DMSO treated cells 
The de novo mouse muscle differentiation interactome map was generated by 
carrying out Biological network analysis from the microarray data using 
Genespring GX v.12.0 from a total of 171 genes that are annotated to be 
involved in myogenic differentiation. The analysis revealed that targeting 
P/CAF acetyltransferase activity by embelin leads to induction in the 
expression of several genes such as TNFα, NOS2, STAT3, PAX 7 [Fig 3.2.9 
and Table 3.2.9 (inner ring)], NOS1, Sox9, BMP4, Socs3 [Fig 3.2.9 and 
Table 3.2.9 (middle ring)], JAK3, KLF4, NFκB [Fig 3.2.9 and Table 3.2.9 
(outer ring)], ( Diao et al., 2009; Jang et al., 2012;Wang et al.,2008;  Yang et 
al., 2009; Kataoka et al., 2003; Chandran et al., 2007; Kaliman et al., 1999; 
Soleimani et al., 2012; Hernández-Hernández  et al., 2009) which are known 
to be essential for myoblast survival, proliferation and inhibition of myogenic 
differentiation. On the other hand, it leads to repression of genes such as 
Adam12, Mef2c, SRF [Fig 3.2.9 and Table 3.2.9 (middle ring)], MyoD and 
laminin-α1[Fig 3.2.9 and Table 3.2.9 (outer ring)], which are essential for 
myogenesis (Lafuste et al., 2005; Braun and Gautel et al., 2011; Kuhl et al., 







that P/CAF regulates skeletal muscle differentiation through various MyoD 
dependent and independent pathways.  
Figure 3.2.9 Biological network analysis from microarray data obtained from 
embelin treated cells vs. DMSO treated cells: Biological network analysis 
exhibiting the differential expression of several genes involved in myogenic 
differentiation in C2C12 cells cultured in DM for 48 hrs (Day 2) in the presence 
of 10µM of DMSO (red bar) or embelin (blue bar). Genes of interest analyzed 
under this result section is highlighted in green and pink for induction and 










Table 3.2.9 A total of 128 genes that are shown in Fig 3.2.9 is being tabulated 
here (genes are tabulated in the order of inner, middle and outer ring of the de 














3.3 Role of G9a in skeletal muscle pathology (Rhabdomyosarcoma) 
Rhabdomyosarcoma is a highly malignant and most common soft tissue 
sarcoma of childhood and adolescence which accounts for approximately 5-
8% of pediatric cancer. It originates as a consequence of disruption of growth 
and differentiation pathways of myogenic precursor cells and is characterized 
by the expression of MyoD and its downstream target genes such as myogenin 
(Scrable et al., 1989; Sebire et al., 2003; Ren et al., 2008; Tapscott et al., 
1993). In spite of the expression of MyoD, it does not lead to cell cycle arrest 
or to terminal differentiation, implicating that MyoD pathway is functionally 
defective. As G9a inhibits myogenesis by affecting the transcriptional activity 
of MyoD, I wanted to know if these findings have any clinical significance; 
hence I analyzed for the relevance of G9a in rhabdomyosarcoma. 
3.3.1 G9a is overexpressed in ARMS cells under differentiation-
permissive conditions 
To investigate the possible role of G9a in RMS, its expression was analyzed in 
Rh30 cells at protein level in proliferating and differentiation-permissive 
conditions by western blot analysis. Rh30 cells were cultured in GM for 24 
hours (Day 0) and then switched to DM for another 24 hours (Day 1), 48 hours 
(Day 2) and 72 hours (Day 3) respectively. In addition, C2C12 cells were 
cultured in GM and then switched to DM for 48 hours (Day 2). Cell lysates 
were collected at day 0, 1, 2 and 3 for Rh30 cells and C2C12 cells respectively 
and analyzed for the expression of G9a by using anti-G9a antibody. Consistent 







0 and declined upon differentiation (Day 2) (Fig 3.3.1A). In contrast, in Rh30 
cells, G9a was expressed at day 0, 2 (Fig 3.3.1B) and its expression was 
sustained at high levels until day 3 of differentiation (Fig 3.3.1C) 
demonstrating deregulated expression of G9a in ARMS cells.  
Figure 3.3.1A&B G9a is overexpressed in Rh30 cells: (A) C2C12 cells were 
grown either in GM (Day 0) or DM for 48 hrs (Day 2). Lysates were collected at 
day 0 and day 2 and analyzed for G9a expression by western blot analysis. β-actin 
was used as internal control. (B) Rh30 cells were grown either in GM (Day 0) or 
DM for 48 hrs (Day 2). Lysates were collected at day 0 and day 2. Lysates (input) 
were analyzed for G9a expression by western blot analysis. β-actin was used as 
internal control. 
Since RMS is characterized by the expression of key early myogenic 
regulators of differentiation namely Myf5 and MyoD as well as its target 
myogenin (Scrable et al., 1989; Sebire et al., 2003; Ren et al., 2008; Tapscott 
et al., 1993), the immunoblot was probed for the expression of MyoD and 
myogenin in addition to G9a. Consistent with previous reports, these MRFs 







the ability to terminally differentiate as evident by the lack of expression of 
terminal differentiation markers like Troponin T (Fig 3.3.1C). 
 
 
Figure 3.3.1C&D G9a is overexpressed in Rh30 cells: (C) Lystaes that were 
collected at day 0 and day 2 from C2C12 and Rh30 cells were then analyzed for 
Troponin-T expression. (D) Rh30 cells were grown either in GM (Day 0) or 
DM for 24, 48 and 72 hrs respectively (Day1, 2 and 3). Lysates were collected 
at day 0, 1, 2 and 3 and analyzed for G9a, MyoD, myogenin and p21 
expression by western blot analysis. β-actin was used as internal control. 
 
Studies have shown that the expression of p21 and MyoD has an inverse 
relationship in these tumors (Weintraub et al., 1997). For example, Rh30 cells 
which express high level of MyoD have lower p21 levels. Conversely, Rh28 
cells which have lower expression of MyoD have higher level of p21. Hence, 
p21 expression was analyzed in Rh30 cells and found to be expressed at lower 








3.3.2 UNC0638 induces expression of myogenin and p21 in Rh30 cells 
Since G9a expression is deregulated in ARMS cells (i.e., Rh 30 cells), its 
methyltransferase activity was targeted using UNC0638 to examine whether it 
rescues the differentiation defect. Rh30 cells were cultured in GM for 24 hours 
(Day 0) and then switched to DM for another 24 hours (Day 1) and48 hours 
(Day 2) respectively in the absence and presence of 1.5µM of UNC0638. Cell 
lysates were collected at day 0, 1 and 2 and analyzed for expression of 
myogenin and p21. Interestingly, Rh30 cells treated with 1.5µM of UNC0638 
exhibited higher expression of myogenin and p21 (Fig 3.3.2) compared to 
untreated control cells at day 1 and day 2 suggesting the role of G9a in the 
differentiation defect of RMS. 
 
Figure 3.3.2 UNC0638 induces expression of myogenin and p21 in Rh30 cells 
Rh30 cells were grown in GM (Day 0) and switched to DM for 24 hrs (Day 1) 
and 48 hrs (Day 2) respectively in the absence and presence of 1.5µM of 
UNC0638. Lysates were collected at day 0, 1 and 2 and analyzed for myogenin 









3.3.3 UNC0638 induces early expression of myogenin in Rh30 cells 
UNC0638 treatment of Rh30 cells in differentiation-permissive condition 
induced higher expression of myogenin at day 1 and day 2 (Fig3.3.2); hence, 
Rh30 cells were treated with UNC0638 at day 0 to examine whether it results 
in early induction of myogenin. Rh30 cells were cultured in GM for 24 hours 
(Day 0) in the absence and presence of 1.5µM of UNC0638 and then switched 
to DM for another 48 hours (Day 2) in the absence and presence of 1.5µM of 
UNC0638. Cell lysates were collected at day 0 and 2 and analyzed for the 
expression of myogenin. Interestingly, Rh30 cells treated with UNC0638 at 
day 0 resulted in early induction of myogenin (Fig3.3.3). 
 
Figure 3.3.3 UNC0638 induces early expression of myogenin in Rh30 cells: 
Rh30 cells were grown for 24 hours in GM (Day 0) in the absence and presence 
of 1.5µM and switched to DM for another 48 hrs (Day 2) in the absence and 
presence of 1.5µM of UNC0638. Lysates were collected at day 0 and day 2 and 









3.3.4 Loss of G9a induces myogenin and p21 expression in Rh30 cells 
Rh30 cells were transfected with 100nM of scrambled siRNA (control) or 
human G9a specific siG9a for 48 hrs in GM. As shown in Fig 3.3.4, siG9a 
reduced endogenous G9a levels in Rh30 cells. To assess the effect of G9a 
knockdown on control and siG9a cells, Rh30 cells were switched to DM for 
another 96 hrs (Day 4). Cell lysates were collected from G9a depleted (siG9a) 
or control (siRNA) Rh30 cells on day 0 and day 4 and western blot analyses 
performed for myogenin as well as p21showed an increase in the expression of 




Figure 3.3.4 Loss of G9a induces higher expression of myogenin and p21 in 
Rh30 cells: Rh30 cells were transfected with human siRNA against G9a (siG9a), 
scrambled siRNA (siRNA) for 48 hours. Lysates were collected for day 0 and 
analyzed for the knockdown of endogenous G9a at protein level by western blot. 
Rh 30 cells were switched to DM for another 96 hours (Day 4) and lysates were 
collected. Cell lysates were then analyzed by western blot for myogenin and 


























Skeletal muscle development and differentiation is controlled by the 
combinatorial activity of two transcription factors families that include 
Myogenic Regulatory Factors (MRFs) and the Myocyte Enhancer Factor-2 
(MEF2) which works in combination with various other transcription factors 
and epigenetic regulatory mechanisms. The goal of this project is to 
investigate the role of G9a in epigenetic regulation of skeletal muscle 
differentiation. I have identified G9a as a novel negative regulator of 
myogenesis which is expressed high in proliferating myoblasts and is down-
regulated upon differentiation. Overexpression of G9a in skeletal muscle 
precursor cells blocks their ability to undergo differentiation. This repression 
of differentiation is dependent on its methyltransferase activity. Thus over-
expression of mutant G9a lacking catalytically active SET domain fails to 
inhibit myogenesis unlike wild-type G9a. Conversely, knockdown of G9a in 
proliferating myoblasts by siRNA results in enhanced myogenic 
differentiation reflected by an increase in the number of myotubes as well as 
early induction of muscle specific genes such as myogenin and Troponin-T. At 
the molecular level, G9a mediated repression of muscle genes is achieved 
through enrichment of transcriptionally repressive H3K9me2 mark on the 
myogenin promoter which is a MyoD target gene. Over-expression of G9a 
results in significant increase in H3K9me2 both in undifferentiated as well as 
in differentiated myotubes. In addition to mediating H3K9me2 on muscle 







MyoD (Fig.4) through its ANK domain, and methylates at a single lysine (K) 
residue 104. The association of G9a with MyoD is essential for methylation, 
as protein interaction studies demonstrate that disruption of the association by 
the deletion of G9a ANK domain abrogates MyoD methylation. Methylation 
of MyoD inhibits its transactivational ability to upregulate myogenin 
expression. Thus mutation of K104 to arginine (K104R) makes MyoD non-
responsive to methylation and this results in mutant MyoD (K104R) exhibiting 
higher myogenic potential compared to wild-type MyoD in myogenic 
conversion assays.  
It is interesting to note that K104, which is subjected to methylation by G9a, 
also happens to be one of the three sites for acetylation by P/CAF. Previous 
studies have shown that P/CAF directly acetylates MyoD at K99, K102 and 
K104 during differentiation, resulting in its transactivation (Sartorelli et al., 
1999; Dilworth et al., 2004; Aziz et al., 2010). As K104 is an overlapping site 
for G9a mediated methylation and P/CAF mediated acetylation, this raised the 
possibility that G9a might disrupt P/CAF-mediated MyoD acetylation. 
Immunoprecipitation assays indeed confirmed this notion and revealed that 
G9a alters the ability of P/CAF to interact with MyoD and correspondingly 
MyoD acetylation. Moreover, depletion of G9a in proliferating myoblasts by 
siRNA mediated knockdown shifted the kinetics of acetylation to an early 
time point. These results demonstrate the potentiality of cross-talk between 
G9a and P/CAF in controlling MyoD transcriptional activity and as a 







To further understand the broader role played by P/CAF in regulating skeletal 
muscle differentiation, embelin, a natural compound which specifically targets 
the acetyltransferase activity of P/CAF was used. This enabled me to analyze 
its global impact on skeletal muscle differentiation. Treatment of C2C12 cells 
with embelin resulted in overall defect in skeletal muscle differentiation with 
lesser number of MHC positive cells as well as down-regulation of myogenin 
and Troponin-T. As P/CAF mediated MyoD acetylation is crucial for the 
differentiation of myoblasts to myotubes, immunoprecipitation assays were 
done to determine the impact of embelin on MyoD acetylation. In embelin 
treated cells, MyoD acetylation was reduced although MyoD-P/CAF 
interaction remained intact. This could attribute to the repression of MyoD 
target genes such as myogenin and Troponin-T and as a consequence 
impairment of myotube formation. Our result from ChIP assays showed that 
embelin treatment did not result in any alteration in the level of histone H3K9 
acetylation at the myogenin and MCK promoters. These results validate 
previously documented studies that have demonstrated the distinct roles 
played by p300 and P/CAF, with p300 first acetylating H3 and H4 within the 
promoter region and then recruiting P/CAF which then interacts and directly 
acetylates MyoD (Sartorelli et al., 1999; Dilworth et al., 2004; Aziz et al., 
2010). Interestingly, the analysis for alteration in global H3K9ac in C2C12 
cells upon embelin treatment yielded a contrasting result as it showed a 
decrease in the level of H3K9ac, suggesting the possibility that in skeletal 







is significant as it enables us to characterize the previously unexplored role of 
P/CAF in mediating global H3K9ac in muscle cells. Our micro-array data and 
subsequent biological network analysis enabled us to identify the wide array 
of genes that are known to be regulated by P/CAF during muscle 
differentiation. More importantly, several new and previously uncharacterized 
targets have been identified. In addition to reduction in the expression of 
MyoD responsive genes, such as myogenin, MRF4 and MHC, there was 
altered expression of muscle structural genes, histone modifiers, and many 
transcription factors. For example, targeting P/CAF acetyltransferase activity 
resulted in repression of genes like laminin-α1, which encodes for one of the 
three non-identical chains of laminin (laminin-1; alpha 1-beta 1-gamma 1), a 
basement membrane protein which plays a prominent role in facilitating 
myoblast adhesion, migration, proliferation and myotube formation (Kuhl et 
al., 1982; Foster et al., 1987; Kroll et al., 1994). In addition to laminin-α1, 
ADAM12 and SRF were found to be repressed. ADAM12 (a disintegrin and 
metalloproteinase domain containing protein 12) is a multi-domain protein 
which binds to α9β1integrin, mediating cell-cell interaction resulting in fusion 
of myoblasts to form multinucleated myotubes (Lafuste et al., 2005). Likewise 
SRF (Serum responsive factor), a MADS box transcription factor related to 
Mef2 plays a central role in skeletal muscle growth and maturation (Li et al., 
2005). 
Embelin treated cells show higher expression of Pax7 which is essential for 







undifferentiated state (Soleimani et al., 2012; Wang and Rudnicki 2011). 
STAT3, a transcription factor which plays a central role in the regulation of 
growth, differentiation and survival in various cell types, is induced in the 
embelin treated cells. Studies have shown that STAT3 can interact with MyoD 
depriving it of transcriptional co-factors p300 and P/CAF thereby affecting its 
transcriptional activity resulting in inhibition of differentiation (Kataoka, et 
al., 2003). 
These results collectively suggest that P/CAF regulates skeletal muscle 
differentiation through various MyoD dependent and independent pathways.  
 
Figure 4 Model for epigenetic regulation of promoters in undifferentiated 



























Conclusion and future studies 
My work has revealed the previously not well-understood epigenetic 
mechanisms by which chromatin modifiers like G9a, an enzyme 
predominantly involved in H3K9me2, regulate the transcriptional activity of 
non-histone substrates such as MyoD by directly methylating them and 
controlling cellular differentiation programs. It is well known that P/CAF 
mediated acetylation of MyoD at three lysine residues is the key determinant 
of MyoD activity during differentiation (Sartorelli et al., 1999; Dilworth et al., 
2004; Aziz et al., 2010). However, it is unclear why P/CAF mediated MyoD 
acetylation primarily occurs upon induction of differentiation although P/CAF 
is expressed even in undifferentiated cells (Sartorelli et al., 1999; Mal et al., 
2001). My work provides a partial explanation for this, as it shows that K104 
is an overlapping site for methylation by G9a and acetylation by P/CAF. G9a 
disrupts P/CAF mediated MyoD acetylation. This suggests that G9a, which is 
expressed in proliferating myoblasts methylates MyoD, and once methylated, 
K104 is unavailable for P/CAF mediated acetylation thereby restrains MyoD 
transcriptional activity in myoblasts. Thus there might be a regulatory axis 
involving G9a and P/CAF in controlling MyoD activity and thereby the 
transition from myoblasts to myotubes which needs to be further investigated. 
As other histone methyltransferases like Suv39h1 and Ezh2 are also expressed 
in proliferating myoblasts and block MyoD transcriptional activity (Mal et al., 
2006; Caretti et al., 2004), it raises the possibility that G9a may be part of a 







activation of muscle differentiation program. Since these HKMTs leave 
different repressive chromatin marks such as H3K9me2, H3K9me3 and 
H3K27me3, whether they act in unison or in sequence to mediate gene 
repression or silencing, to maintain an undifferentiated state, remains to be 
investigated. However, unlike G9a, which inhibits MyoD activity at multiple 
levels by directly methylating it as well as mediating H3K9me2 on muscle 
promoters, the repressive function of Suv39h1 and Ezh2 remains restricted to 
chromatin modification as they have not been reported to target MyoD for 
methylation. Interestingly, G9a methylation consensus extends beyond MyoD 
to include all other members of MRFs (Fig 3.1.12) and if all the MRFs are 
indeed the targets for its methylation, the consequences of such methylations 
need to be examined. 
In addition, the analysis for a broader role of P/CAF in skeletal myogenesis by 
pharmacological inhibition of P/CAF activity enabled us to identify a wide 
array of genes that exhibited altered expression. Some of these genes may be 
direct P/CAF targets (those that are down regulated), whereas genes 
upregulated by embelin treatment likely reflect its indirect targets. Future 
studies aimed at dissecting the functional role of some previously unknown 
putative direct targets of P/CAF should shed insights into their role in 
myogenesis.  
My preliminary result shows deregulated expression of G9a in 
rhabdomyosarcoma which are characterized by a differentiation defect despite 







chemical probe UNC0638 or depletion of G9a by siRNA mediated 
knockdown resulted in the induction of MyoD target genes such as myogenin 
and p21. These studies will be continued to determine whether targeting G9a 
expression/activity leads to induction of differentiation in cell culture and 
animal models. Through such studies we hope to have a better understanding 
about the role of deregulated expression of epigenome in skeletal muscle 
pathologies like rhabdomyosarcoma. Eventually, this might lead to 

























Table I. Primers for Q-PCR 
 





TCGGGCAATCAGTCAGACAG TGAGGAACCCACACCATTCAC 60 
MYH1 AACAGCAGCGGCTGATCAAT GCTGCCTCTTCAGCTCCTCA 60 
MRF4 CTACATTGAGCGTCTACAGGACC CTGAAGACTGCTGGAGGCTG 60 
Myogenin 
promoter 
TGGCTATATTTATCTCTGGGTTCATG GCTCCCGCAGCCCCT 60 
     MCK 
   promoter 
CGCCAGCTAGACTCAGCACT CCCTGAGAGCAGATGAGCTT 60 
GAPDH ATCAACCGGGAAGCCCATCAC CCTTTTGGCTCCACCCTTCA 60 




TABLE II. Primers for human siRNA 
 
Smart pool siRNA sequences sequence 
Non-targeting siRNA -1 UGGUUUACAUGUCGACUAA 
Non-targeting siRNA -2 UGGUUUACAUGUUGUGUGA 
Non-targeting siRNA -3 UGGUUUACAUGUUUUCUGA 





















TABLE III. Primers for mouse siRNA 
 
Smart pool siRNA sequences sequence 
Non-targeting siRNA -1 UGGUUUACAUGUCGACUAA 
Non-targeting siRNA -2 UGGUUUACAUGUUGUGUGA 
Non-targeting siRNA -3 UGGUUUACAUGUUUUCUGA 
Non-targeting siRNA -4 UGGUUUACAUGUUUUCCUA 
siG9a-1 UAACAAGGAUGGCGAGGUU 































Albini S, Puri PL. SWI/SNF complexes, chromatin remodeling and skeletal 
myogenesis: it's time to exchange! Exp Cell Res. 2010; 316(18):3073-80.  
 
Amack JD, Mahadevan MS. Myogenic defects in myotonic dystrophy. Dev 
Biol. 2004;265(2):294-301. 
 
Amthor H, Christ B, Weil M, Patel K. The importance of timing 
differentiation during limb muscle development. Curr Biol. 1998 May; 
8(11):642-52. 
 
Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K. Disruption 
of imprinted genes at chromosome region 11p15.5 in paediatric 
rhabdomyosarcoma. Neoplasia. 1999; 1(4):340-8. 
 
Andrés V, Walsh K. Myogenin expression, cell cycle withdrawal, and 
phenotypic differentiation are temporally separable events that precede cell 
fusion upon myogenesis. J Cell Biol. 1996; 132(4):657-66. 
 
Asakura A, Fujisawa-Sehara A, Komiya T, Nabeshima Y, Nabeshima Y. 
MyoD and myogenin act on the chicken myosin light-chain 1 gene as distinct 
transcriptional factors. Mol Cell Biol. 1993; 13(11):7153-62. 
 
Atchley WR, Fitch WM, Bronner-Fraser M. Molecular evolution of the MyoD 
family of transcription factors. Proc Natl Acad Sci U S A. 1994; 
91(24):11522-6. 
 
Aziz A, Liu QC, Dilworth FJ. Regulating a master regulator: establishing 









Azmi S, Ozog A, Taneja R. Sharp-1/DEC2 inhibits skeletal muscle 
differentiation through repression of myogenic transcription factors. J Biol 
Chem. 2004; 279(50):52643-52. 
 
Baxter CS, Byvoet P. Intercalating agents as probes of the spatial relationship 
between chromatin components. Biochem Biophys Res Commun. 
1975;63(1):286-91. 
 
Benezra R, Davis RL, Lassar A, Tapscott S, Thayer M, Lockshon D, 
Weintraub H. Id: a negative regulator of helix-loop-helix DNA binding 
proteins. Control of terminal myogenic differentiation. Ann N Y Acad Sci. 
1990; 599:1-11. 
 
Bengal E, Ransone L, Scharfmann R, Dwarki VJ, Tapscott SJ, Weintraub H, 
Verma IM. Functional antagonism between c-Jun and MyoD proteins: a direct 
physical association. Cell. 1992; 68(3):507-19.  
 
Bergstrom DA, Penn BH, Strand A, Perry RL, Rudnicki MA, Tapscott SJ. 
Promoter-specific regulation of MyoD binding and signal transduction 
cooperate to pattern gene expression. Mol Cell. 2002; 9(3):587-600. 
 
Bharathy N, Ling BM, Taneja R. Epigenetic regulation of skeletal muscle 
development and differentiation. Subcell Biochem. 2012; 61:139-50. 
 
Bharathy N, Taneja R. Methylation Muscles into Transcription Factor 
Silencing. Transcription.2012; 3(5):1-6. 
 
Black BL, Olson EN. Transcriptional control of muscle development by 









Blackwell TK, Weintraub H. Differences and similarities in DNA-binding 
preferences of MyoD and E2A protein complexes revealed by binding site 
selection. Science. 1990; 250(4984):1104-10. 
 
Bober E, Franz T, Arnold HH, Gruss P, Tremblay P. Pax-3 is required for the 
development of limb muscles: a possible role for the migration of 
dermomyotomal muscle progenitor cells. Development. 1994; 120(3):603-12. 
 
Borycki AG, Brunk B, Tajbakhsh S, Buckingham M, Chiang C, Emerson CP 
Jr. Sonic hedgehog controls epaxial muscle determination through Myf5 
activation.Development. 1999; 126(18):4053-63. 
 
Branscombe TL, Frankel A, Lee JH, Cook JR, Yang Z, Pestka S, Clarke S. 
PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric 
dimethylarginine residues in proteins. J Biol Chem. 2001; 276(35):32971-6.  
 
Braun T, Bober E, Winter B, Rosenthal N, Arnold HH. Myf-6, a new member 
of the human gene family of myogenic determination factors: evidence for a 
gene cluster on chromosome 12. EMBO J. 1990; 9(3):821-31. 
 
Braun T, Buschhausen-Denker G, Bober E, Tannich E, Arnold HH. A novel 
human muscle factor related to but distinct from MyoD1 induces myogenic 
conversion in10T1/2 fibroblasts. EMBO J. 1989; 8(3):701-9. 
 
Braun T, Rudnicki MA, Arnold HH, Jaenisch R. Targeted inactivation of the 
muscle regulatory gene Myf-5 results in abnormal rib development and 








Braun T, Arnold HH. Myf-5 and myoD genes are activated in distinct 
mesenchymal stem cells and determine different skeletal muscle cell lineages. 
EMBO J. 1996; 15(2):310-18. 
 
Braun T, Gautel M. Transcriptional mechanisms regulating skeletal muscle 
differentiation, growth and homeostasis. Nat Rev Mol Cell Biol. 2011; 
12(6):349-61.  
 
Breitbart RE, Liang CS, Smoot LB, Laheru DA, Mahdavi V, Nadal-Ginard B. 
A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the 
myogenic lineage. Development. 1993; 118(4):1095-106. 
 
Buckingham M. Skeletal muscle formation in vertebrates. Curr Opin Genet 
Dev. 2001; 11(4):440-8. 
 
Byvoet P, Barber M, Amidei K, Lowell N, Trudeau W. Effect of exogenous 
histone H5 on integration of histone H1 in rat liver chromatin. Correlations 
with aberrant epsilon-N-methylation of histone H1. Biochim Biophys Acta. 
1986; 867(3):163-75. 
 
Byvoet P, Shepherd GR, Hardin JM, Noland BJ. The distribution and turnover 
of labeled methyl groups in histone fractions of cultured mammalian cells. 
Arch Biochem Biophys. 1972; 148(2):558-67. 
 
Cairns BR, Kim YJ, Sayre MH, Laurent BC, Kornberg RD. A multisubunit 
complex containing the SWI1/ADR6, SWI2/SNF2, SWI3, SNF5, and SNF6 
gene products isolated from yeast. Proc Natl Acad Sci U S A. 1994 Mar 1; 
91(5):1950-4. 
 
Cairns BR. Emerging roles for chromatin remodeling in cancer biology. 








Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb 
Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle 
differentiation. Genes Dev. 2004; 18(21):2627-38. 
 
Chandran R, Knobloch TJ, Anghelina M, Agarwal S. Biomechanical signals 
upregulate myogenic gene induction in the presence or absence of 
inflammation. Am J Physiol Cell Physiol. 2007; 293(1):C267-76. 
 
Chang Y, Zhang X, Horton JR, Upadhyay AK, Spannhoff A, Liu J, Snyder JP, 
Bedford MT, Cheng X. Structural basis for G9a-like protein lysine 
methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol. 2009; 
16(3):312-7 
 
Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle 
regeneration. Physiol Rev. 2004; 84(1):209-38. 
 
Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, 
Stallcup MR. Regulation of transcription by a protein methyltransferase. 
Science. 1999; 284(5423):2174-7. 
 
Cheng TC, Wallace MC, Merlie JP, Olson EN. Separable regulatory elements 
governing myogenin transcription in mouse embryogenesis. Science. 1993; 
261(5118):215-8. 
 
Chi T, Yan Z, Xue Y, Wang W. Purification and functional analysis of the 
mammalian SWI/SNF-family of chromatin-remodeling complexes. Methods 








Chin HG, Estève PO, Pradhan M, Benner J, Patnaik D, Carey MF, Pradhan S. 
Automethylation of G9a and its implication in wider substrate specificity and 
HP1 binding. Nucleic Acids Res. 2007; 35(21):7313-23.  
 
Chinnadurai G. Modulation of oncogenic transformation by the human 
adenovirus E1A C-terminal region. Curr Top Microbiol Immunol. 2004; 
273:139-61.  
 
Christ B, Ordahl CP. Early stages of chick somite development. Anat Embryol 
(Berl). 1995;191(5):381-96. 
 
Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney 
K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D. Regulation of 
p53 activity through lysine methylation. Nature. 2004 ;432(7015):353-60.  
 
Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, 
Giordano A. Deregulated expression of miR-26a and Ezh2 in 
rhabdomyosarcoma. Cell Cycle. 2009; 8(1):172-5. 
 
Côté J, Quinn J, Workman JL, Peterson CL. Stimulation of GAL4 derivative 
binding to nucleosomal DNA by the yeast SWI/SNF complex. Science. 1994; 
265(5168):53-60. 
 
COOPER WG, KONIGSBERG IR. Dynamics of myogenesis in vitro. Anat 
Rec. 1961; 140:195-205. PubMed 
 
Cserjesi P, Olson EN. Myogenin induces the myocyte-specific enhancer 
binding factor MEF-2 independently of other muscle-specific gene products. 








Dacwag CS, Ohkawa Y, Pal S, Sif S, Imbalzano AN. The protein arginine 
methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-
dependent chromatin remodeling. Mol Cell Biol. 2007; 27(1):384-94.  
 
Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA 
converts fibroblasts to myoblasts. Cell. 1987; 51(6):987-1000. 
 
de la Serna IL, Carlson KA, Imbalzano AN. Mammalian SWI/SNF complexes 
promote MyoD-mediated muscle differentiation. Nat Genet. 2001; 27(2):187-
90. 
 
de la Serna IL, Ohkawa Y, Berkes CA, Bergstrom DA, Dacwag CS, Tapscott 
SJ, Imbalzano AN. MyoD targets chromatin remodeling complexes to the 
myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol. 
2005; 25(10):3997-4009. 
 
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. 
Histone deacetylases (HDACs): characterization of the classical HDAC 
family. Biochem J. 2003; 370(Pt 3):737-49.  
 
DeLange RJ, Smith EL, Bonner J. Calf thymus histone 3: sequences of the 
amino-and carboxyl-terminal regions and of the regions containing lysyl 
residues modified by acetylation and methylation. Biochem Biophys Res 
Commun. 1970; 40(4):989-93. 
Dev. 2005; 19(7):815-26. 
 
Dias P, Dilling M, Houghton P. The molecular basis of skeletal muscle 
differentiation. Semin Diagn Pathol. 1994; 11(1):3-14. 
 
Dichoso D, Brodigan T, Chwoe KY, Lee JS, Llacer R, Park M, Corsi AK, 







essential for Caenorhabditis elegans myogenesis and development. Dev Biol. 
2000; 223(2):431-40. 
 
Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein 
superfamily: protein lysine methyltransferases. Genome Biol. 2005; 6:227.  
 
Dilworth FJ, Seaver KJ, Fishburn AL, Htet SL, Tapscott SJ. In vitro 
transcription system delineates the distinct roles of the coactivators pCAF and 
p300 during MyoD/E47-dependent transactivation. Proc Natl Acad Sci U S A. 
2004 Aug 10; 101(32):11593-8. 
 
Diao Y, Wang X, Wu Z. SOCS1, SOCS3, and PIAS1 promote myogenic 
differentiation by inhibiting the leukemia inhibitory factor-induced 
JAK1/STAT1/STAT3 pathway.Mol Cell Biol. 2009;29(18):5084-93.  
 
Doberstein SK, Fetter RD, Mehta AY, Goodman CS. Genetic analysis of 
myoblast fusion: blown fuse is required for progression beyond the prefusion 
complex. J Cell Biol. 1997; 136(6):1249-61. 
 
Dodge JE, Kang YK, Beppu H, Lei H, Li E. Histone H3-K9 methyltransferase 
ESET is essential for early development. Mol Cell Biol. 2004; 24(6):2478-86. 
 
Dong KB, Maksakova IA, Mohn F, Leung D, Appanah R, Lee S, Yang HW, 
Lam LL, Mager DL, Schübeler D, Tachibana M, Shinkai Y, Lorincz MC. 
DNA methylation in ES cells requires the lysine methyltransferase G9a but 
not its catalytic activity. EMBO J. 2008; 27(20):2691-701. 
 
Duan Z, Zarebski A, Montoya-Durango D, Grimes HL, Horwitz M. Gfi1 
coordinates epigenetic repression of p21Cip/WAF1 by recruitment of histone 








Dunham I, Sargent CA, Kendall E, Campbell RD. Characterization of the 
class III region in different MHC haplotypes by pulsed-field gel 
electrophoresis. Immunogenetics. 1990; 32(3):175-82. 
 
Duprez D, Fournier-Thibault C, Le Douarin N. Sonic Hedgehog induces 
proliferation of committed skeletal muscle cells in the chick limb. 
Development. 1998; 125(3):495-505. 
 
Edmondson DG, Lyons GE, Martin JF, Olson EN. Mef2 gene expression 
marks the cardiac and skeletal muscle lineages during mouse embryogenesis. 
Development.1994; 120(5):1251-63. 
 
Edmondson DG, Olson EN. A gene with homology to the myc similarity 
region of MyoD1 is expressed during myogenesis and is sufficient to activate 
the muscle differentiation program. Genes Dev. 1989; 3(5):628-40. 
 
Eisen JA, Sweder KS, Hanawalt PC. Evolution of the SNF2 family of 
proteins: subfamilies with distinct sequences and functions. Nucleic Acids 
Res. 1995; 23(14):2715-23. 
 
Elgin SC. “Heterochromatin and gene regulation in Drosophila”. Curr Opin 
Genet Dev. 1996; 6(2):193-202. 
 
Endo T, Nadal-Ginard B. Transcriptional and posttranscriptional control of c-
myc during myogenesis: its mRNA remains inducible in differentiated cells 
and does not suppress the differentiated phenotype. Mol Cell Biol. 1986; 
6(5):1412-21. 
 
Epstein JA, Shapiro DN, Cheng J, Lam PY, Maas RL. Pax3 modulates 
expression of the c-Met receptor during limb muscle development. Proc Natl 









Epsztejn-Litman S, Feldman N, Abu-Remaileh M, Shufaro Y, Gerson A, Ueda 
J, Deplus R, Fuks F, Shinkai Y, Cedar H, Bergman Y. De novo DNA 
methylation promoted by G9a prevents reprogramming of embryonically 
silenced genes. Nat Struct Mol Biol. 2008; 15(11):1176-83. 
 
Estève PO, Patnaik D, Chin HG, Benner J, Teitell MA, Pradhan S. Functional 
analysis of the N- and C-terminus of mammalian G9a histone H3 
methyltransferase. Nucleic Acids Res. 2005 Jun 6; 33(10):3211-23. 
 
Fan CM, Tessier-Lavigne M. Patterning of mammalian somites by surface 
ectodermand notochord: evidence for sclerotome induction by a hedgehog 
homolog. Cell.1994; 79(7):1175-86. 
 
Fan CM, Porter JA, Chiang C, Chang DT, Beachy PA, Tessier-Lavigne M. 
Long-range sclerotome induction by sonic hedgehog: direct role of theamino-
terminal cleavage product and modulation by the cyclic AMP signalling 
pathway. Cell. 1995; 81(3):457-65. 
 
Feldman N, Gerson A, Fang J, Li E, Zhang Y, Shinkai Y, Cedar H, Bergman 
Y. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early 
embryogenesis. Nat Cell Biol. 2006; 8(2):188-94. 
 
Felsenfeld G, Groudine M. Controlling the double helix. Nature. 2003; 
421(6921):448-53. 
 
Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K, Zhang 
Y. Methylation of H3-lysine 79 is mediated by a new family of HMTases 








Fickett JW. Coordinate positioning of MEF2 and myogenin binding sites. 
Gene.1996; 172(1):GC19-32. 
 
Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin 
Cell Biol. 2003; 15(2):172-83 
 
Forcales SV. The BAF60c-MyoD complex poises chromatin for rapid 
transcription. Bioarchitecture. 2012; 2(3):104-109. 
 
Foster RF, Thompson JM, Kaufman SJ. A laminin substrate promotes 
myogenesis in rat skeletal muscle cultures: analysis of replication and 
development using antidesmin and anti-BrdUrd monoclonal antibodies. Dev 
Biol. 1987;122(1):11-20. 
 
Friday BB, Horsley V, Pavlath GK. Calcineurin activity is required for the 
initiation of skeletal muscle differentiation. J Cell Biol. 2000; 149(3):657-66. 
 
Fulco M, Schiltz RL, Iezzi S, King MT, Zhao P, Kashiwaya Y, Hoffman E, 
Veech RL, Sartorelli V. Sir2 regulates skeletal muscle differentiation as a 
potential sensor of the redox state. Mol Cell. 2003; 12(1):51-62.  
 
Gary JD, Clarke S. RNA and protein interactions modulated by protein 
arginine methylation. Prog Nucleic Acid Res Mol Biol.1998; 61:65-131. 
 
El Gazzar M, Yoza BK, Chen X, Hu J, Hawkins GA, McCall CE. G9a and 
HP1 couple histone and DNA methylation to TNFalpha transcription silencing 
during endotoxin tolerance. J Biol Chem. 2008; 283(47):32198-208. 
 
Gossett LA, Kelvin DJ, Sternberg EA, Olson EN. A new myocyte-specific 
enhancer-binding factor that recognizes a conserved element associated with 








Goulding M, Lumsden A, Paquette AJ. Regulation of Pax-3 expression in the 
dermomyotome and its role in muscle development. Development. 1994; 
120(4):957-71. 
 
Gros J, Manceau M, Thomé V, Marcelle C. A common somitic origin for 
embryonic muscle progenitors and satellite cells. Nature. 2005; 
435(7044):954-8. 
 
Grounds MD, Yablonka-Reuveni Z. Molecular and cell biology of skeletal 
muscle regeneration. Mol Cell Biol Hum Dis Ser. 1993; 3:210-56. 
 
Grunstein M. Histone acetylation in chromatin structure and transcription. 
Nature. 1997; 389(6649):349-52. 
 
Gulbagci NT, Li L, Ling B, Gopinadhan S, Walsh M, Rossner M, Nave KA, 
TanejaR. SHARP1/DEC2 inhibits adipogenic differentiation by regulating the 
activity of C/EBP. EMBO Rep. 2009; 10(1):79-86. 
 
Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, 
LassarAB. Correlation of terminal cell cycle arrest of skeletal muscle with 
inductionof p21 by MyoD. Science. 1995; 267(5200):1018-21. 
 
Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, Klein 
WH. Muscle deficiency and neonatal death in mice with a targeted mutation in 
the myogenin gene. Nature. 1993; 364(6437):501-6. 
 
Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular 








Hermann A, Gowher H, Jeltsch A. Biochemistry and biology of mammalian 
DNA methyltransferases. Cell Mol Life Sci. 2004; 61(19-20):2571-87. 
Hernández-Hernández JM, Delgado-Olguín P, Aguillón-Huerta V, Furlan-
Magaril M, Recillas-Targa F, Coral-Vázquez RM. Sox9 represses alpha-
sarcoglycan gene expression in early myogenic differentiation. J Mol Biol. 
2009; 394(1):1-14. 
 
Hinterberger TJ, Sassoon DA, Rhodes SJ, Konieczny SF. Expression of the 
muscle regulatory factor MRF4 during somite and skeletal myofiber 
development. Dev Biol.1991; 147(1):144-56. 
 
Holliday R. Epigenetics: an overview. Dev Genet. 1994; 15(6):453-7.  
 
Horn PJ, Peterson CL. The bromodomain: a regulator of ATP-dependent 
chromatin remodeling? Front Biosci. 2001; 6:D1019-23. 
 
Huang J, Dorsey J, Chuikov S, Pérez-Burgos L, Zhang X, Jenuwein T, 
Reinberg D, Berger SL. G9a and Glp methylate lysine 373 in the tumor 
suppressor p53. J Biol Chem. 2010; 285(13):9636-41.  
 
Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, 
Kubicek S, Opravil S, Jenuwein T, Berger SL. Repression of p53 activity by 
Smyd2-mediated methylation. Nature. 2006; 444(7119):629-32. 
 
Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno 
K.Inhibitory effects of sudanese medicinal plant extracts on hepatitis C virus 
(HCV) protease. Phytother Res. 2000; 14(7):510-6. 
 
Imhof A. Histone modifications: an assembly line for active chromatin? Curr 








Ivanov GS, Ivanova T, Kurash J, Ivanov A, Chuikov S, Gizatullin F, Herrera-
Medina EM, Rauscher F 3rd, Reinberg D, Barlev NA. Methylation-acetylation 
interplay activates p53 in response to DNA damage. Mol Cell Biol. 2007; 
27(19):6756-69. 
 
Jang YN, Lee IJ, Park MC, Baik EJ. Role of JAK3 in myogenic 
differentiation.Cell Signal. 2012; 24(3):742-9.  
 
Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass 
anddistribution in 468 men and women aged 18-88 yr. J Appl Physiol. 
2000;89(1):81-8. 
 
Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 
293(5532):1074-80. 
 
Jenuwein T, Laible G, Dorn R, Reuter G. SET domain proteins modulate 
chromatin domains in eu- and heterochromatin. Cell Mol Life Sci. 1998; 
54(1):80-93. 
 
Johnson RL, Laufer E, Riddle RD, Tabin C. Ectopic expression of Sonic 
hedgehog alters dorsal-ventral patterning of somites. Cell. 1994; 79(7):1165-
73. 
 
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat 
Rev Genet. 2002; 3(6):415-28. 
 
Jones RS, Gelbart WM. The Drosophila Polycomb-group gene Enhancer of 
zeste contains a region with sequence similarity to trithorax. Mol Cell Biol. 








Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-dependent 
regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic 
stem cells. Mol Cell. 2009; 36(1):61-74. 
Kablar B, Krastel K, Ying C, Asakura A, Tapscott SJ, Rudnicki MA. MyoD 
and Myf-5 differentially regulate the development of limb versus trunk 
skeletal muscle. Development. 1997; 124(23):4729-38. 
 
Kadam S, Emerson BM. Transcriptional specificity of human SWI/SNF 
BRG1 and BRM chromatin remodeling complexes. Mol Cell. 2003; 
11(2):377-89. 
 
Kaliman P, Canicio J, Testar X, Palacín M, Zorzano A. Insulin-like growth 
factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappaB and inducible 
nitric-oxide synthase define a common myogenic signaling pathway. J Biol 
Chem; 274(25):17437-44. 
 
Karpen GH, Allshire RC. The case for epigenetic effects on centromere 
identity and function. Trends Genet. 1997; 13(12):489-96. 
 
Katz B. The terminations of the afferent nerve fibre in the muscle spindle of 
the frog. Philos Trans R Soc Lond (Biol). 1961; 243(703): 221-240. 
 
Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-
myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 
1983; 35(3 Pt 2):603-10. 
 
Kennison JA. The Polycomb and trithorax group proteins of Drosophila: trans-
regulators of homeotic gene function. Annu Rev Genet. 1995; 29:289-303. 
 









Konigsberg IR. Clonal analysis of myogenesis. Science. 1963; 
140(3573):1273-84. 
 
Kornberg RD. Chromatin structure: a repeating unit of histones and DNA. 
Science. 1974; 184(4139):868-71.  
 
Kourmouli N, Sun YM, van der Sar S, Singh PB, Brown JP. Epigenetic 
regulation of mammalian pericentric heterochromatin in vivo by HP1. 
Biochem Biophys Res Commun. 2005; 337(3):901-7. 
 
Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet 
Dev. 2002; 12(2):198-209. 
 
Kramer S, Meadows AT, Jarrett P, Evans AE. Incidence of childhood cancer: 
experience of a decade in a population-based registry. J Natl Cancer Inst. 
1983; 70(1):49-55. 
 
Kroll TG, Peters BP, Hustad CM, Jones PA, Killen PD, Ruddon RW. 
Expression of laminin chains during myogenic differentiation. J Biol Chem. 
1994;269(12):9270-7. 
 
Krüger M, Mennerich D, Fees S, Schäfer R, Mundlos S, Braun T. Sonic 
hedgehogis a survival factor for hypaxial muscles during mouse development. 
Development. 2001; 128(5):743-52. 
 
Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009; 137(4):609-22. 
Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. 
Histone methyltransferase activity associated with a human multiprotein 









Kühl U, Timpl R, von der Mark K. Synthesis of type IV collagen and laminin 
in cultures of skeletal muscle cells and their assembly on the surface of 
myotubes. Dev Biol. 1982; 93(2):344-54. 
 
Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, 
Rea S, Mechtler K, Kowalski JA, Homon CA, Kelly TA, Jenuwein T. 
Reversal of H3K9me2 by asmall-molecule inhibitor for the G9a histone 
methyltransferase. Mol Cell. 2007; 25(3):473-81.  
 
Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr 
OpinCell Biol. 2002; 14(3):286-98. 
 
Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, 
Pillus L, Jenuwein T. Mammalian homologues of the Polycomb-group gene 
Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and 
at S. cerevisiae telomeres. EMBO J. 1997; 16(11):3219-32. 
 
Lafuste P, Sonnet C, Chazaud B, Dreyfus PA, Gherardi RK, Wewer UM, 
Authier FJ. ADAM12 and alpha9beta1 integrin are instrumental in human 
myogenic cell differentiation. Mol Biol Cell. 2005; 16(2):861-70. 
 
Lassar AB, Paterson BM, Weintraub H. Transfection of a DNA locus that 
mediates the conversion of 10T1/2 fibroblasts to myoblasts. Cell. 1986; 
47(5):649-56. 
 
Lassar, A.B., Thayer, M.J., Overell, R.W., Weintraub, H. Transformation by 
activated ras or fos prevents myogenesis by inhibiting expression of MyoD1. 








Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Voronova A, 
Baltimore D, Weintraub H. Functional activity of myogenic HLH proteins 
requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell. 1991; 
66(2):305-15. 
 
Lassar AB, Münsterberg AE. The role of positive and negative signals in 
somite patterning. Curr Opin Neurobiol. 1996; 6(1):57-63. 
 
Lassar, A.B., Skapek, S.X., Novitch, B. Regulatory mechanisms that 
coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr 
Opin Cell Biol .1994; 6:788-794. 
 
Lee J, Hagerty S, Cormier KA, Kim J, Kung AL, Ferrante RJ, Ryu H. 
Monoallele deletion of CBP leads to pericentromeric heterochromatin 
condensation through ESET expression and histone H3 (K9) methylation. 
Hum Mol Genet. 2008;17(12):1774-82. 
 
Lee JS, Kim Y, Kim IS, Kim B, Choi HJ, Lee JM, Shin HJ, Kim JH, Kim JY, 
Seo SB, Lee H, Binda O, Gozani O, Semenza GL, Kim M, Kim KI, Hwang D, 
Baek SH. Negative regulation of hypoxic responses via induced Reptin 
methylation. Mol Cell. 2010; 39(1):71-85. 
 
Lee MH, Jothi M, Gudkov AV, Mal AK. Histone methyltransferase KMT1A 
restrains entry of alveolar rhabdomyosarcoma cells into a myogenic 
differentiated state. Cancer Res 2011; 71: 3921-31. 
 
Lee NM, Loh HH. Phosphorylation and methylation of chromatin proteins 
from mouse brain nuclei. J Neurochem. 1977; 29(3):547-50. 
 
Lehnertz B, Northrop JP, Antignano F, Burrows K, Hadidi S, Mullaly SC et 







G9a in T helper cell differentiation and function. J Exp Med 2010; 207:915-
22. 
Lemercier C, To RQ, Carrasco RA, Konieczny SF. The basic helix-loop-helix 
transcription factor Mist1 functions as a transcriptional repressor of myoD. 
EMBOJ. 1998; 17(5):1412-22. 
 
Letunic I, Copley RR, Schmidt S, Ciccarelli FD, Doerks T, Schultz J, Ponting 
CP, Bork P. SMART 4.0: towards genomic data integration. Nucleic Acids 
Res. 2004; 32:D142-4. 
 
Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. 
Nature. 1993; 366(6453):362-5. 
 
Li H, Rauch T, Chen ZX, Szabó PE, Riggs AD, Pfeifer GP. The histone 
methyltransferase SETDB1 and the DNA methyltransferase DNMT3A 
interact directly and localize to promoters silenced in cancer cells. J Biol 
Chem. 2006; 281(28):19489-500. 
 
Li L, Heller-Harrison R, Czech M, Olson EN. Cyclic AMP-dependent protein 
kinase inhibits the activity of myogenic helix-loop-helix proteins. Mol Cell 
Biol. 1992(a); 12(10):4478-85. 
 
Li L, Zhou J, James G, Heller-Harrison R, Czech MP, Olson EN. FGF 
inactivates myogenic helix-loop-helix proteins through phosphorylation of a 
conserved protein kinase C site in their DNA-binding domains. Cell. 1992(b); 
71(7):1181-94. 
 
Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination 








Li S, Czubryt MP, McAnally J, Bassel-Duby R, Richardson JA, Wiebel FF, 
Nordheim A, Olson EN. Requirement for serum response factor for skeletal 
muscle growth and maturation revealed by tissue-specific gene deletion in 
mice. Proc Natl Acad Sci U S A. 2005; 102(4):1082-7. 
 
Lieber RL. Skeletal muscle structure and function. Implications for physical 
therapy and sports medicine. Williams and Wilkins, Baltimore. 1992;303. 
 
Lilly B, Galewsky S, Firulli AB, Schulz RA, Olson EN. D-MEF2: a MADS 
box transcription factor expressed in differentiating mesoderm and muscle cell 
lineages during Drosophila embryogenesis. Proc Natl Acad Sci U S A. 1994; 
91(12):5662-6. 
 
Liu Y, Oakeley EJ, Sun L, Jost JP. Multiple domains are involved in the 
targeting of the mouse DNA methyltransferase to the DNA replication foci. 
Nucleic Acids Res. 1998; 26(4):1038-45. 
 
Loidl P. Histone acetylation: facts and questions. Chromosoma. 1994; 
103(7):441-9. 
 
Loyola A, Tagami H, Bonaldi T, Roche D, Quivy JP, Imhof A, Nakatani Y, 
Dent SY, Almouzni G. The HP1alpha-CAF1-SetDB1-containing complex 
provides H3K9me1 for Suv39-mediated K9me3 in pericentric 
heterochromatin. EMBO Rep. 2009; 10(7):769-75. 
 
Lu J, Webb R, Richardson JA, Olson EN. MyoR: a muscle-restricted basic 
helix-loop-helix transcription factor that antagonizes the actions of MyoD. 








Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myogenesis 
by association of the MEF2 transcription factor with class II histone 
deacetylases. Mol Cell. 2000; 6(2):233-44.  
 
Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ. Crystal 
structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997; 
389(6648):251-60. 
 
Lusser A, Kadonaga JT. Chromatin remodeling by ATP-dependent molecular 
machines. Bioessays. 2003; 25(12):1192-200. 
 
Mal A, Sturniolo M, Schiltz RL, Ghosh MK, Harter ML. A role for histone 
deacetylase HDAC1 in modulating the transcriptional activity of MyoD: 
inhibition of the myogenic program. EMBO J. 2001; 20(7):1739-53.  
 
Mal A, Harter ML. MyoD is functionally linked to the silencing of a muscle-
specific regulatory gene prior to skeletal myogenesis. Proc Natl Acad Sci U S 
A. 2003; 100(4):1735-9.  
 
Mal AK. Histone methyltransferase Suv39h1 represses MyoD-stimulated 
myogenic differentiation. EMBO J. 2006; 25(14):3323-34. 
 
Mansouri A, Hallonet M, Gruss P. Pax genes and their roles in cell 
differentiation and development. Curr Opin Cell Biol. 1996; 8(6):851-7. 
 
Marcelle C, Stark MR, Bronner-Fraser M. Coordinate actions of BMPs, Wnts, 











Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of  
EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle. 
2012; 11(20):3828-36. 
 
Maroto M, Reshef R, Münsterberg AE, Koester S, Goulding M, Lassar AB. 
Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm 
and neural tissue. Cell. 1997; 89(1):139-48. 
 
Martens JA, Winston F. Recent advances in understanding chromatin 
remodeling by Swi/Snf complexes. Curr Opin Genet Dev. 2003 Apr; 
13(2):136-42. 
 
Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat 
Rev Mol Cell Biol. 2005; 6(11):838-49. 
 
Martin PT. Role of transcription factors in skeletal muscle and the potential 
for pharmacological manipulation. Curr Opin Pharmacol. 2003 Jun; 3(3):300-
8. 
 
Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem 
Cytol.1961; 9(2):493-5. 
 
McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export 
of a histone deacetylase regulates muscle differentiation. Nature. 2000(b); 
408(6808):106-11. 
 
McKinsey TA, Zhang CL, Olson EN. Activation of the myocyte enhancer 
factor-2transcription factor by calcium/calmodulin-dependent protein kinase-
stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci U S 








Megeney LA, Rudnicki MA. Determination versus differentiation and the 
MyoD family of transcription factors. Biochem Cell Biol. 1995; 73(9-10):723-
32. 
 
Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, Ladanyi M, 
Barr FG. Identification of PAX3-FKHR-regulated genes differentially 
expressed between alveolar and embryonal rhabdomyosarcoma: focus on 
MYCN as a biologically relevant target. Genes Chromosomes Cancer. 2008; 
47(6):510-20. 
 
Merlino G, Helman LJ. Rhabdomyosarcoma--working out the pathways. 
Oncogene. 1999; 20; 18(38):5340-8. 
 
Miner JH, Wold B. Herculin, a fourth member of the MyoD family of 
myogenic regulatory genes. Proc Natl Acad Sci U S A. 1990; 87(3):1089-93. 
 
Miner JH, Wold BJ. c-myc inhibition of MyoD and myogenin-initiated 
myogenic differentiation. Mol Cell Biol. 1991; 11(5):2842-51. 
 
Mintz B, Baker WW. Normal mammalian muscle differentiation and gene 
control of isocitrate dehydrogenase synthesis. Proc Natl Acad Sci U S A. 
1967; 58(2):592-8. 
 
Molkentin JD, Black BL, Martin JF, Olson EN. Cooperative activation of 
muscle gene expression by MEF2 and myogenic bHLH proteins. Cell. 1995; 
83(7):1125-36. 
 
Molkentin JD, Olson EN. Combinatorial control of muscle development by 
basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad 








Münsterberg AE, Lassar AB. Combinatorial signals from the neural tube, floor 
plate and notochord induce myogenic bHLH gene expression in the somite. 
Development. 1995;121(3):651-60. 
 
Münsterberg AE, Kitajewski J, Bumcrot DA, McMahon AP, Lassar AB. 
Combinatorial signaling by Sonic hedgehog and Wnt family members induces 
myogenic bHLH gene expression in the somite. Genes Dev. 1995 Dec 1; 
9(23):2911-22. 
 
Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization 
motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc 
proteins. Cell. 1989a; 56(5):777-83. 
 
Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, Cabrera CV, 
Buskin JN, Hauschka SD, Lassar AB, et al. Interactions between heterologous 
helix-loop-helix proteins generate complexes that bind specifically to a 
common DNA sequence. Cell. 1989b; 58(3):537-44. 
 
Myant K, Termanis A, Sundaram AY, Boe T, Li C, Merusi C et al. LSH and 
G9a/GLP complex are required for developmentally programmed DNA 
methylation. Genome Res 2011; 21:83-94. 
 
Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I, Nabeshima 
Y. Myogenin gene disruption results in perinatal lethality because of severe 
muscle defect. Nature. 1993; 364(6437):532-5. 
 
Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that 








Nishio H, Walsh MJ. CCAAT displacement protein/cut homolog recruits G9a 
histone lysine methyltransferase to repress transcription. Proc Natl Acad Sci U 
S A. 2004; 101(31):11257-62. 
 
North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein 
deacetylases. Genome Biol. 2004; 5(5):224. 
 
O'Carroll D, Scherthan H, Peters AH, Opravil S, Haynes AR, Laible G, et al. 
Isolation and characterization of Suv39h2, a second histone H3 
methyltransferase gene that displays testis-specific expression. Mol Cell Biol. 
2000; 20(24):9423-33. 
 
Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y. A complex 
with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 
cells. Science. 2002; 296:1132-6. 
 
O'Geen H, Squazzo SL, Iyengar S, Blahnik K, Rinn JL, Chang HY, Green R, 
Farnham PJ. Genome-wide analysis of KAP1 binding suggests autoregulation 
of KRAB-ZNFs. PLoS Genet. 2007; 3(6):e89. 
 
Ohkawa Y, Yoshimura S, Higashi C, Marfella CG, Dacwag CS, Tachibana T, 
Imbalzano AN. Myogenin and the SWI/SNF ATPase Brg1 maintain myogenic 
gene expression at different stages of skeletal myogenesis. J Biol Chem. 2007; 
282(9):6564-70. 
 
Olson EN, Perry M, Schulz RA. Regulation of muscle differentiation by the 
MEF2 family of MADS box transcription factors. Dev Biol. 1995; 172(1):2-
14. 
 
Ordahl CP, Le Douarin NM. Two myogenic lineages within the developing 








Orlando V, Paro R. Chromatin multiprotein complexes involved in the 
maintenance of transcription patterns. Curr Opin Genet Dev. 1995; 5(2):174-9.  
 
Ornatsky OI, Andreucci JJ, McDermott JC. A dominant-negative form of 
transcription factor MEF2 inhibits myogenesis. J Biol Chem. 1997; 
272(52):33271-8. 
 
Ott MO, Bober E, Lyons G, Arnold H, Buckingham M. Early expression of 
the myogenic regulatory gene, myf-5, in precursor cells of skeletal muscle in 
the mouse embryo. Development. 1991; 111(4):1097-107. 
 
Oustanina S, Hause G, Braun T. Pax7 directs postnatal renewal and 
propagation of myogenic satellite cells but not their specification. EMBO J. 
2004; 23(16):3430-9. 
Parker MH, Seale P, Rudnicki MA. Looking back to the embryo: 
definingtranscriptional networks in adult myogenesis. Nat Rev Genet. 2003; 
4(7):497-507. 
 
Perdiguero E, Sousa-Victor P, Ballestar E, Muñoz-Cánoves P. Epigenetic 
regulation of myogenesis. Epigenetics. 2009; 4(8):541-50. 
 
Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schöfer C, 
Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, 
Sibilia M, Jenuwein T. Loss of the Suv39h histone methyltransferases impairs 
mammalian heterochromatin and genome stability. Cell. 2001; 107(3):323-37. 
 
Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsh MJ, 
Leutz A. G9a-mediated lysine methylation alters the function of 








Pollock R, Treisman R. Human SRF-related proteins: DNA-binding properties 
and potential regulatory targets. Genes Dev. 1991; 5(12A):2327-41. 
 
Prives C, Manley JL. Why is p53 acetylated? Cell. 2001; 107(7):815-8. 
 
Prokhortchouk A, Hendrich B, Jørgensen H, Ruzov A, Wilm M, Georgiev G, 
Bird A, Prokhortchouk E. The p120 catenin partner Kaiso is a DNA 
methylation-dependent transcriptional repressor. Genes Dev. 2001; 
15(13):1613-8. 
 
Puri PL, Iezzi S, Stiegler P, Chen TT, Schiltz RL, Muscat GE, Giordano A, 
Kedes L, Wang JY, Sartorelli V. Class I histone deacetylases sequentially 
interact with MyoD and pRb during skeletal myogenesis. Mol Cell. 2001; 
8(4):885-97. 
 
Qian C, Zhou MM. SET domain protein lysine methyltransferases: Structure, 
specificity and catalysis. Cell Mol Life Sci. 2006; 63(23):2755-63. 
 
Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R, 
Komatsu Y, Shinkai Y, Cheng X, Jeltsch A. Protein lysine methyltransferase 
G9a acts on non-histone targets. Nat Chem Biol. 2008; 4(6):344-6.  
 
Rawls A, Valdez MR, Zhang W, Richardson J, Klein WH, Olson EN. 
Overlapping functions of the myogenic bHLH genes MRF4 and MyoD 
revealed in double mutant mice. Development. 1998; 125(13):2349-58. 
 
Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, et al. 
Regulation of chromatin structure by site-specific histone H3 








Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. 
Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev. 2002; 
12(2):162-9. 
 
Regha K, Sloane MA, Huang R, Pauler FM, Warczok KE, Melikant B, Radolf 
M, Martens JH, Schotta G, Jenuwein T, Barlow DP. Active and repressive 
chromatin are interspersed without spreading in an imprinted gene cluster in 
the mammalian genome. Mol Cell. 2007; 27(3):353-66. 
 
Relaix F, Montarras D, Zaffran S, Gayraud-Morel B, Rocancourt D, 
Tajbakhsh S, Mansouri A, Cumano A, Buckingham M. Pax3 and Pax7 have 
distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol. 
2006; 172(1):91-102. 
 
Relaix F, Rocancourt D, Mansouri A, Buckingham M. A Pax3/Pax7-
dependent population of skeletal muscle progenitor cells. Nature. 2005; 
435(7044):948-53. 
 
Ren YX, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg 
KI, Triche TJ, Shimada H, Anderson MJ. Mouse mesenchymal stem cells 
expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating 
with secondary mutations. Cancer Res 2008; 68(16):6587-97. 
 
Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB. 
Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB 
ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling 
pathway. Mol Cancer Res. 2010; 8(10):1425-36. 
 
Rhodes SJ, Konieczny SF. Identification of MRF4: a new member of the 








Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, 
ShinkaiY, Allis CD. Histone methyltransferases direct different degrees of 
methylation to define distinct chromatin domains. Mol Cell. 2003; 
12(6):15918. 
 
Rudnicki MA, Braun T, Hinuma S, Jaenisch R. Inactivation of MyoD in mice 
leads to up-regulation of the myogenic HLH gene Myf-5 and results in 
apparently normal muscle development. Cell. 1992; 71(3):383-90. 
 
Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch 
R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell. 
1993; 75(7):1351-9. 
 
Sabourin LA, Rudnicki MA. The molecular regulation of myogenesis. Clin 
Genet. 2000; 57(1):16-25.  
 
Saccone V, Puri PL. Epigenetic regulation of skeletal myogenesis. 
Organogenesis. 2010; 6(1):48-53. 
 
Sartorelli V, Caretti G. Mechanisms underlying the transcriptional regulation  
of skeletal myogenesis. Curr Opin Genet Dev. 2005;15(5):528-35. 
 
Sampath SC, Marazzi I, Yap KL, Sampath SC, Krutchinsky AN, 
Mecklenbräuker I, Viale A, Rudensky E, Zhou MM, Chait BT, Tarakhovsky 
A. Methylation of a histone mimic within the histone methyltransferase G9a 
regulates protein complex assembly. Mol Cell. 2007; 27(4):596-608. 
 
Sarnow P, Rasched I, Knippers R. A histone H4-specific methyltransferase. 
Properties, specificity and effects on nucleosomal histones. Biochim Biophys 








Sartorelli V, Puri PL, Hamamori Y, Ogryzko V, Chung G, Nakatani Y, Wang 
JY, Kedes L. Acetylation of MyoD directed by PCAF is necessary for the 
execution of the muscle program. Mol Cell. 1999; 4(5):725-34. 
 
Sassoon D, Lyons G, Wright WE, Lin V, Lassar A, Weintraub H, Buckingham 
M.Expression of two myogenic regulatory factors myogenin and MyoD1 
during mouseembryogenesis. Nature. 1989; 341(6240):303-7. 
 
Schuettengruber B, Cavalli G. Recruitment of polycomb group complexes and 
their role in the dynamic regulation of cell fate choice. Development. 2009; 
136(21):3531-42 
 
Schultz E, McCormick KM. Skeletal muscle satellite cells. Rev Physiol 
Biochem Pharmacol. 1994; 123:213-57. 
 
Schwarz JJ, Chakraborty T, Martin J, Zhou JM, Olson EN. The basic region of 
myogenin cooperates with two transcription activation domains to induce 
muscle-specific transcription. Mol Cell Biol. 1992; 12(1):266-75. 
 
Scrable H, Witte D, Shimada H, Seemayer T, Sheng WW, Soukup S, Koufos 
A,Houghton P, Lampkin B, Cavenee W. Molecular differential pathology of 
rhabdomyosarcoma. Genes Chromosomes Cancer. 1989; 1(1):23-35. 
 
Sebire NJ, Malone M. Myogenin and MyoD1 expression in paediatric 
rhabdomyosarcomas. J Clin Pathol. 2003; 56(6):412-6. 
 
Sejersen T, Sümegi J, Ringertz NR. Density-dependent arrest of DNA 
replication is accompanied by decreased levels of c-myc mRNA in myogenic 









Shankar SR, Bahirvani AG, Rao VK, Bharathy N, Ow JR, Taneja R. G9a, 
amultipotent regulator of gene expression. Epigenetics. 2012; 8(1). 
 
Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, Ogawa H, Luke MP, 
Nakatani Y, Shi Y. Coordinated histone modifications mediated by a CtBP co-
repressor complex. Nature. 2003; 422(6933):735-8. 
 
Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation 
of p53 alleviates inhibition by MDM2. Cell. 1997; 91(3):325-34. 
 
Shirakata M, Friedman FK, Wei Q, Paterson BM. Dimerization specificity of 
myogenic helix-loop-helix DNA-binding factors directed by nonconserved 
hydrophilic residues. Genes Dev. 1993; 7(12A):2456-70. 
 
Sif S. ATP-dependent nucleosome remodeling complexes: enzymes tailored to 
deal with chromatin. J Cell Biochem. 2004; 91(6):1087-98. 
 
Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns 
and unknowns. Nat Rev Mol Cell Biol. 2009 Oct; 10(10):697-708. 
 
Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer 
epigenetics. Mutat Res. 2008; 647(1-2):21-9. 
 
Simone C, Forcales SV, Hill DA, Imbalzano AN, Latella L, Puri PL. p38 
pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific 
loci. Nat Genet. 2004; 36(7):738-43. 
 
Simone C. SWI/SNF: the crossroads where extracellular signaling pathways 








Smith TH, Block NE, Rhodes SJ, Konieczny SF, Miller JB. A unique pattern 
of expression of the four muscle regulatory factor proteins distinguishes 
somatic from embryonic, fetal and newborn mouse myogenic cells. 
Development. 1993; 117(3):1125-33. 
 
Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, 
development and cancer. Nat Rev Cancer. 2006; 6(11):846-56. 
 
Spicer DB, Rhee J, Cheung WL, Lassar AB. Inhibition of myogenic bHLH 
and MEF2 transcription factors by the bHLH protein Twist. Science. 1996; 
272(5267):1476-80. 
 
Spies T, Bresnahan M, Strominger JL. Human major histocompatibility 
complex contains a minimum of 19 genes between the complement cluster and 
HLA-B. Proc Natl Acad Sci U S A. 1989; 86(22):8955-8. 
 
Soleimani VD, Punch VG, Kawabe Y, Jones AE, Palidwor GA, Porter CJ, 
Cross JW, Carvajal JJ, Kockx CE, van IJcken WF, Perkins TJ, Rigby PW, 
Grosveld F, Rudnicki MA. Transcriptional dominance of Pax7 in adult 
myogenesis is due to high-affinity recognition of homeodomain motifs. Dev 
Cell. 2012; 22(6):1208-20. 
 
Sterner DE, Berger SL. Acetylation of histones and transcription-related 
factors. Microbiol Mol Biol Rev. 2000; 64(2):435-59. 
 
STOCKDALE FE, HOLTZER H. DNA synthesis and myogenesis. Exp Cell 
Res. 1961; 24:508-20. 
 









Strahl BD, Briggs SD, Brame CJ, Caldwell JA, Koh SS, Ma H, Cook RG, 
Shabanowitz J, Hunt DF, Stallcup MR, Allis CD. Methylation of histone H4 at 
arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator 
PRMT1. Curr Biol. 2001; 11(12):996-1000. 
 
Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 at lysine 4 
is highly conserved and correlates with transcriptionally active nuclei in 
Tetrahymena. Proc Natl Acad Sci U S A. 1999; 96(26):14967-72. 
 
Summerbell D, Rigby PW. Transcriptional regulation during somitogenesis. 
Curr Top Dev Biol. 2000; 48:301-18. 
 
Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. Set domain-containing 
protein, G9a, is a novel lysine-preferring mammalian histone 
methyltransferase with hyperactivity and specific selectivity to lysines 9 and 
27 of histone H3. J Biol Chem. 2001; 276(27):25309-17. 
 
Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, 
Takeda N, Niida H, Kato H, Shinkai Y. G9a histone methyltransferase plays a 
dominant role in euchromatic histone H3 lysine 9 methylation and is essential 
for early embryogenesis. Genes Dev. 2002; 16(14):1779-91. 
 
Tachibana M, Ueda J, Fukuda M, Takeda N, Ohta T, Iwanari H, Sakihama T, 
KodamaT, Hamakubo T, Shinkai Y. Histone methyltransferases G9a and GLP 
form heteromeric complexes and are both crucial for methylation of 
euchromatin at H3-K9. Genes Dev. 2005; 19(7):815-26. 
 
Tajbakhsh S, Cossu G. Establishing myogenic identity during somitogenesis. 








Tajbakhsh S. Skeletal muscle stem cells in developmental versus regenerative 
myogenesis. J Intern Med. 2009; 266(4):372-89. 
 
Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a 
factor required for MyoD activity and myogenesis. Science 1993; 
259(5100):1450-3. 
 
Tapscott SJ. The circuitry of a master switch: MyoD and the regulation of 
skeletal muscle gene transcription. Development. 2005; 32(12):2685-95. 
 
Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 
cells treated with 5-azacytidine. Cell. 1979; 17(4):771-9. 
 
Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. 
Histone deacetylases: unique players in shaping the epigenetic histone code. 
Ann N Y Acad Sci. 2003; 983:84-100. 
 
Ting AH, McGarvey KM, Baylin SB. The cancer epigenome--components and 
functional correlates. Genes Dev. 2006; 20(23):3215-31. 
 
Tremblay P, Dietrich S, Mericskay M, Schubert FR, Li Z, Paulin D. A crucial 
role for Pax3 in the development of the hypaxial musculature and the long-
range migration of muscle precursors. Dev Biol. 1998; 203(1):49-61. 
 
Trojer P, Zhang J, Yonezawa M, Schmidt A, Zheng H, Jenuwein T, Reinberg 
D. Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone 
Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing 
JMJD2/KDM4 Proteins. J Biol Chem. 2009; 284(13):8395-405. 
 
Tschiersch B, Hofmann A, Krauss V, Dorn R, Korge G, Reuter G. The protein 







Su(var)3-9 combines domains of antagonistic regulators of homeotic gene 
complexes. EMBO J.1994; 13(16):3822-31. 
 
Tsokos M, Webber BL, Parham DM, Wesley RA, Miser A, Miser JS, 
Etcubanas E, Kinsella T, Grayson J, Glatstein E, et al. Rhabdomyosarcoma. A 
new classification scheme related to prognosis. Arch Pathol Lab Med. 1992; 
116(8):847-55. 
 
Turner BM. Cellular memory and the histone code. Cell. 2002; 111(3):285-91. 
 
Ueda J, Tachibana M, Ikura T, Shinkai Y. Zinc finger protein Wiz links 
G9a/GLP histone methyltransferases to the co-repressor molecule CtBP. J Biol 
Chem. 2006; 281(29):20120-8.  
 
Van der Vlag J, Otte AP. Transcriptional repression mediated by the human 
polycomb-group protein EED involves histone deacetylation. Nat Genet. 
1999; 23(4):474-8. 
 
Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, 
Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, Dong A, 
Tempel W, Wang SC,Chen X, Chau I, Mangano TJ, Huang XP, Simpson CD, 
Pattenden SG, Norris JL, KireevDB, Tripathy A, Edwards A, Roth BL, Janzen 
WP, Garcia BA, Petronis A, Ellis J,Brown PJ, Frye SV, Arrowsmith CH, Jin J. 
A chemical probe selectively inhibits G9a and GLP methyltransferase activity 
in cells. Nat Chem Biol. 2011;7(8):566-74.  
 
Wachtler F, Christ B. The basic embryology of skeletal muscle formation in 
vertebrates. Sem.Dev.Biol.1992; 3: 217-27. 
 
Wang H, An W, Cao R, Xia L, Erdjument-Bromage H, Chatton B, Tempst P, 







trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell. 
2003; 12(2):475-87. 
 
Wang K, Wang C, Xiao F, Wang H, Wu Z. JAK2/STAT2/STAT3 are required 
for myogenic differentiation. J Biol Chem. 2008; 283(49):34029-36. 
 
Wang YX, Rudnicki MA. Satellite cells, the engines of muscle repair. Nat Rev 
Mol Cell Biol. 2011; 13(2):127-33. 
 
Weintraub M, Kalebic T, Helman LJ, Bhatia KG. Disruption of the MyoD/p21 
Pathway in Rhabdomyosarcoma. Sarcoma. 1997; 1(3-4):135-41. 
 
Weiss T, Hergeth S, Zeissler U, Izzo A, Tropberger P, Zee BM, Dundr M, 
Garcia BA, Daujat S, Schneider R. Histone H1 variant-specific lysine 
methylation by G9a/KMT1C and Glp1/KMT1D. Epigenetics Chromatin. 
2010; 3(1):7. 
 
Workman JL, Kingston RE. Alteration of nucleosome structure as a 
mechanism of transcriptional regulation. Annu Rev Biochem. 1998; 67:545-
79.  
 
Wright WE, Sassoon DA, Lin VK. Myogenin, a factor regulating myogenesis, 
has a domain homologous to MyoD. Cell. 1989; 56(4):607-17. 
 
Yamamizu K, Fujihara M, Tachibana M, Katayama S, Takahashi A, Hara E, 
Imai H, Shinkai Y, Yamashita JK. Protein kinase A determines timing of early 
differentiation through epigenetic regulation with G9a. Cell Stem Cell. 2012; 
10(6):759-70.  
 
Yee SP, Rigby PW. The regulation of myogenin gene expression during the 








Zhang CL, McKinsey TA, Olson EN. Association of class II histone 
deacetylases with heterochromatin protein 1: potential role for histone 
methylation in control of muscle differentiation. Mol Cell Biol. 2002; 
22(20):7302-12. 
 
